ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES

Information

  • Patent Application
  • 20130172365
  • Publication Number
    20130172365
  • Date Filed
    September 16, 2011
    13 years ago
  • Date Published
    July 04, 2013
    11 years ago
Abstract
Arylsulphonamide derivatives of formula (I) and pharmaceutically acceptable salts thereof. The compounds may be useful for the treatment and/or prevention of disorders of the central nervous system.
Description
FIELD OF THE INVENTION

The present invention relates to novel arylsulphonamides having affinity to dopaminergic, serotoninergic, adrenergic, sigma and serotonine transporter receptors, pharmaceutical compositions containing the same and to the use thereof. The compounds may be useful for the treatment of diseases of the central nervous system, such as schizophrenia, bipolar affective disorder, depression, anxiety disorders, sleep disorders or Alzheimer disease.


STATE OF THE ART

CNS disorders are considered a global medical problem. A number of people suffering from those diseases constantly grows, particularly in highly developed countries and intensively developing ones. Approximately 20% of population in highly developed societies suffers from CNS disorders. In addition a cost of treatment of such disorders represents nearly 35% of total expenses spent for treatment of all medical diseases in seven countries considered as the biggest pharmaceutical markets.


Among all psychiatric diseases, schizophrenia, bipolar disorder, depression, anxiety, sleep disorders and addictions are the major ones. The main neurologic disorders are Alzheimer's disease, Parkinson's disease, epilepsy and different pain disorders.


Antipsychotic drugs, which are main treatment of schizophrenia, are divided into two main classes on the basis of their liability to induce neurological side effects after long-term treatment. Typical antipsychotic drugs, such as chlorpromazine and haloperidol, induce after repeated administration various extrapyramidal side effects (EPS) including Parkinson-like symptoms and tardive dyskinesia. Repeated treatment with so called atypical antipsychotic drugs, such as clozapine, risperidone, olanzapine, quetiapine, ziprasidone and aripiprazole, is associated with a lower incidence of neurological side effects. Typical antipsychotics reduce positive symptoms but do not reduce negative symptoms and cognitive dysfunctions. Plasma prolactin levels are increased in humans, and there is a gain in bodyweight potentially leading to the development of metabolic syndrome. Atypical antipsychotic drugs effectively reduce positive symptoms and also to some extent negative symptoms and cognitive disturbances producing less serious EPS. Atypical antipsychotic drugs differ in their propensity to elevate plasma prolactin levels in humans. Typical antipsychotic drugs block dopamine D2 receptors in the mesolimbic and nigrostriatal system. This mechanism is responsible for the antipsychotic effect (reduction of positive symptoms) as well as induction of EPS. Clinical support for the dopamine hypothesis of antipsychotic drug action was provided by PET findings of high dopamine D2 receptor occupancy in the striatum of patients responding to different antipsychotic drug treatments. Patients with a good response show dopamine D2 receptor occupancy of more than 65% (Nord and Farde 2010). The occurrence of EPS seems to be related to a higher occupancy of dopamine D2 receptors (above 80%). Atypical antipsychotics, also called second generation antipsychotic drugs, have clinical approvals for the treatment of psychosis and mania. Each drug has a unique pharmacodynamic and pharmacokinetic profile. Some of atypical antipsychotic drugs have additional antidepressant, anxiolytic or hypnotic profile (Schwartz and Stahl 2011). Atypical antipsychotic drugs have in common a potent serotonin 5-HT2A receptor antagonism in relation to a weaker dopamine D2 receptor antagonism. This pharmacodynamic property is the basis of “atypicality” (Meltzer 1989). Antagonism of 5-HT2A receptors likely allows more dopamine activity and neurotransmission to occur in the nigrostriatal system to avoid EPS. The same mechanism may allow small improvement in negative symptoms, and 5-HT2 antagonism in the tuberoinfundibular pathway may help to avoid hyperprolactinemia (Schwartz and Stahl 2011).


The atypical antipsychotics have not fulfilled the initial expectations of improved negative symptoms and cognitive dysfunctions in schizophrenia. Therefore, more molecular targets are presently under investigation for the development of new drugs for the treatment of schizophrenia (Gray and Roth 2007; Schizophrenia Research Forum 2007).


Dopaminergic D3 receptors are localized in limbic cortex and thus a preferential blockade of these receptors offers locally selective antidopaminergic activity. This results in increased effectiveness in reducing positive symptoms of schizophrenia sparing the blockade of extrapyramidal system and therefore reduces the risk of the main side effect such as pseudoparkinson's syndrome. Moreover, several preclinical data suggests that D3 dopamine receptor antagonism is more efficient in reducing the negative symptoms of schizophrenia and improves working memory.


Agonism or partial agonism of 5-HT1A receptors is considered a possible mechanism associated with the activity of some atypical antipsychotics such as aripiprazole and ziprasidone. It is assumed that stimulation of 5-HT1A receptors takes part in the antipsychotic effect in combination with D2 receptor blockade, especially in the safety profile of drug as well as is beneficial in fighting mood and cognitive symptoms of schizophrenia (Kim D., Building a Better Antipsychotic: Receptor Targets for the Treatment of Multiple Symptom Dimensions of Schizophrenia, Neurotherapeutics, 6(1), 78-85, 2009).


Serotoninergic receptors type 5-HT6 are exclusively localized in the central nervous system (CNS). Both the localization of the 5-HT6 receptors in limbic and cortical brain areas and relatively potent affinity and antagonistic activity of several antipsychotics (clozapine, olanzapine, sertindole) and antidepressants (mianserin, amitryptiline) at 5-HT6 receptors are suggestive of a potential role in pathophysiology and treatment of CNS disorders. Recent data in the literature indicate that blockade of 5-HT6 receptors may be implicated in a pro-cognitive effect due to the increase in cholinergic transmission, in antidepressant activity due to the increase in noradrenergic and dopaminergic one, as well as in an anxiolytic effect. It is evident that the 5-HT6 receptor has emerged as a very interesting molecular target and antagonists of that receptor may serve as potential drugs in treatment of disorders characterized by cognitive impairments, such as Alzheimer's disease, schizophrenia, depression, anxiety is (Liu K. i Robichaud A., 5-HT6 Antagonists as Potential Treatment for Cognitive Dysfunction, 2009; Wesotowska A. i Nikiforuk A., Effects of the brain-penetrant and selective 5-HT6 receptor antagonist SB-399885 in animal models of anxiety and depression, 2007). Moreover, 5-HT6 receptor antagonists have been demonstrated to be active in reduction of food intake and body weight by clinically approved mechanism that is consistent with an enhancement of satiety. Hence, several compounds with 5-HT6 receptor antagonistic activity are currently being clinically evaluated for the treatment of obesity (Heal D. et al., Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders, 2008).


Intensive research conducted since 1993 indicates that serotoninergic 5-HT7 receptors may play some role in the control of circadian rhythms, sleep, thermoregulation, cognitive processes, pain and migraine, as well as in neuronal excitability. Potent affinity and antagonistic activity of several antipsychotic and antidepressant drugs at 5-HT7 receptors suggest a potential role of these receptors in the pathophysiology of many neuropsychiatric disorders. Taking account of the behavioral data presented in the literature, it has been established that selective 5-HT7 receptor antagonists produce antidepressant and anxiolytic activity in rats and mice (Wesotowska A. et al., Effect of the selective 5-HT7 receptor antagonist SB-269970 in animal models of anxiety and depression, 2006). Using mouse models of antipsychotic activity, Galici et al. showed that a selective 5-HT7 receptor antagonist SB-269970 may also evoke antipsychotic-like effects (Galici R. et al., Effects of SB-269970, a 5-HT7 receptor antagonist, in mouse models predictive of antipsychotic-like activity, 2008).


Serotoninergic 5-HT2C and histaminergic H1 receptors localized in hypothalamus play an important role in food intake regulation. Blockade of both types of these receptors produced by antipsychotic drugs is most closely correlated with an increased risk of weight gain and diabetes. On the other hand, blockade of 5-HT2C receptors, mostly localized in cortical areas and in the hippocampus, striatum, septal nuclei, thalamic and midbrain nuclei, may produce profitable antidepressant and pro-cognitive effects. In the substantia nigra, 5-HT2C receptors are co-localised with GABA, indicating that they so yield indirect control of dopaminergic transmission. Consequently, the blockade of 5-HT2C receptors, together with the 5-HT2A receptor one, would potentiate the D2 receptor-mediated tonic inhibitory control of dopaminergic projection, with protective effect against extrapyramidal symptoms (Kim D., Building a Better Antipsychotic: Receptor Targets for the Treatment of Multiple Symptom Dimensions of Schizophrenia, 2009). Histaminergic H1 receptor blockade produced by antipsychotic drugs may be implicated in sedative effect that is clinically profitable in controlling arousal accompanies the acute phase of psychosis. It seems that simultaneous reduction in affinity of new molecule for both types of these receptors may be an element that protects against excessive body weight. However, the total elimination of affinity for these receptors may not be necessary because of certain benefits of blockade of 5-HT2C and H1 receptors.


Blockade of alpha1 adrenergic receptors, despite potential peripheral adverse effects involving hypotension, may cause some central nervous system benefits involving decrease in the risk of extrapyramidal side effects caused be antipsychotics. This may be associated with interaction between noradrenergic and serotoninergic neurons (Horacek J. et al., Mechanism of Action of Atypical Antipsychotic Drugs and the Neurobiology of Schizophrenia, CNS Drugs, 20(5), 389-409, 2006).


Blockade of alpha2 adrenergic receptors potentiates antidepressants-induced increase of extracellular monoamines. This may suggest that substances inhibiting monoamine transporters and simultaneously blocking alpha2 adrenergic receptors may be potent and fast acting new antidepressants. Moreover, alpha2 antagonists potentiate acetylcholine secretion in the frontal cortex and may improve cognitive functions, what may provide additional advantages both in antidepressant therapy and antipsychotic therapy (especially improvement in negative symptoms). Blockade of alpha2 adrenergic receptors may also counteract sexual dysfunctions caused by serotonin reuptake inhibitors (Millan M., Dual- and Triple-Acting Agents for Treating Core and Co-morbid Symptoms of Major Depression: Novel Concepts, New Drugs, 2009). Alpha2 antagonists may also be beneficial in reducing extrapyramidal symptoms caused by blockade of D2 receptors in the striatum.


Sigma receptors are a separate group of CNS receptors; however their physiological role is still unknown. It has been shown that some psychotomimetic substances like phencyclidine, metamphetamine, heroin or dextrometorphan are potent sigma receptor agonist. On the other hand, a classic antipsychotic drug, haloperidol, is a strong antagonist of sigma receptors, what may be important for its antipsychotic potential. It has been established that selective sigma receptor agonists may produce antidepressant effect (Cobos E. et al., Pharmacology and Therapeutic Potential of Sigma Receptor Ligands, 2008). The above findings provide evidence that sigma receptors affinity may contribute to the overall beneficial pharmacological profile of a new psychotropic drug. Because of important role of cholinergic system in the cognitive processes, current research is focused on substances which can directly or indirectly potentiate the activity of cholinergic system. This includes substances which are agonists of selected subtypes of nicotinic or muscarinic receptors and antagonists of 5-HT6 receptors. On the other hand, potential procognitive effects evoked by interaction with the above receptors may be masked by cholinolytic activity. Thus, in the scope of interest are substances free of antagonistic properties against cholinergic receptors. Moreover this strategy allows elimination of many undesired peripheral autonomic effects like constipations, dry mouth or tachycardia (Miamoto S., Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs, 2005). In addition, it has been found that M3 muscarinic receptors are engaged in the control of insulin secretion, and their activation stimulates pancreas to secrete insulin. Hence, it can be expected that M3 receptors blockade may be unfavorable in terms of the risk of development of type II diabetes in patients treated with second generation antipsychotics (ex. olanzapine, clozapine, quetiapine). Recent research is focused on substances free of this undesired effect (Silvestre J. i Prous J., Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes, 2005).


Another serious side effects caused by antipsychotic drugs, e.g. sertindole, ziprasidone, are cardiac arrhythmias associated with delayed repolarization of cardiomyocytes. This condition appears on electrocardiograms (ECG) as prolonged corrected QT interval (QTc), what is most often evoked by substances which block hERG potassium channels.


To prevent introduction to the developmental pipelines drugs with pro-arrhythmic potential, at a very early stage of research new substances are screened in vitro for their potency to block hERG potassium channels, using electrophysiological methods (Recanatni M., QT Prolongation Through hERG K+ Channel Blockade: Current Knowledge and Strategies for the Early Prediction During Drug Development, 2005).


Despite the advances that have been made in the development of antidepressants, there are clearly still unmet clinical needs with respect to both efficacy and side effects. These needs range from efficacy in treatment resistant patients (about 30%) to improved onset, to reductions in side effects such as sexual dysfunction, gastrointestinal events, sedation, weight gain. There are multiple approaches to improve current pharmacological means of modulating biogenic amines neurotransmission by either combining mechanisms or alternatively selectively stimulating/blocking receptor subtypes that may trigger improved efficacy or fewer side effects. One of them is combination therapies that maintain the benefits associated with selective serotonin reuptake inhibitors (SSRIs) (blockers of serotonin transporter) but attempt to either improve efficacy or reduce side effects by adding additional mechanism involving blockade of 5-HT2A or 5-HT2C receptors (Millan M., Dual- and Triple-Acting Agents for Treating Core and Co-morbid Symptoms of Major Depression: Novel Concepts, New Drugs, Neurotherapeutics, 6(1), 53-77, 2009). 5-HT2A receptor antagonists administered alone may produce antidepressant activity and also co-administered with SSRIs augment their antidepressant effects. The mechanism for this interaction may be a further increase in extracellular serotonin levels produced when SSRIs are given with 5-HT2A antagonists. Moreover, blockade of 5-HT2A receptors is part of the pharmacological profile of antidepressant drugs such as mianserin and mirtazapine. Presynaptic 5-HT1A receptors are associated with the risk for depressive behavior and their blockade augments the effects of SSRIs. Postsynaptic 5-HT1A receptors are essential for producing the antidepressant effects of 5-HT1A receptor agonists and possibly SSRIs. Thus partial agonism of 5-HT1A receptors is a preferred feature for new molecules the more that this mechanism occurs in approved anxiolytic buspirone and antidepressant/anxiolytic tandospirone.


Although introduction of new psychotropic drugs (among others narcoleptics, antidepressants, benzodiazepines, acetylocholinesterase inhibitors) since 50-thies of the XX century was an unquestioned breakthrough, therapy of neuropsychiatric disorders is still far from satisfactory both because of limited efficacy and wide spectrum of side effects evoked by available drugs. These disadvantages are a challenge for modern pharmacotherapy and there is a continuous effort to search for new, more effective psychotropic drugs.


Arylsulphonamide derivatives potentially useful for treating cardiovascular diseases, such as angina pectoris, cerebral circulation disorder and thrombosis, were described in the publication of European patent application EP0330065A. Disclosed compounds had aromatic ring, for instance phenyl, naphthyl or pyridil, bound to piperazine ring.




embedded image


Publication of International patent application WO98/43956 discloses 1,4-disubstituted cyclic amines of the following formula wherein cyclic amine can be linked to bicyclic system.




embedded image


Derivatives mentioned above were described as having antagonistic activity toward serotoninergic receptors and featuring absent or very low affinity toward alpha adrenergic receptors.


In the publication of International patent application WO2004/069794 arylsulphonamide derivatives of the following formula were described as 5-HT1A receptor agonists, having very high activity and selectivity and low or absent cross-reactivity with other receptors.




embedded image


The publication of European patent application EP190472A discloses compounds having antipsychotic activity of the general formula presented below.




embedded image


Derivatives of cyclic amines, including derivatives having arylsulphonamide moieties were described in scientific papers as well.


In publication of Ishizumi K. et al. Chem. Pharm. Bull. 43 (12), 2139-2151, 1995, directed to research on structure-activity relationship for succinimide derivatives, a compound of the following structure was disclosed:




embedded image


The compound was proposed as a structural modification of another compound, N-[4-[4 (1,2-benzoxazol-3-yl)-1-piperazinyl]butyl]-1,2-cis-cyclohexanedicarboxylmide (Perospiron, SM-9018), showing high affinity toward 5-HT2 and D2 receptors. Reportedly, replacement of succinimide with 4-methylbenzenesulphonamide moiety resulted however in decrease of affinity toward receptors mentioned above, in particular toward D2 receptor.


Similarly as in the publication mentioned above, also article of Navas F. et al., Bioorg. Med. Chem. 6 (1998), 811-823 related to structure-activity relationship research. A compound of the following formula was disclosed:




embedded image


It was found that replacement of amide group with sulphonamide moiety as in the disclosed compound resulted in considerable decrease of affinity toward serotoninergic 5-HT1A and dopaminergic D2 receptors.


Publication of Forbes I. T. et al., Bioorg. Med. Chem. Lett. 10 (2000) 1803-1806 disclosed indolopiperidine derivatives having antagonistic activity toward chemokine receptor CCR2B, potentially useful for the treatment of diseases of inflammatory origin, such as atherosclerosis and rheumatoid arthritis. Among tested derivatives 3,4-dichloro-N-{[4-(1H-indol-3-yl)piperidin-1-yl]pentyl}benzensulphonamide of the following formula was disclosed:




embedded image


However, the above publication did not suggest that this compound could possess activity toward therapeutic targets related to treatment of diseases of central nervous system.


Extended affinity of N-{4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl}benzene-sulphonamide toward 5-HT1A, 5-HT2A, 5-HT6, 5-HT7, α1 and dopaminergic D2 receptors was disclosed by R. Bugno et al., in the poster “Examination of 5-HT6 receptor affinity in the group of arylsulfonamide derivatives” published on May 10, 2010 during The Seventh Multidiscliplinary Conference on Drug Research, May 9-12, 2010, Zakopane, Poland.


AIM OF THE INVENTION

The aim of the present invention is to provide novel compounds potentially useful for the treatment of diseases of the central nervous system. A further aim of the invention is to provide novel compounds useful for the treatment of diseases of central nervous system having higher effectiveness compared to currently used medicaments. Yet further aim of the present invention is to provide novel compounds useful for the treatment of diseases of the central nervous system, which could allow to eliminate or minimize adverse effects associated with currently used therapies.


DISCLOSURE OF THE INVENTION

The present invention relates to novel arylsulphonamide compounds having the structure represented by the general formula (I)




embedded image


and pharmaceutically acceptable salts thereof,


wherein:


E represents N, C or CH;

custom-character represents single bond or double bond;


n represents an integer from 2 to 6, inclusive;


A represents a 9- or 10-membered bicyclic group, consisting of benzene ring fused with a 5- or 6-membered heterocyclic ring, which group is linked to E through one of its carbon atoms and has the following formula (A):




embedded image


wherein

    • X represents CR5, C(R5)2, NH or O;
    • Z represents CR5, C(R5)2, or N;
    • R5 represents hydrogen atom, halogen atom or C1-C4-alkyl;
    • Y represents NH, O or S;
    • each of R1, R2, R3, and R4 independently represents hydrogen atom or halogen atom;
    • each of R6 and R7 independently represents hydrogen atom, halogen atom or C1-C4-alkyl;
    • or R5 and R7 together form ═O;
    • custom-character represents single bond or double bond;
    • m is 0 or 1;
    • q is 0 or 1;
    • wherein at least one of q and m is 1;


      D is selected from:
    • unsubstituted phenyl or phenyl substituted with one or more substituents independently selected from the group consisting of branched C1-C4-alkyl, straight C1-C4-alkyl in ortho or meta position with respect to sulphonamide group, C1-C3-alkyloxy, halogeno-C1-C3-alkyl, halogeno-C1-C3-alkyloxy, halogen atom, —CN, —OH, and phenyl;
    • unsubstituted naphthyl or naphthyl substituted with one or more substituents independently selected from the group consisting of C1-C4-alkyl, C1-C3-alkyloxy, halogeno-C1-C3-alkyl, halogen atom, —CN, —OH, and phenyl;
    • a 5-membered aromatic heterocyclic group having 1 to 3 heteroatoms independently selected from the group consisting of N, O and S, which is unsubstituted or substituted with one or more substituents independently selected from the group consisting of C1-C4-alkyl, C1-C3-alkyloxy, halogeno-C1-C3-alkyl, halogen atom, —CN, —OH, and phenyl;
    • a bicyclic group consisting of a ring selected from benzene and pyridine fused with a 5-membered aromatic or non-aromatic heterocyclic ring having 1 to 3 heteroatoms independently selected from the group consisting of N, O, S, said bicyclic group being unsubstituted or substituted with one or more substituent independently selected from the group consisting of C1-C4-alkyl, C1-C3-alkyloxy, halogeno-C1-C3-alkyl, halogen atom, ═O, —CN, —OH, and phenyl;
    • a bicyclic group consisting of a ring selected from benzene and pyridine fused with a 6-membered non-aromatic heterocyclic ring having 1 to 3 heteroatoms independently selected from the group consisting of N, O, and S, said bicyclic group being unsubstituted or substituted with one or more substituents independently selected from the group consisting of C1-C4-alkyl, C1-C3-alkyloxy, halogeno-C1-C3-alkyl, halogen atom, ═O, —CN, —OH, and phenyl;


      with the proviso that 3,4-dichloro-N-{[4-(1H-indol-3-yl)piperidin-1-yl]pentyl}benzenesulphonamide and N-{4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl}benzenesulphonamide are excluded.


In one embodiment of the compounds of the present invention group A is linked to E through carbon atom of benzene ring.


In an alternative embodiment of the compounds of the present invention group A is linked to E through carbon atom of heterocyclic ring.


It will be appreciated by a person skilled in the art that respective substituent R1, R2, R3, R4, R5, R6 or R7 at the carbon atom through which group A is linked to E is absent and is replaced by a bond.


According to one of the variants, compounds of the present invention have the formula (I), wherein in group A custom-character represents double bond, q is 0, X represents C(R5), and Z represents N. In these compounds A corresponds to the following general formula (A1), wherein Y, R1, R2, R3, R4 and R5 have the same meanings as defined above, and which is specific variant of the formula (A):




embedded image


Group of formula (A1) may be linked to E through carbon atom of phenyl ring or through carbon atom of 5-membered heterocyclic ring.


Preferably, in the above variant (A1) represents 1,2-benzothiazol-3-yl or 1,2-benzoxazol-3-yl, which may be optionally substituted with halogen atom.


Further variant of the compounds of the present invention are compounds of formula (I), wherein in group A custom-character represents double bond, q is 0, X represents C(R5), and Z represents C(R5). In these compounds A corresponds to the following general formula (A2), wherein Y, R1, R2, R3, R4 and R5 have meanings as defined above, and which is specific variant of the formula (A)




embedded image


Group of formula (A2) may be linked to E through carbon atom of phenyl ring or through carbon atom of 5-membered heteroaromatic ring.


Preferably, in the above variant (A2) represents 1H-indol-3-yl, 2-(C1-C4-alkyl)-1H-indol-3-yl or 1H-indol-4-yl, which may be optionally substituted with halogen atom.


Another variant of the compounds of the present invention are compounds of formula (I), wherein in group A custom-character represents single bond, and m is 0. In these compounds A corresponds to the following general formula (A3), wherein X, Y, R1, R2, R3, R4, R6 and R7 have the meanings as defined above, and which is specific variant of the formula (A):




embedded image


Group of formula (A3) may be linked to E through carbon atom of phenyl ring or through carbon atom of heterocyclic ring.


Preferably, in the above variant (A3) represents 2-oxo-2,3-dihydro-1H-benzimidazol-4-yl, 2-oxo-2,3-dihydro-1,3-benzoxazol-4-yl, 2-oxo-2,3-dihydro-1,3-benzoxazol-7-yl, 2-oxo-2,3-dihydro-1H-indol-4-yl, 2,2-dimethyl-1,3-benzodioxol-4-yl, or 2,2-difluoro-1,3-benzodioxol-4-yl.


Yet another variant of the compounds of the present invention are compounds of formula (I), wherein in group A custom-character represents single bond, m is 1, q is 1, and Z represents CH2. In these compounds A corresponds to the following general formula (A4), wherein X, Y, R1, R2, R3, R4, R6 and R7 have the meanings as defined above, and which is specific variant of the formula (A):




embedded image


Group of formula (A4) may be linked to E through carbon atom of phenyl ring or through carbon atom of 6-membered heterocyclic ring.


Preferably, in the above variant (A4) represents 1,4-benzodioxan-5-yl or 3-okso-3,4-dihydro-2H-1,4-benzoxazin-8-yl.


One of further embodiments of the compounds of the present invention are compounds of formula (I), wherein E represents nitrogen atom. It will be therefore obvious that in such a case custom-character in formula (I) will represent single bond.


Another embodiment of compounds of the present invention are compounds of formula (I), wherein E represents CH. It will be therefore obvious that in such a case custom-character in formula (I) will represent single bond.


Further embodiment of the compounds of the present invention are compounds (I), wherein E represents C, and thus custom-character in formula (I) represents double bond.


Another sub-group of compounds of the invention are compounds of formula (I) wherein D represents phenyl. Phenyl may be unsubstituted or substituted as defined for substituent D above, for example with one or more substituent independently selected the group consisting of straight C1-C4-alkyl in position ortho or meta with respect to sulphonamide group, halogen atom, —CN, —OH, and phenyl;


Yet another sub-group of the compounds of the invention are compounds of formula (I), wherein D represents naphthyl. Naphthyl may be linked to sulphur atom of sulphonamide moiety in position 1 (alpha) or 2 (beta) of naphthyl ring. Naphthyl may be unsubstituted or substituted, as defined for substituent D above, for example with halogen atom.


Yet another group of compounds of the present invention are compounds of formula (I), wherein D represents a 5-membered aromatic heterocyclic group having 1 to 3 heteroatoms independently selected from the group consisting of N, O and S. Preferred aromatic heterocyclic group is thienyl, that is heteroatom represents sulphur atom. 5-Membered aromatic heterocyclic group may be unsubstituted or substituted as defined for substituent D above.


Another sub-group of the compounds of the present invention are compounds of formula (I), wherein D represents a bicyclic group consisting of benzene ring fused with 5-membered aromatic heterocyclic ring having 1 to 3 heteroatoms independently selected from the group consisting of N, O, and S. This bicyclic group may be unsubstituted or substituted as defined above for substituent D, for instance with halogen atom and/or C1-C4-alkyl. Preferably, bicyclic group is selected from the group consisting of 1-benzothiophen-3-yl, 1-benzothiophen-2-yl, 1-benzofuran-2-yl, 1-benzofuran-3-yl, 1H-benzimidazol-2-yl, 1H-indol-2-yl, 1H-indol-5-yl, 1H-indol-6-yl, 1H-indazol-7-yl, 1H-indazol-6-yl, 1,2-benzoxazol-5-yl, 1,3-benzoxazol-4-yl, 1,3-benzothiazol-4-yl, and 1,3-benzothiazol-5-yl.


Further sub-group of the compounds of the present invention are compounds of formula (I), wherein D represents bicyclic group consisting of pyridine ring fused with 5-membered heterocyclic aromatic ring having 1 to 3 heteroatoms independently selected from the group consisting of N, O, and S. This bicyclic group may be unsubstituted or substituted as defined above for substituent D, for instance with halogen atom and/or C1-C4-alkyl. Preferably, bicyclic group is selected from the group consisting of imidazo[1,2-a]-pyridin-3-yl and 1H-pyrrolo[2,3-b]-pyridin-3-yl.


Yet another sub-group of the compounds of the present invention are compounds of formula (I), wherein D represents bicyclic group consisting of benzene ring fused with a 5-membered non-aromatic heterocyclic ring having 1 to 3 heteroatoms independently selected from the group consisting of N, O, and S. This bicyclic group may be unsubstituted or substituted as defined above for substituent D. Preferred bicyclic group is selected from the group consisting of 2,3-dihydro-1-benzofuran-5-yl, 2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl, 2-oxo-1,3-dihydro-2H-indol-5-yl and 1,3-benzodioxol-5-yl.


Yet another sub-group of the compounds of the present invention are compounds of formula (I), wherein D represents bicyclic group consisting of benzene ring, fused with 6-membered non-aromatic heterocyclic ring having from 1 to 3 heteroatoms independently selected from the group consisting of N, O, and S. This bicyclic group may be unsubstituted or substituted as defined above for substituent D. Preferred bicyclic group is 2,3-dihydro-1,4-benzodioxine-6-yl.


Further sub-group of the compounds of the present invention are compounds of formula (I), wherein A represents group of formula (A2) linked to E through carbon atom of heterocyclic ring; E represents CH; and D represents phenyl substituted with one or more halogen atoms.


Another sub-group of the compounds of the present invention are compounds of formula (I), wherein A represents group of formula (A1) wherein Y represents O linked to E through carbon atom of heterocyclic ring; E represents N; and D represents unsubstituted phenyl or phenyl substituted with one or more substituents independently selected from the group as defined for formula (I).


Another sub-group of the compounds of the present invention are compounds of formula (I), wherein n is 2.


Further sub-group of compounds of the present invention are compounds of formula (I), wherein n is 3.


Further sub-group of the compounds of the present invention are compounds of formula (I), wherein n is 4.


The following specific compounds of formula (I) of the invention can be mentioned:

  • 1) N-(4-(4-(1,2-benzothiazol-3-yl)piperazin-1-yl)butyl)naphthalene-1-sulphonamide,
  • 2) N-(4-(4-(1,2-benzothiazol-3-yl)piperazin-1-yl)butyl)naphthalene-2-sulphonamide,
  • 3) N-(4-(4-(1,2-benzothiazol-3-yl)piperazin-1-yl)butyl)-3-methylbenzenesulphonamide,
  • 4) N-(4-(4-(1,2-benzothiazol-3-yl)piperazin-1-yl)butyl)-2-oxo-3H-1,3-benzoxazole-6-sulphonamide,
  • 5) N-(3-(4-(1,2-benzothiazol-3-yl)piperazin-1-yl)propyl)naphthalene-1-sulphonamide,
  • 6) N-(3-(4-(1,2-benzothiazol-3-yl)piperazin-1-yl)propyl)naphthalene-2-sulphonamide,
  • 7) N-(3-(4-(1,2-benzothiazol-3-yl)piperazin-1-yl)propyl)-3-methylbenzenesulphonamide,
  • 8) N-(3-(4-(1,2-benzothiazol-3-yl)piperazin-1-yl)propyl)-2-oxo-3H-1,3-benzoxazole-6-so sulphonamide,
  • 9) N-(2-(4-(1,2-benzothiazol-3-yl)piperazin-1-yl)ethyl)naphthalene-1-sulphonamide,
  • 10) N-(2-(4-(1,2-benzothiazol-3-yl)piperazin-1-yl)ethyl)naphthalene-2-sulphonamide,
  • 11) N-(2-(4-(1,2-benzothiazol-3-yl)piperazin-1-yl)ethyl)-3-methylbenzenesulphonamide,
  • 12) N-(2-(4-(1,2-benzothiazol-3-yl)piperazin-1-yl)ethyl)-2-oxo-3H-1,3-benzoxazole-6-sulphonamide,
  • 13) N-(4-(4-(1,2-benzoxazol-3-yl)piperazin-1-yl)butyl)naphthalene-1-sulphonamide,
  • 14) N-(4-(4-(1,2-benzoxazol-3-yl)piperazin-1-yl)butyl)naphthalene-2-sulphonamide,
  • 15) N-(4-(4-(1,2-benzoxazol-3-yl)piperazin-1-yl)butyl)-3-methylbenzenesulphonamide,
  • 16) N-(4-(4-(1,2-benzoxazol-3-yl)piperazin-1-yl)butyl)-2-oxo-3H-1,3-benzoxazole-6-sulphonamide,
  • 17) N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]naphthalene-1-sulphonamide,
  • 18) N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]naphthalene-2-sulphonamide,
  • 19) N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-3-methylbenzenesulphonamide,
  • 20) N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]naphthalene-1-sulphonamide,
  • 21) N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]naphthalene-2-sulphonamide,
  • 22) N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-3-methylbenzene-sulphonamide,
  • 23) N-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]naphthalene-1-sulphonamide,
  • 24) N-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]naphthalene-2-sulphonamide,
  • 25) N-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-3-methylbenzenesulphonamide,
  • 26) N-{4-[4-(1H-indol-4-yl)piperazin-1-yl]butyl}naphthalene-2-sulphonamide,
  • 27) N-{4-[4-(1H-indol-4-yl)piperazin-1-yl]butyl}benzenesulphonamide,
  • 28) 3-fluoro-N-{4-[4-(1H-indol-4-yl)piperazin-1-yl]butyl}benzenesulphonamide,
  • 29) 3,4-difluoro-N-{4-[4-(1H-indol-4-yl)piperazin-1-yl]butyl}benzenesulphonamide,
  • 30) N-{4-[4-(1H-indol-4-yl)piperazin-1-yl]butyl}-imidazo[1,2-a]pyridine-3-sulphonamide,
  • 31) N-{4-[4-(1H-indol-4-yl)piperazin-1-yl]butyl}-1H-pyrrolo[2,3-b]pyridine-3-sulphonamide,
  • 32) N-{4-[4-(1H-indol-4-yl)piperazin-1-yl]butyl}-1-benzothiophene-3-sulphonamide,
  • 33) N-{4-[4-(1H-indol-4-yl)piperazin-1-yl]butyl}-1-benzothiophene-2-sulphonamide,
  • 34) N-{4-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]butyl}naphthalene-1-sulphonamide,
  • 35) N-{4-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]butyl}naphthalene-2-sulphonamide,
  • 36) 4-fluoro-N-{4-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]butyl}benzenesulphonamide,
  • 37) 3-fluoro-N-{4-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]butyl}benzenesulphonamide,
  • 38) 4-chloro-N-{4-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]butyl}benzenesulphonamide
  • 39) 3-chloro-N-{4-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]butyl}benzenesulphonamide,
  • 40) 3-methyl-N-{4-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]butyl}benzenesulphonamide,
  • 41) 3-hydroxy-N-{4-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]butyl}benzenesulphonamide,
  • 42) 4-methoxy-N-{4-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]butyl}benzenesulphonamide
  • 43) N-{3-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]propyl}naphthalene-1-sulphonamide,
  • 44) N-{3-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]propyl}naphthalene-2-sulphonamide,
  • 45) 4-fluoro-N-{3-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]propyl}benzenesulphonamide,
  • 46) 3-fluoro-N-{3-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]propyl}benzenesulphonamide,
  • 47) 4-chloro-N-{3-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]propyl}benzenesulphonamide,
  • 48) 3-chloro-N-{3-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]propyl}benzenesulphonamide,
  • 49) 3-hydroxy-N-{3-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]propyl}benzenesulphonamide,
  • 50) N-{2-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]ethyl}naphthalene-1-sulphonamide,
  • 51) N-{2-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]ethyl}naphthalene-2-sulphonamide,
  • 52) N-{2-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]ethyl}-4-fluorobenzene-sulphonamide,
  • 53) 3-fluoro-N-{2-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]ethyl}benzenesulphonamide,
  • 54) 4-chloro-N-{2-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]ethyl}benzenesulphonamide,
  • 55) 3-chloro-N-{2-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]ethyl}benzene-sulphonamide,
  • 56) 3-methyl-N-{2-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]ethyl}benzenesulphonamide,
  • 57) 3-hydroxy-N-{2-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]ethyl}benzenesulphonamide,
  • 58) 4-chloro-N-{4-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]-butyl}benzenesulphonamide,
  • 59) 7-chloro-N-{4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl}naphthalene-2-sulphonamide,
  • 60) 7-chloro-N-{3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl}naphthalene-2-sulphonamide,
  • 61) 6-chloro-N-{4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl}naphthalene-2-sulphonamide,
  • 62) 6-chloro-N-{3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl}naphthalene-2-sulphonamide,
  • 63) 3-chloro-4-fluoro-N-{4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl}benzenesulphonamide,
  • 64) 3-chloro-4-fluoro-N-{3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl}benzenesulphonamide,
  • 65) 5-fluoro-3-methyl-N-{4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl}-1-benzothiophene-2-sulphonamide,
  • 66) 5-fluoro-3-methyl-N-{3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl}-1-benzothiophene-2-sulphonamide,
  • 67) 5-chloro-N-{4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl}-1-benzothiophene-2-sulphonamide,
  • 68) 5-chloro-N-{3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl}-1-benzothiophene-2-sulphonamide,
  • 69) 3-chloro-N-{4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl}benzenesulphonamide,
  • 70) 3-chloro-N-{3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl}benzenesulphonamide,
  • 71) 3-fluoro-N-{4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl}benzenesulphonamide,
  • 72) 3-fluoro-N-{3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl}benzenesulphonamide,
  • 73) 3-cyano-N-{4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl}benzenesulphonamide,
  • 74) 3-cyano-N-{3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl}benzenesulphonamide,
  • 75) N-{4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl}-imidazo[1,2-a]pyridine-3-sulphonamide,
  • 76) N-{3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl}-imidazo[1,2-a]pyridine-3-sulphonamide,
  • 77) 7-chloro-N-{4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl}naphthalene-2-sulphonamide,
  • 78) 7-chloro-N-{3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl}naphthalene-2-sulphonamide,
  • 79) 6-chloro-N-{4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl}naphthalene-2-sulphonamide,
  • 80) 6-chloro-N-{3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl}naphthalene-2-sulphonamide,
  • 81) 5-fluoro-3-methyl-N-{4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl}-1-benzothiophene-2-sulphonamide,
  • 82) 5-fluoro-3-methyl-N-{3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl}-1-benzo-thiophene-2-sulphonamide,
  • 83) 5-chloro-N-{4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl}-1-benzothiophene-2-sulphonamide,
  • 84) 5-chloro-N-{3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl}-1-benzothiophene-2-sulphonamide,
  • 85) 3-chloro-N-{4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl}benzenesulphonamide,
  • 86) 3-chloro-N-{3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl}benzenesulphonamide,
  • 87) 3-fluoro-N-{4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl}benzenesulphonamide,
  • 88) 3-fluoro-N-{3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl}benzenesulphonamide,
  • 89) N-{4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl}-1H-pyrrolo[2,3-b]pyridine-3-sulphonamide,
  • 90) N-{3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl}-1H-pyrrolo[2,3-b]pyridine-3-sulphonamide,
  • 91) 3-trifluoromethyl-N-{4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl}benzenesulphonamide
  • 92) 3-trifluoromethyl-N-{3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl}benzenesulphonamide,
  • 93) 3,4-dichloro-N-{4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl}benzenesulphonamide,
  • 94) 3,4-dichloro-N-{3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl}benzenesulphonamide,
  • 95) 7-chloro-N-{4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl}naphthalene-2-sulphonamide,
  • 96) 7-chloro-N-{3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl}naphthalene-2-sulphonamide,
  • 97) 6-chloro-N-{4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl}naphthalene-2-sulphonamide,
  • 98) 6-chloro-N-{3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl}naphthalene-2-sulphonamide,
  • 99) N-{4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl}-1H-benzimidazole-2-sulphonamide,
  • 100) N-{3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl}-1H-benzimidazole-2-sulphonamide,
  • 101) 5-fluoro-3-methyl-N-{4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl}-1-benzothiophene-2-sulphonamide,
  • 102) 5-fluoro-3-methyl-N-{3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl}-1-benzothiophene-2-sulphonamide,
  • 103) 5-chloro-N-{4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl}-1-benzothiophene-2-sulphonamide,
  • 104) 5-chloro-N-{3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl}-1-benzothiophene-2-sulphonamide,
  • 105) 3-chloro-N-{4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl}benzenesulphonamide,
  • 106) 3-chloro-N-{3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl}benzenesulphonamide,
  • 107) 3-fluoro-N-{4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl}benzenesulphonamide,
  • 108) 3-fluoro-N-{3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl}benzenesulphonamide,
  • 109) 3-bromo-N-{4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl}benzenesulphonamide,
  • 110) 3-bromo-N-{3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl}benzenesulphonamide,
  • 111) 4-phenyl-N-{4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl}benzenesulphonamide,
  • 112) 4-phenyl-N-{3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl}benzenesulphonamide,
  • 113) 3-chloro-N-{4-[4-(1H-indol-4-yl)piperazin-1-yl]butyl}benzenesulphonamide,
  • 114) 3-chloro-N-{3-[4-(1H-indol-4-yl)piperazin-1-yl]propyl}benzenesulphonamide,
  • 115) N-{4-[4-(1H-indol-4-yl)piperazin-1-yl]butyl}-1,3-benzothiazole-4-sulphonamide,
  • 116) N-{3-[4-(1H-indol-4-yl)piperazin-1-yl]propyl}-1,3-benzothiazole-4-sulphonamide,
  • 117) 7-chloro-N-{4-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]butyl}-naphthalene-2-sulphonamide,
  • 118) 7-chloro-N-{3-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]propyl}-naphthalene-2-sulphonamide,
  • 119) 6-chloro-N-{4-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]butyl}-naphthalene-2-sulphonamide,
  • 120) 6-chloro-N-{3-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]propyl}-naphthalene-2-sulphonamide,
  • 121) 5-fluoro-3-methyl-N-{4-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]butyl}-1-benzothiophene-2-sulphonamide,
  • 122) 5-fluoro-3-methyl-N-{3-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]propyl}-1-benzothiophene-2-sulphonamide,
  • 123) 5-chloro-N-{4-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]butyl}-1-benzothiophene-2-sulphonamide,
  • 124) 5-chloro-N-{3-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]propyl}-1-benzothiophene-2-sulphonamide,
  • 125) N-{4-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]butyl}-1H-indazole-7-sulphonamide,
  • 126) N-{3-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]propyl}-1H-indazole-7-sulphonamide,
  • 127) 7-chloro-N-{4-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]-butyl}naphthalene-2-sulphonamide,
  • 128) 7-chloro-N-{3-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]-propyl}naphthalene-2-sulphonamide,
  • 129) 6-chloro-N-{4-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]-butyl}naphthalene-2-sulphonamide,
  • 130) 6-chloro-N-{3-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]-propyl}naphthalene-2-sulphonamide,
  • 131) 5-fluoro-3-methyl-N-{4-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]butyl}-1-benzothiophene-2-sulphonamide,
  • 132) 5-fluoro-3-methyl-N-{3-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]propyl}-1-benzothiophene-2-sulphonamide,
  • 133) 5-chloro-N-{4-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]-butyl}-1-benzothiophene-2-sulphonamide,
  • 134) 5-chloro-N-{3-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]-propyl}-1-benzothiophene-2-sulphonamide,
  • 135) N-{4-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]butyl}-1H-indazole-7-sulphonamide,
  • 136) N-{3-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]propyl}-1H-indazole-7-sulphonamide,
  • 137) 3-chloro-N-{4-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]-butyl}benzenesulphonamide,
  • 138) 3-chloro-N-{3-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]-propyl}benzenesulphonamide,
  • 139) 3-fluoro-N-{4-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]-butyl}benzenesulphonamide,
  • 140) 3-fluoro-N-{3-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]-propyl}benzenesulphonamide,
  • 141) 4-tert-butyl-N-{4-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]-butyl}benzenesulphonamide,
  • 142) 4-tert-butyl-N-{4-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]-propyl}benzenesulphonamide,
  • 143) 7-chloro-N-{4-[4-(2-oxo-2,3-dihydro-1,3-benzoxazol-4-yl)piperazin-1-yl]butyl}-naphthalene-2-sulphonamide,
  • 144) 7-chloro-N-{3-[4-(2-oxo-2,3-dihydro-1,3-benzoxazol-4-yl)piperazin-1-yl]propyl}-naphthalene-2-sulphonamide,
  • 145) 6-chloro-N-{4-[4-(2-oxo-2,3-dihydro-1,3-benzoxazol-4-yl)piperazin-1-yl]butyl}-naphthalene-2-sulphonamide,
  • 146) 6-chloro-N-{3-[4-(2-oxo-2,3-dihydro-1,3-benzoxazol-4-yl)piperazin-1-yl]propyl}-naphthalene-2-sulphonamide,
  • 147) 5-fluoro-3-methyl-N-{4-[4-(2-oxo-2,3-dihydro-1,3-benzoxazol-4-yl)piperazin-1-yl]-butyl}-1-benzothiophene-2-sulphonamide,
  • 148) 5-fluoro-3-methyl-N-{3-[4-(2-oxo-2,3-dihydro-1,3-benzoxazol-4-yl)piperazin-1-yl]propyl}-1-benzothiophene-2-sulphonamide,
  • 149) 5-chloro-N-{4-[4-(2-oxo-2,3-dihydro-1,3-benzoxazol-4-yl)piperazin-1-yl]butyl}-1-benzothiophene-2-sulphonamide,
  • 150) 5-chloro-N-{3-[4-(2-oxo-2,3-dihydro-1,3-benzoxazol-4-yl)piperazin-1-yl]propyl}-1-benzothiophene-2-sulphonamide,
  • 151) N-{4-[4-(2-oxo-2,3-dihydro-1,3-benzoxazol-4-yl)piperazin-1-yl]butyl}-1,2-benzoxazole-5-sulphonamide,
  • 152) N-{3-[4-(2-oxo-2,3-dihydro-1,3-benzoxazol-4-yl)piperazin-1-yl]propyl}-1,2-benzoxazole-5-sulphonamide,
  • 153) 3-chloro-N-{4-[4-(2-oxo-2,3-dihydro-1,3-benzoxazol-4-yl)piperazin-1-yl]butyl}benzenesulphonamide,
  • 154) 3-chloro-N-{3-[4-(2-oxo-2,3-dihydro-1,3-benzoxazol-4-yl)piperazin-1-yl]propyl}benzenesulphonamide,
  • 155) 4-trifluoromethyl-N-{4-[4-(2-oxo-2,3-dihydro-1,3-benzoxazol-4-yl)piperazin-1-yl]-butyl}benzenesulphonamide,
  • 156) 4-trifluoromethyl-N-{3-[4-(2-oxo-2,3-dihydro-1,3-benzoxazol-4-yl)piperazin-1-yl]-propyl}benzenesulphonamide,
  • 157) 3-hydroxy-N-{4-[4-(2-oxo-2,3-dihydro-1,3-benzoxazol-4-yl)piperazin-1-yl]butyl}benzenesulphonamide,
  • 158) 3-hydroxy-N-{3-[4-(2-oxo-2,3-dihydro-1,3-benzoxazol-4-yl)piperazin-1-yl]propyl}benzenesulphonamide,
  • 159) 7-chloro-N-{4-[4-(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)piperazin-1-yl]butyl}-naphthalene-2-sulphonamide,
  • 160) 7-chloro-N-{3-[4-(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)piperazin-1-yl]propyl}-naphthalene-2-sulphonamide,
  • 161) 6-chloro-N-{4-[4-(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)piperazin-1-yl]butyl}-naphthalene-2-sulphonamide,
  • 162) 6-chloro-N-{3-[4-(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)piperazin-1-yl]propyl}-naphthalene-2-sulphonamide,
  • 163) 5-fluoro-3-methyl-N-{4-[4-(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)piperazin-1-yl]-butyl}-1-benzothiophene-2-sulphonamide,
  • 164) 5-fluoro-3-methyl-N-{3-[4-(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)piperazin-1-yl]-propyl}-1-benzothiophene-2-sulphonamide,
  • 165) 5-chloro-3-methyl-N-{4-[4-(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)piperazin-1-yl]-butyl}-1-benzothiophene-2-sulphonamide,
  • 166) 5-chloro-3-methyl-N-{3-[4-(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)piperazin-1-yl]-propyl}-1-benzothiophene-2-sulphonamide,
  • 167) 5-chloro-N-{4-[4-(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)piperazin-1-yl]butyl}-1-benzothiophene-2-sulphonamide,
  • 168) 5-chloro-N-{3-[4-(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)piperazin-1-yl]propyl}-1-benzothiophene-2-sulphonamide,
  • 169) N-{4-[4-(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)piperazin-1-yl]butyl}-1,3-benzoxazole-4-sulphonamide,
  • 170) N-{3-[4-(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)piperazin-1-yl]propyl}-1,3-benzoxazole-4-sulphonamide,
  • 171) 4-cyano-N-{4-[4-(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)piperazin-1-yl]butyl}benzenesulphonamide,
  • 172) 4-cyano-N-{3-[4-(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)piperazin-1-yl]propyl}benzenesulphonamide,
  • 173) 3-chloro-N-{4-[4-(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)piperazin-1-yl]butyl}benzenesulphonamide,
  • 174) 3-chloro-N-{3-[4-(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)piperazin-1-yl]propyl}benzenesulphonamide,
  • 175) 3-fluoro-N-{4-[4-(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)piperazin-1-yl]butyl}benzenesulphonamide,
  • 176) 3-fluoro-N-{3-[4-(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)piperazin-1-yl]propyl}benzenesulphonamide,
  • 177) 7-chloro-N-{4-[4-(2-oxo-2,3-dihydro-1,3-benzoxazol-7-yl)piperazin-1-yl]butyl}-naphthalene-2-sulphonamide,
  • 178) 7-chloro-N-{3-[4-(2-oxo-2,3-dihydro-1,3-benzoxazol-7-yl)piperazin-1-yl]propyl}-naphthalene-2-sulphonamide,
  • 179) 6-chloro-N-{4-[4-(2-oxo-2,3-dihydro-1,3-benzoxazol-7-yl)piperazin-1-yl]butyl}-naphthalene-2-sulphonamide,
  • 180) 6-chloro-N-{3-[4-(2-oxo-2,3-dihydro-1,3-benzoxazol-7-yl)piperazin-1-yl]propyl}-naphthalene-2-sulphonamide,
  • 181) 5-fluoro-3-methyl-N-{4-[4-(2-oxo-2,3-dihydro-1,3-benzoxazol-7-yl)piperazin-1-yl]-butyl}-1-benzothiophene-2-sulphonamide,
  • 182) 5-fluoro-3-methyl-N-{3-[4-(2-oxo-2,3-dihydro-1,3-benzoxazol-7-yl)piperazin-1-yl]-propyl}-1-benzothiophene-2-sulphonamide,
  • 183) 5-chloro-N-{4-[4-(2-oxo-2,3-dihydro-1,3-benzoxazol-7-yl)piperazin-1-yl]butyl}-1-benzothiophene-2-sulphonamide,
  • 184) 5-chloro-N-{3-[4-(2-oxo-2,3-dihydro-1,3-benzoxazol-7-yl)piperazin-1-yl]propyl}-1-benzothiophene-2-sulphonamide,
  • 185) N-{4-[4-(2-oxo-2,3-dihydro-1,3-benzoxazol-7-yl)piperazin-1-yl]butyl}-1-benzothiophene-2-sulphonamide,
  • 186) N-{3-[4-(2-oxo-2,3-dihydro-1,3-benzoxazol-7-yl)piperazin-1-yl]propyl}-1-benzothiophene-2-sulphonamide,
  • 187) N-{4-[4-(2-oxo-2,3-dihydro-1,3-benzoxazol-7-yl)piperazin-1-yl]butyl}-2,3-dihydro-1-benzofurane-5-sulphonamide,
  • 188) N-{3-[4-(2-oxo-2,3-dihydro-1,3-benzoxazol-7-yl)piperazin-1-yl]propyl}-2,3-dihydro-1-benzofurane-5-sulphonamide,
  • 189) 4-bromo-N-{4-[4-(2-oxo-2,3-dihydro-1,3-benzoxazol-7-yl)piperazin-1-yl]butyl}benzenesulphonamide,
  • 190) 4-bromo-N-{3-[4-(2-oxo-2,3-dihydro-1,3-benzoxazol-7-yl)piperazin-1-yl]propyl}benzenesulphonamide,
  • 191) 3-chloro-N-{4-[4-(2-oxo-2,3-dihydro-1,3-benzoxazol-7-yl)piperazin-1-yl]butyl}benzenesulphonamide,
  • 192) 3-chloro-N-{3-[4-(2-oxo-2,3-dihydro-1,3-benzoxazol-7-yl)piperazin-1-yl]propyl}benzenesulphonamide,
  • 193) 3-fluoro-N-{4-[4-(2-oxo-2,3-dihydro-1,3-benzoxazol-7-yl)piperazin-1-yl]butyl}benzenesulphonamide,
  • 194) 3-fluoro-N-{3-[4-(2-oxo-2,3-dihydro-1,3-benzoxazol-7-yl)piperazin-1-yl]propyl}benzenesulphonamide,
  • 195) N-{4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl}-5-chlorothiophene-2-sulphonamide,
  • 196) N-{3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl}-5-chlorothiophene-2-sulphonamide,
  • 197) 7-chloro-N-{4-[4-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-8-yl)piperazin-1-yl]butyl}-naphthalene-2-sulphonamide,
  • 198) 7-chloro-N-{3-[4-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-8-yl)piperazin-1-yl]propyl}-naphthalene-2-sulphonamide,
  • 199) 6-chloro-N-{4-[4-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-8-yl)piperazin-1-yl]butyl}-naphthalene-2-sulphonamide,
  • 200) 6-chloro-N-{3-[4-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-8-yl)piperazin-1-yl]propyl}-naphthalene-2-sulphonamide,
  • 201) 5-fluoro-3-methyl-N-{4-[4-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-8-yl)piperazin-1-yl]butyl}-1-benzothiophene-2-sulphonamide,
  • 202) 5-fluoro-3-methyl-N-{3-[4-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-8-yl)piperazin-1-yl]propyl}-1-benzothiophene-2-sulphonamide,
  • 203) 5-chloro-N-{4-[4-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-8-yl)piperazin-1-yl]butyl}-1-benzothiophene-2-sulphonamide,
  • 204) 5-chloro-N-{3-[4-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-8-yl)piperazin-1-yl]propyl}-1-benzothiophene-2-sulphonamide,
  • 205) N-{4-[4-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-8-yl)piperazin-1-yl]butyl}-1-benzothiophene-3-sulphonamide,
  • 206) N-{3-[4-(3-oxo-3,4-dihydro-2H-1,4-benzoksazyn-8-ylo)piperazyn-1-yl]propyl}-1-benzothiophene-3-sulphonamide,
  • 207) N-{4-[4-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-8-yl)piperazin-1-yl]butyl}-1,3-benzodioxole-5-sulphonamide,
  • 208) N-{3-[4-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-8-yl)piperazin-1-yl]propyl}-1,3-benzodioxole-5-sulphonamide,
  • 209) 3-chloro-N-{4-[4-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-8-yl)piperazin-1-yl]butyl}benzenesulphonamide,
  • 210) 3-chloro-N-{3-[4-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-8-yl)piperazin-1-yl]propyl}benzenesulphonamide,
  • 211) 3-fluoro-N-{4-[4-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-8-yl)piperazin-1-yl]butyl}benzenesulphonamide,
  • 212) 3-fluoro-N-{3-[4-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-8-yl)piperazin-1-yl]propyl}benzenesulphonamide,
  • 213) 4-isopropyl-N-{4-[4-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-8-yl)piperazin-1-yl]-butyl}benzenesulphonamide,
  • 214) 4-isopropyl-N-{3-[4-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-8-yl)piperazin-1-yl]-propyl}benzenesulphonamide,
  • 215) N-{4-[4-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-8-yl)piperazin-1-yl]butyl}thiophene-2-sulphonamide,
  • 216) N-{3-[4-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-8-yl)piperazin-1-yl]propyl}thiophene-2-sulphonamide,
  • 217) N-{4-[4-(2,2-difluoro-1,3-benzodioxol-4-yl)piperazin-1-yl]butyl}-naphthalene-2-sulphonamide,
  • 218) N-{3-[4-(2,2-difluoro-1,3-benzodioxol-4-yl)piperazin-1-yl]propyl}-naphthalene-2-sulphonamide,
  • 219) N-{4-[4-(2,2-difluoro-1,3-benzodioxol-4-yl)piperazin-1-yl]butyl}-naphthalene-1-sulphonamide,
  • 220) N-{3-[4-(2,2-difluoro-1,3-benzodioxol-4-yl)piperazin-1-yl]propyl}-naphthalene-1-sulphonamide,
  • 221) 3-fluoro-N-{4-[4-(2,2-difluoro-1,3-benzodioxol-4-yl)piperazin-1-yl]butyl}benzenesulphonamide,
  • 222) 3-fluoro-N-{3-[4-(2,2-difluoro-1,3-benzodioxol-4-ylo)piperazyn-1-yl]propyl}-benzenesulphonamide,
  • 223) 3-chloro-N-{4-[4-(2,2-difluoro-1,3-benzodioxol-4-yl)piperazin-1-yl]butyl}benzenesulphonamide,
  • 224) 3-chloro-N-{3-[4-(2,2-difluoro-1,3-benzodioxol-4-yl)piperazin-1-yl]propyl}benzenesulphonamide,
  • 225) N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-4-fluorobenzenesulphonamide,
  • 226) N-[4-[4-(1,2-benzothiazol-3-yl) piperazin-1-yl]butyl]-3,4-difluorobenzenesulphonamide,
  • 227) N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-4-chlorobenzenesulphonamide,
  • 228) N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-3,4-dichlorobenzenesulphonamide,
  • 229) N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-4-bromobenzenesulphonamide,
  • 230) N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-3-bromobenzenesulphonamide,
  • 231) N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-3-hydroxybenzenesulphonamide,
  • 232) N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-3-methoxybenzenesulphonamide,
  • 233) N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-4-tert-butylbenzenesulphonamide,
  • 234) N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-4-(trifluoromethyl)benzenesulphonamide,
  • 235) N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-3-(trifluoromethyl)benzenesulphonamide,
  • 236) N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-4-(trifluoromethoxy)benzenesulphonamide,
  • 237) N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-4-phenylbenzenesulphonamide,
  • 238) N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]thiophene-2-sulphonamide,
  • 239) N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]benzothiophene-2-sulphonamide,
  • 240) N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]benzothiophene-3-sulphonamide,
  • 241) N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-6-chlorobenzothiophene-2-sulphonamide,
  • 242) N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-2,3-dihydrobenzofuran-5-sulphonamide,
  • 243) N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-1,3-benzothiazole-4-sulphonamide,
  • 244) N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-1H-indazole-6-sulphonamide,
  • 245) N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-1,3-benzodioxole-5-sulphonamide,
  • 246) N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]imidazo[1,2-a]pyridine-3-sulphonamide,
  • 247) N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-1H-pyrrolo[2,3-b]pyridine-3-sulphonamide,
  • 248) N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-4-fluorobenzenesulphonamide,
  • 249) N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-3,4-difluorobenzenesulphonamide,
  • 250) N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-4-chlorobenzenesulphonamide,
  • 251) N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-3,4-dichlorobenzenesulphonamide,
  • 252) N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-4-bromobenzenesulphonamide,
  • 253) N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-3-bromobenzenesulphonamide,
  • 254) N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-3-hydroxybenzenesulphonamide,
  • 255) N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-3-methoxybenzenesulphonamide,
  • 256) N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-4-tert-butylbenzenesulphonamide,
  • 257) N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-4-(trifluoromethyl)benzenesulphonamide,
  • 258) N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-3-(trifluoromethyl)benzenesulphonamide,
  • 259) N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-4-(trifluoromethoxy)benzenesulphonamide,
  • 260) N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-4-phenylbenzenesulphonamide,
  • 261) N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]thiophene-2-sulphonamide,
  • 262) N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]benzothiophene-2-sulphonamide,
  • 263) N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]benzothiophene-3-sulphonamide,
  • 264) N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-6-chlorobenzothiophene-2-sulphonamide,
  • 265) N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-2,3-dihydrobenzofuran-5-sulphonamide,
  • 266) N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-1,2-benzoxazole-5-sulphonamide,
  • 267) N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-1,3-benzothiazole-4-sulphonamide,
  • 268) N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-1H-indazole-6-sulphonamide,
  • 269) N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-1,3-benzodioxole-5-sulphonamide,
  • 270) N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-1H-pyrrolo[2,3-b]pyridine-3-sulphonamide,
  • 271) N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]-4-fluorobenzenesulphonamide,
  • 272) N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]-3,4-difluorobenzene-sulphonamide,
  • 273) N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]-4-chlorobenzenesulphonamide,
  • 274) N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]-4-bromobenzenesulphonamide,
  • 275) N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]-3-bromobenzenesulphonamide,
  • 276) N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]-3-chloro-4-fluorobenzene-sulphonamide,
  • 277) N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]-3-hydroxybenzenesulphonamide,
  • 278) N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]-3-methoxybenzene-sulphonamide,
  • 279) N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]-4-tert-butylbenzene-sulphonamide,
  • 280) N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]-4-(trifluoromethyl)benzene-sulphonamide,
  • 281) N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]-4-(trifluoromethoxy)benzenesulphonamide,
  • 282) N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]-3-cyanobenzenesulphonamide,
  • 283) N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]-4-phenylbenzenesulphonamide,
  • 284) N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]thiophene-2-sulphonamide,
  • 285) N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]-5-chloro-thiophene-2-sulphonamide,
  • 286) N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]benzothiophene-2-sulphonamide,
  • 287) N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]benzothiophene-3-sulphonamide,
  • 288) N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]-6-chlorobenzothiophene-2-sulphonamide,
  • 289) N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]-2,3-dihydrobenzofuran-5-sulphonamide,
  • 290) N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]-1,3-benzothiazole-4-sulphonamide,
  • 291) N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]-1H-indazole-6-sulphonamide,
  • 292) N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]-1,3-benzodioxole-5-sulphonamide,
  • 293) N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]imidazo[1,2-a]pyridine-3-sulphonamide,
  • 294) 4-fluoro-N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]benzenesulphonamide,
  • 295) 3,4-difluoro-N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]benzenesulphonamide,
  • 296) 4-chloro-N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]benzenesulphonamide,
  • 297) 3,4-dichloro-N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]benzenesulphonamide,
  • 298) 4-bromo-N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]benzenesulphonamide,
  • 299) 3-chloro-4-fluoro-N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-benzenesulphonamide,
  • 300) N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-3-methoxybenzenesulphonamide,
  • 301) 4-tert-butyl-N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]benzenesulphonamide,
  • 302) N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-4-(trifluoromethyl)-benzenesulphonamide,
  • 303) N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-3-(trifluoromethyl)-benzenesulphonamide,
  • 304) N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-4-(trifluoromethoxy)-benzenesulphonamide,
  • 305) 4-cyano-N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]benzenesulphonamide,
  • 306) 3-cyano-N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]benzenesulphonamide,
  • 307) N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]thiophene-3-sulphonamide,
  • 308) 5-chloro-N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]thiophene-2-sulphonamide,
  • 309) N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-2,5-dimethyl-thiophene-3-sulphonamide,
  • 310) N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-1-methyl-indole-4-sulphonamide,
  • 311) N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-1-methyl-indole-6-sulphonamide,
  • 312) N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]benzothiophene-2-sulphonamide,
  • 313) N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]benzothiophene-3-sulphonamide,
  • 314) 6-chloro-N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl) piperidin-1-yl]butyl]benzothiophene-2-sulphonamide,
  • 315) 5-chloro-N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-3-methyl-benzothiophene-2-sulphonamide,
  • 316) N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]benzofuran-2-sulphonamide,
  • 317) N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-2,3-dihydrobenzofuran-5-sulphonamide,
  • 318) N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-1,3-benzothiazole-4-sulphonamide,
  • 319) N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-1H-indazole-6-sulphonamide,
  • 320) N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-1,3-benzodioxole-5-sulphonamide,
  • 321) N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-2,3-dihydro-1,4-benzodioxine-6-sulphonamide,
  • 322) N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]imidazo[1,2-a]pyridine-3-sulphonamide,
  • 323) N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-1H-pyrrolo[2,3-b]-pyridine-3-sulphonamide,
  • 324) N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-2-oxo-indoline-5-sulphonamide,
  • 325) N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]thiophene-2-sulphonamide,
  • 326) 4-fluoro-N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]benzenesulphonamide,
  • 327) 3,4-difluoro-N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]benzenesulphonamide,
  • 328) 4-chloro-N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]benzenesulphonamide,
  • 329) 3,4-dichloro-N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]benzenesulphonamide,
  • 330) 4-bromo-N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]benzenesulphonamide,
  • 331) 3-chloro-4-fluoro-N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-benzenesulphonamide,
  • 332) N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-3-methoxybenzene-sulphonamide,


is 333) 4-tert-butyl-N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]benzenesulphonamide,

  • 334) N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-4-(trifluoromethyl)-benzenesulphonamide,
  • 335) N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-3-(trifluoromethyl)-benzenesulphonamide,
  • 336) N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-4-(trifluoromethoxy)-benzenesulphonamide,
  • 337) 4-cyano-N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]benzenesulphonamide,
  • 338) 3-cyano-N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]benzenesulphonamide,
  • 339) N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]thiophene-2-sulphonamide,
  • 340) N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]thiophene-3-sulphonamide,
  • 341) 5-chloro-N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]thiophene-2-sulphonamide,
  • 342) N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl) piperidin-1-yl]propyl]-2,5-dimethyl-thiophene-3-sulphonamide,
  • 343) N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-1-methyl-indole-4-sulphonamide,


    344) N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-1-methyl-indole-5-sulphonamide,
  • 345) N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]benzothiophene-2-sulphonamide,
  • 346) N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]benzothiophene-3-sulphonamide,
  • 347) 6-chloro-N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]benzothiophene-2-sulphonamide,
  • 348) 5-chloro-N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-3-methylbenzothiophene-2-sulphonamide,
  • 349) N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]benzofuran-2-sulphonamide,
  • 350) N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-2,3-dihydrobenzofuran-5-sulphonamide,
  • 351) N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-1,3-benzothiazole-4-sulphonamide,
  • 352) N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-1H-indazole-6-sulphonamide,
  • 353) N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-2-oxo-3H-1,3-benzoxazole-6-sulphonamide,
  • 354) N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-1,3-benzodioxole-5-sulphonamide,
  • 355) N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-2,3-dihydro-1,4-benzodioxine-6-sulphonamide,
  • 356) N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]imidazo[1,2-a]pyridine-3-sulphonamide,
  • 357) N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-1H-pyrrolo[2,3-b]-pyridine-2-sulphonamide,
  • 358) 6-chloro-N-[4-[4-(1H-indol-4-yl)piperazin-1-yl]butyl]naphthalene-2-sulphonamide,
  • 359) 4-fluoro-N-[4-[4-(1H-indol-4-yl)piperazin-1-yl]butyl]benzenesulphonamide,
  • 360) N-[4-[4-(1H-indol-4-yl)piperazin-1-yl]butyl]-4-(trifluoromethyl)benzenesulphonamide,
  • 361) N-[4-[4-(1H-indol-4-yl)piperazin-1-yl]butyl]-3-(trifluoromethyl)benzenesulphonamide,
  • 362) 3-cyano-N-[4-[4-(1H-indol-4-yl)piperazin-1-yl]butyl]benzenesulphonamide,
  • 363) 6-chloro-N-[4-[4-(1H-indol-4-yl)piperazin-1-yl]butyl]benzothiophene-2-sulphonamide,
  • 364) 5-fluoro-N-[4-[4-(1H-indol-4-yl)piperazin-1-yl]butyl]-3-methylbenzothiophene-2-sulphonamide,
  • 365) N-[4-[4-(1H-indol-4-yl)piperazin-1-yl]butyl]-1,3-benzodioxole-5-sulphonamide,
  • 366) N-[3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl]naphthalene-1-sulphonamide,
  • 367) N-[3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl]naphthalene-2-sulphonamide,
  • 368) N-[3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl]-4-fluorobenzenesulphonamide,
  • 369) N-[3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl]-3,4-difluorobenzene-sulphonamide,
  • 370) N-[3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl]-4-chlorobenzenesulphonamide,
  • 371) N-[3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl]-4-bromobenzenesulphonamide,
  • 372) N-[3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl]-3-bromobenzenesulphonamide,
  • 373) N-[3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl]-3-chloro-4-fluorobenzene-sulphonamide,
  • 374) N-[3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl]-4-tert-butyl-benzenesulphonamide,
  • 375) N-[3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl]-4-(trifluoromethyl)benzenesulphonamide,
  • 376) N-[3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl]-3-cyanobenzenesulphonamide,
  • 377) N-[3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl]-4-phenylbenzenesulphonamide,
  • 378) N-[3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl]-2,3-dihydrobenzofuran-5-sulphonamide,
  • 379) N-[3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl]-1,3-benzothiazole-4-sulphonamide,
  • 380) N-[4-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]naphthalene-1-sulphonamide,
  • 381) N-[4-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]naphthalene-2-sulphonamide,
  • 382) 6-chloro-N-[4-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]-naphthalene-2-sulphonamide,
  • 383) N-[4-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]-3-fluorobenzene-sulphonamide,
  • 384) N-[4-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]-3,4-difluoro-benzenesulphonamide,
  • 385) 3-chloro-N-[4-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]benzenesulphonamide,
  • 386) 3-bromo-N-[4-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]benzenesulphonamide,
  • 387) 3-chloro-N-[4-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]-4-fluorobenzenesulphonamide,
  • 388) N-[4-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]-3-hydroxybenzene-sulphonamide,
  • 389) N-[4-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]-3-methoxybenzene-sulphonamide,
  • 390) N-[4-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]-3-methylbenzene-sulphonamide,
  • 391) N-[4-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]-4-phenylbenzene-sulphonamide,
  • 392) N-[4-[4-(2,3-dihydro-1,4-benzodioxin-8-yl)piperazin-1-yl]butyl]thiophene-2-sulphonamide,
  • 393) 5-chloro-N-[4-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]thiophene-2-sulphonamide,
  • 394) N-[4-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]benzothiophene-2-sulphonamide,
  • 395) N-[4-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]benzothiophene-3-sulphonamide,
  • 396) 6-chloro-N-[4-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]-benzothiophene-2-sulphonamide,
  • 397) N-[4-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]-1H-indazole-6-sulphonamide,
  • 398) N-[4-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]-2-oxo-3H-1,3-benzoxazole-6-sulphonamide,
  • 399) N-[4-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]-1,3-benzodioxole-5-sulphonamide,
  • 400) N-[3-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]naphthalene-1-sulphonamide,
  • 401) N-[3-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]naphthalene-2-sulphonamide,
  • 402) 6-chloro-N-[3-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]-naphthalene-2-sulphonamide,
  • 403) N-[3-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]-4-fluorobenzene-sulphonamide,
  • 404) N-[3-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]-3-fluorobenzene-sulphonamide,
  • 405) N-[3-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]-3,4-difluoro-benzenesulphonamide,
  • 406) 3-chloro-N-[3-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]-benzenesulphonamide,
  • 407) 4-bromo-N-[3-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]-benzenesulphonamide,
  • 408) 3-bromo-N-[3-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]-benzenesulphonamide,
  • 409) N-[3-[4-(2,3-dihydro-1,4-benzodioxin-8-yl)piperazin-1-yl]propyl]-3-methyl-benzenesulphonamide,
  • 410) N-[3-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]-4-phenylbenzene-sulphonamide,
  • 411) N-[3-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]benzothiophene-3-sulphonamide,
  • 412) N-[3-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]-2,3-dihydrobenzo-furan-5-sulphonamide,
  • 413) N-[4-[4-(2-oxo-1,3-dihydrobenzimidazol-4-yl)piperazin-1-yl]butyl]naphthalene-1-sulphonamide,
  • 414) N-[4-[4-(2-oxo-1,3-dihydrobenzimidazol-4-yl)piperazin-1-yl]butyl]naphthalene-2-sulphonamide,
  • 415) 4-fluoro-N-[4-[4-(2-oxo-1,3-dihydrobenzimidazol-4-yl)piperazin-1-yl]butyl]benzenesulphonamide,
  • 416) 4-chloro-N-[4-[4-(2-oxo-1,3-dihydrobenzimidazol-4-yl)piperazin-1-yl]butyl]benzenesulphonamide,
  • 417) 3-methyl-N-[4-[4-(2-oxo-1,3-dihydrobenzimidazol-4-yl)piperazin-1-yl]butyl]-benzenesulphonamide,
  • 418) N-[3-[4-(2-oxo-1,3-dihydrobenzimidazol-4-yl)piperazin-1-yl]propyl]naphthalene-1-sulphonamide,
  • 419) N-[3-[4-(2-oxo-1,3-dihydrobenzimidazol-4-yl)piperazin-1-yl]propyl]naphthalene-2-sulphonamide,
  • 420) 4-chloro-N-[3-[4-(2-oxo-1,3-dihydrobenzimidazol-4-yl)piperazin-1-yl]propyl]-benzenesulphonamide,
  • 421) 3-methyl-N-[3-[4-(2-oxo-1,3-dihydrobenzimidazol-4-yl)piperazin-1-yl]propyl]-benzenesulphonamide,
  • 422) N-[4-[4-(3-oxo-4H-1,4-benzoxazin-8-yl)piperazin-1-yl]butyl]naphthalene-2-sulphonamide,
  • 423) 4-fluoro-N-[4-[4-(3-oxo-4H-1,4-benzoxazin-8-yl)piperazin-1-yl]butyl]benzenesulphonamide,
  • 424) N-[4-[4-(3-oxo-4H-1,4-benzoxazin-8-yl)piperazin-1-yl]butyl]-4-(trifluoromethyl)-benzenesulphonamide,
  • 425) N-[4-[4-(3-oxo-4H-1,4-benzoxazin-8-yl)piperazin-1-yl]butyl]-3-(trifluoromethyl)-benzenesulphonamide,
  • 426) 5-chloro-N-[4-[4-(3-oxo-4H-1,4-benzoxazin-8-yl)piperazin-1-yl]butyl]thiophene-2-sulphonamide,
  • 427) N-[4-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]butyl]-naphthalene-1-sulphonamide,
  • 428) N-[4-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]butyl]-naphthalene-2-sulphonamide, 429) N-[4-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]butyl]-4-fluorobenzenesulphonamide
  • 430) N-[4-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]butyl]-3-hydroxybenzenesulphonamide,
  • 431) N-[4-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]butyl]-3-methylbenzenesulphonamide,
  • 432) N-[4-[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]butyl]naphthalene-2-sulphonamide,
  • 433) 3-fluoro-N-[4-[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]butyl]-benzenesulphonamide,
  • 434) N-[4-[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]butyl]-3-hydroxy-benzenesulphonamide,
  • 435) N-[4-[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]butyl]-3-methyl-benzenesulphonamide,
  • 436) 3-fluoro-N-[3-[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]propyl]-benzenesulphonamide,
  • 437) N-[3-[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]propyl]-3-hydroxy-benzenesulphonamide,
  • 438) N-[2-[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]ethyl]naphthalene-2-sulphonamide,
  • 439) 3-fluoro-N-[2-[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]ethyl]-benzenesulphonamide,
  • 440) N-[2-[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]ethyl]-3-methyl-benzenesulphonamide,
  • 441) N-[3-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]propyl]-naphthalene-1-sulphonamide,
  • 442) N-[3-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]propyl]-naphthalene-2-sulphonamide,
  • 443) N-[3-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]propyl]-4-fluorobenzenesulphonamide,
  • 444) 4-chloro-N-[3-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]-propyl]benzenesulphonamide,
  • 445) N-[3-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]propyl]-3-hydroxybenzenesulphonamide,
  • 446) N-[3-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]propyl]-3-methylbenzenesulphonamide,
  • 447) N-[2-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]ethyl]-naphthalene-1-sulphonamide,
  • 448) N-[2-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]ethyl]-naphthalene-2-sulphonamide,
  • 449) N-[2-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]ethyl]-4-fluorobenzenesulphonamide,
  • 450) N-[2-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]ethyl]-3-fluorobenzenesulphonamide,
  • 451) 4-chloro-N-[2-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]-ethyl]benzenesulphonamide,
  • 452) 3-chloro-N-[2-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]-ethyl]benzenesulphonamide,
  • 453) N-[2-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]ethyl]-3-hydroxybenzenesulphonamide,
  • 454) N-[2-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]ethyl]-3-methylbenzenesulphonamide,
  • and pharmaceutically acceptable salts thereof.


Arylsulphonamide derivatives of the above formula (I) exhibit affinity to receptors which are recognized therapeutical targets in the treatment of CNS disorders, such as dopaminergic, in particular D2 and D3, serotoninergic, in particular 5-HT1A, 5-HT2A, 5-HT6, 5-HT7, adrenergic, in particular α1 and α2C, sigma and serotonine transporter receptors and do not exhibit or have low affinity toward biological targets associated with adverse effects, such as potassium channel hERG, muscarinic receptors, histaminergic receptors and serotoninergic receptor 5-HT2C. Due to such a broad pharmacological profile, the compounds of the invention may be useful in medicine as medicaments, for the treatment and/or prevention of the central nervous system disorders such as schizophrenia, schizoaffective disorders, schizophreniform disorders, delusional syndromes and other psychotic conditions related and not related to taking so psychoactive substances, affective disorder, bipolar disorder, mania, depression, anxiety disorders of various aetiology, stress reactions, consciousness disorders, coma, delirium of alcoholic or other aetiology, aggression, psychomotor agitation and other conduct disorders, sleep disorders of various aetiology, withdrawal syndromes of various aetiology, addiction, pain syndromes of various aetiology, intoxication with psychoactive substances, cerebral circulatory disorders of various aetiology, psychosomatic disorders of various aetiology, conversion disorders, dissociative disorders, urination disorders, autism and other developmental disorders, including nocturia, stuttering, tics, cognitive disorders of various types, such as Alzheimer's disease, psychopatological symptoms and neurological disorders in the course of other diseases of the central and peripheral nervous systems.


Thus, the subject of the present invention are the compounds of formula (I) as defined above, for use as a medicament.


In the treatment of central nervous system disorders compound of formula (I) may be administered in the form of a pharmaceutical composition or preparation containing it.


Thus, the subject of the present invention is also the pharmaceutical composition containing a compound or compounds of formula (I) as defined above as an active substance, in combination with pharmaceutically acceptable carrier(s) and/or excipient(s).


The subject of the invention is also a use of arylsulphonamide derivatives of the above so formula (I) for the treatment of disorders of central nervous system.


The invention relates also to a method for the treatment of disorders of the central nervous system in mammals, including humans, comprising administration of a therapeutically effective amount of the compound of above formula (I) or the pharmaceutical composition containing the compound of formula (I) as defined above as an active substance.


Terms used in the description of the present invention have the following meanings.


Unless otherwise indicated, the term “C1-C4-alkyl” relates to a saturated, straight or branched hydrocarbon group, having indicated number of carbon atoms. Specific examples of groups encompassed by this term are methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, and sec-butyl.


The term “C1-C3-alkyloxy” relates to a —O—C1-C3-alkyl group, wherein C1-C3-alkyl represents saturated hydrocarbon group having indicated number of carbon atoms, and which is a straight- or branched-chain. Specific examples of groups encompassed by this term are methoxy, ethoxy, n-propoxy, and iso-propoxy.


The term “halogen atom” relates to a substituent selected from F, Cl, Br and I.


The term “halogeno-C1-C3-alkyl” relates to a saturated, straight or branched hydrocarbon group, having indicated number of carbon atoms and in which one carbon atom may be substituted with from 1-3 halogen atoms, depending on the number of carbon atoms bonded to it. Halogen atom has the meaning as defined above. Particularly preferred example of a group encompassed by this term is trifluoromethyl group —CF3.


The term “halogeno-C1-C3-alkyloxy” relates to a —O—C3-C3-halogenoalkyl group, wherein C1-C3-halogenoalkyl means saturated, straight or branched hydrocarbon group having indicated number of carbon atoms and in which one carbon atom may be substituted with 1-3 halogen atoms, depending on the number of carbon atoms bonded to it. Halogen atom has the meaning as defined above. Particularly preferred example of a group encompassed by his term is trifluoromethoxy group —O—CF3.


The compounds of formula (I) can be prepared in a process presented in the following scheme:




embedded image


In the first step compound (IVa), for example as hydrochloride, is reacted with appropriate 2-(bromoalkyl)-1H-isoindoline-1,3(2H)-dione (IVb) in a solvent, such as N,N-dimethylformamide or acetonitrile, in the presence of a base at room temperature or at elevated temperature, to give a compound of formula (III). Then imide (III) is hydrolysed using 40% aqueous methylamine solution at room temperature, to obtain amine derivative (IIa). Compound (IIa) is reacted with appropriate arylsulphonyl chloride (IIb), for example in methylene chloride in the presence of triethylamine, at room temperature, to give arylsulphonamide derivative (I) of the invention.


Starting compounds of formulas (IVa) and (IVb) are either well known or commercially available, or can be prepared from commercially available starting materials by adapting and applying known methods, such as described in publication of Hallett D. J. et al., J. Org. Chem. 2000, 65, 4984-4993.


Preparation of exemplary starting compounds of formula (III) is described in detail in the experimental part.


Since the compounds of formula (I) have alkaline character (contain at least one tertiary amine group), they can form acid addition salts.


Salts with acids can be pharmaceutically acceptable, especially when they are intended to be an active ingredient in pharmaceutical composition. The present invention relates also to salts of the compounds of formula (I) with acids other than pharmaceutically acceptable ones, which may be useful for example as intermediates suitable for purification of the compounds of the invention. In practice, it is often desirable to isolate first the compound from a reaction mixture in the form of a salt which is not pharmaceutically acceptable to purify the compound, and then convert the salt into free base by treatment with alkaline agent and to isolate, and optionally convert into the salt again.


Acid addition salts can be formed with inorganic (mineral) or organic acids. In particular, hydrochloric, hydrobromic, hydroiodic, phosphoric, sulphuric, nitric, carbonic, succinic, maleic, formic, acetic, propionic, fumaric, citric, tartaric, lactic, benzoic, salicylic, glutamic, aspargic, p-toluenesulphonic, benzenesulphonic, methanesulphonic, ethanesulphonic, naphthalenesulphonic such as 2-naphthalene-sulphonic, pamoic, xinafoic or hexanoic acids can be mentioned as examples of acids.


Acid addition salt can be prepared in a simple manner by reaction of the compound of so formula (I) with suitable inorganic or organic acid, optionally in suitable solvent, such as organic solvent, to form a salt that is usually isolated, for example by crystallization and filtration. For example, compounds in the form of a free base can be converted into corresponding hydrochloride salts by reaction of a compound in a solution, for example in methanol, with stoichiometric amount of hydrochloric acid or with solution of hydrochloric acid in methanol, ethanol or diethyl ether, followed by evaporation of solvent(s).


The term “disorders of the central nervous system” should be understood as including disorders selected from schizophrenia, schizoaffective disorders, schizophreniform disorders, delusional syndromes and other psychotic conditions related and not related to taking psychoactive substances, affective disorder, bipolar disorder, mania, depression, anxiety disorders of various aetiology, stress reactions, consciousness disorders, coma, delirium of alcoholic and other aetiology, aggression, psychomotor agitation and other conduct disorders, sleep disorders of various aetiology, withdrawal syndromes of various aetiology, addiction, pain syndromes of various aetiology, intoxication with psychoactive substances, cerebral circulatory disorders of various aetiology, psychosomatic disorders of various aetiology, conversion disorders, dissociative disorders, urination disorders, autism and other developmental disorders, including nocturia, stuttering, and tics, cognitive disorders of various types, like Alzheimer's disease, psychopatological symptoms and neurological disorders in the course of other diseases of the central and peripheral nervous systems are.


In the treatment of the disorders mentioned above, compounds of formula (I) of the present invention can be administered as a chemical compound, but usually will be applied in the form of a pharmaceutical compositions containing the compound of the present invention or its pharmaceutically acceptable salt as defined above as an active ingredient in combination with pharmaceutically acceptable carrier(s) and/or excipient(s).


In the treatment of the above mentioned disorders the pharmaceutical compositions of the invention can be delivered by any route of administration, preferably oral or parenteral, and will have the form of a preparation for use in medicine, depending on the intended route of administration.


Compositions for oral administration may have the form of solid or liquid preparations. Solid preparations may be in the form, for example, tablets or capsules prepared in so conventional manner using pharmaceutically acceptable inactive ingredients, such as binding agents (e.g. pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropylmethylcellulose); fillers (e.g. lactose, sucrose, carboxymethylcellulose, microcrystalline cellulose or calcium hydrogen phosphate) lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. crospovidone, maize starch or sodium starch glycolate); wetting agents (e.g. sodium lauryl sulfate). The tablets may be coated using methods well known in the art with conventional coatings, delaying/controlling release coatings or enteric coatings. Liquid preparations for oral administration may have the form of e.g. solutions, syrups or suspensions, or may be prepared from a dry product suitable for reconstitution with water or other suitable carrier ex tempore. Such liquid preparations may be prepared by conventional methods with pharmaceutically acceptable inactive ingredients, such as suspending agents (e.g. sorbitol syrup, cellulose derivatives or hydrogenated edible fats), emulsifying agents (e.g. lecithin or acacia gum), non-aqueous matrix components (e.g. almond oil, oils esters, ethyl alcohol or fractionated vegetable oils) and preservatives (e.g. methyl or propyl p-hydroxybenzoates or sorbic acid). The preparations may also contain suitable buffering systems, flavouring and aroma agents, colourants and sweeteners.


Preparations for oral administration can be formulated according to methods well known to those skilled in the art to afford a controlled release of the active compound.


The parenteral route of administration comprises administration by intramuscular and intravenous injections and intravenous continuous infusions. Compositions for parenteral administration may be in the form of a dosage unit, e.g. in ampoules or in multidose containers with the addition of a preservative. The compositions may be in a form of suspensions, solutions or emulsions in oily or aqueous media, and may contain pharmaceutically acceptable excipients, such as suspending agents, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in the form of a powder for reconstitution ex tempore in a suitable carrier, e.g. sterile pyrogen-free water.


Method of treatment using compounds of this invention will be based on administration of a therapeutically effective amount of the compound of the invention, preferably in the form of a pharmaceutical composition, to a subject in need of such a treatment.


The proposed dose of the compounds of the invention will be comprised in the range from 1 to about 1000 mg per day, in a single dose or in divided doses. It will be apparent to those skilled in the art that selection of a dose required to achieve the desired biological effect will depend on several factors, such as the type of specific compound, the indication, route of administration, age and condition of a patient and the exact dose will be finally determined at the discretion of attending physician.







EXAMPLE 1
Preparation of Starting Materials of the General Formula (III)



embedded image


a) General Procedure for Compounds Wherein in Formula (IVa) Represents Single Bond

A mixture of 10 mmol of compound (IVa) as hydrochloride and 10 mmol of compound (IVb), 30 mmol of potassium carbonate, small crystal of potassium iodide and 20 ml of N,N-dimethylformamide was stirred at room temperature until disappearance of starting materials (TLC monitoring). Usually, the reaction was carried out for 2 days. The reaction mixture was subsequently poured into 50 ml of water, and precipitate thus formed was isolated by filtration. For purification, crude product was suspended in 20 ml of methanol, then the solid was filtered off and dried to constant weight.


Alternatively (for III-8), the reaction was carried out in acetonitrile, after completion of the reaction the solvent was evaporated and product was purified by column chromatography on silica gel using chloroform/methanol 95:5 as eluent.


Structures of products were confirmed by mass spectrometry.


According to the above procedure the following compounds were prepared:

  • 2-(4-(4-(1,2-benzothiazol-3-yl)piperazin-1-yl)butyl)-1H-isoindole-1,3(2H)-dione (III-1), reaction in N,N-dimethylformamide, MS: 421 [M+H+], yield: 87%;
  • 2-(3-(4-(1,2-benzothiazol-3-yl)piperazin-1-yl)propyl)-1H-isoindole-1,3(2H)-dione (III-2), reaction in N,N-dimethylformamide, MS: 407 [M+H+], yield: 77%;
  • 2-(2-(4-(1,2-benzothiazol-3-yl)piperazin-1-yl)ethyl)-1H-isoindole-1,3(2H)-dione (III-3), reaction in N,N-dimethylformamide, MS: 393 [M+H+], yield: 37%;
  • 2-(4-(4-(1,2-benzoxazol-3-yl)piperazin-1-yl)butyl)-1H-isoindole-1,3(2H)-dione (III-4), reaction in N,N-dimethylformamide, MS: 405 [M+H+], yield: 75%;
  • 2-(4-(4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl)butyl)-1H-isoindole-1,3(2H)-dione (III-5), reaction in N,N-dimethylformamide, MS: 422 [M+H+], yield: 71%;
  • 2-(3-(4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl)propyl)-1H-isoindole-1,3(2H)-dione (III-6), reaction in N,N-dimethylformamide, MS: 408 [M+H+], yield: 55%;
  • 2-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl]piperydyn-1-yl]ethyl}-1H-isoindole-1,3(2H)-dione (III-7), reaction in N,N-dimethylformamide, MS: 394 [M+H+], yield: 47%;
  • 2-{4-[4-(1H-indol-4-yl)piperazin-1-yl]butyl}-1H-isoindole-1,3(2H)-dione (III-8), reaction in acetonitrile, MS: 403 [M+H+], yield: 71%.
  • 2-(3-(4-(1,2-benzoxazol-3-yl)piperazin-1-yl)propyl)-1H-isoindole-1,3(2H)-dione (III-13), reaction in N,N-dimethylformamide, MS: 391 [M+H+], yield: 77%;
  • 2-[4-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]-1H-isoindole-1,3(2H)-dione (III-14), reaction in N,N-dimethylformamide, MS: 422 [M+H+], yield: 73%;
  • 2-[3-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]-1H-isoindole-1,3(2H)-dione (III-15), reaction in N,N-dimethylformamide, MS: 408 [M+H+], yield: 68%;
  • 2-[4-[4-(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)piperazin-1-yl]butyl]-1H-isoindole-1,3(2H)-dione (III-16), reaction in N,N-dimethylformamide, MS: 420 [M+H+], yield: 70%;
  • 2-[3-[4-(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)piperazin-1-yl]propyl]-1H-isoindole-1,3(2H)-dione (III-17), reaction in N,N-dimethylformamide, MS: 406 [M+H+], yield: 72%;
  • 2-{4-[4-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-8-yl)piperazin-1-yl]butyl}-1H-isoindole-1,3(2H)-dione (III-18), reaction in N,N-dimethylformamide, MS: 435 [M+H+], yield: 79%;


b) General Procedure for Compounds Wherein in Formula (IVa) Represents Double Bond:

b1) General Procedure for Starting Compounds (IVa) Easily Soluble in N,N-Dimethylformamide:


A mixture of 5.6 mmol of compound (IVa) and 5.6 mmol of compound (IVb), 12 mmol of N,N-diisopropylethylamine, and 20 ml of N,N-dimethylformamide was stirred at room temperature until disappearance of starting materials (TLC monitoring). Usually, the so reaction was carried out for 2.5 days. Then to the mixture 100 ml of water was added and the whole was left for 1 hour. Subsequently, 20 ml of methanol was added to the resulting mixture and after heating, it was refluxed for 20 minutes. Precipitated product was isolated by filtration and dried to the constant weight. Structure of the product was confirmed by mass spectrometry.


The following compounds were prepared according to the above procedure:

  • 2-{4-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]butyl}-1H-isoindole-1,3(2H)-dione (III-9) MS: 434 [M+H+], yield: 57%;
  • 2-{3-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]propyl}-1H-isoindole-1,3(2H)-dione (III-10) MS: 420 [M+H+], yield: 45%;
  • 2-{2-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]ethyl}-1H-isoindole-1,3(2H)-dione (III-11) MS: 406 [M++], yield: 30%.
  • 2-{4-[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]butyl}-1H-isoindole-1,3(2H)-dione (III-19) MS: 418 [M+H+], yield: 79%;
  • 2-{3-[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]propyl}-1H-isoindole-1,3(2H)-dione (III-20) MS: 404 [M+H+], yield: 84%;
  • 2-{2-[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]ethyl}-1H-isoindole-1,3(2H)-dione (III-21) MS: 390 [M+H+], yield: 77%.


    b2) General Procedure for Starting Compounds (IVa) Poorly Soluble in Acetonitrile:


A mixture of 13 mmol of compound (IVa) and 13 mmol of compound (IVb), 13 mmol N,N-diisopropylethylamine, catalytic amount of potassium iodide and 300 ml of mixture of N,N-dimethylformamide and acetonitrile 1:1 was stirred at 70° C. for 3 days. Then the reaction mixture was concentrated under reduced pressure and the residue was purified using column chromatography on silica gel using methylene chloride:methanol=9:1 as eluent. Structure of the product was confirmed by mass spectrometry.


According to the above procedure, the following compounds were prepared:

  • 2-{4-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]butyl}-1H-isoindole-1,3(2H)-dione (III-12) MS: 448 [M+H+], yield: 36%.
  • 2-{3-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]propyl}-1H-isoindole-1,3(2H)-dione (III-22) MS: 404 [M+H+], yield: 40%.
  • 2-{2-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]ethyl}-1H-isoindole-1,3(2H)-dione (III-23) MS: 390 [M+H+], yield: 47%.


EXAMPLE 2
General Procedure for the Preparation of Starting Materials of General Formula (IIa) by Hydrolysis of Imide (III)



embedded image


a) General Procedure for Compounds Wherein in Formula (III) Represents Single Bond.

A mixture of 6 mmol of compound (III) and 30 ml of 40% aqueous solution of methylamine was stirred at room temperature for 3 days. To the resulting solution 30 ml of 20% aqueous solution of sodium hydroxide was added and the whole was stirred for 1.5 hours. Then 4 g of sodium chloride was added and the solution was extracted with methylene chloride (2×30 ml). Organic layer was washed with water (2×30 ml), and then dried over anhydrous magnesium sulphate. Product was obtained by evaporation of methylene chloride from dry solution. If necessary, the product was purified using column chromatography on silica gel, with chloroform/methanol 95:5 as eluent. Structure of the product was confirmed by mass spectrometry.


According to the above procedure the following compounds were prepared:

  • 4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butan-1-amine (IIa-1) from compound (III-1) MS: 291 [M+H+], yield: 81%;
  • 3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propan-1-amine (IIa-2) from compound (III-2) MS: 277 [M+H+], yield: 78%;
  • 2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethan-1-amine (IIa-3) from compound (III-3) MS: 263 [M+H+], yield: 71%;
  • 4-(4-(1,2-benzoxazol-3-yl)piperazin-1-yl)butan-1-amine (IIa-4) from compound (III-4) MS: 275 [M+H+], yield: 88%;
  • 4-(4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl)butan-1-amine (IIa-5) from compound (III-5) MS: 292 [M+H+], yield: 82%;
  • 3-(4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl)propan-1-amine (IIa-6) from compound (III-7) MS: 278 [M+H+], yield: 86%;
  • 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethan-1-amine (IIa-7) from compound (III-7) MS: 264 [M+H+], yield: 74%;
  • 4-[4-(1H-indol-4-yl)piperazin-1-yl]butan-1-amine (IIa-8) from compound (III-8) MS: 273 [M+H+], yield: 67%.
  • 3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propan-1-amine (IIa-13) from compound (III-13) MS: 261 [M+H+], yield: 77%.
  • 4-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butan-1-amine (IIa-14) from compound (III-14) MS: 292 [M+H+], yield: 83%.
  • 3-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propan-1-amine (II-15) from compound (III-15) MS: 278 [M+H+], yield: 85%.
  • 4-[4-(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)piperazin-1-yl]butan-1-amine (IIa-16) from compound (III-16) MS: 290 [M+H+], yield: 70%.
  • 3-[4-(2-oxo-2,3-dihydro-1H-benzimidazol-4-yl)piperazin-1-yl]propan-1-amine (IIa-17) from compound (III-17) MS: 276 [M+H+], yield: 74%.
  • 4-[4-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-8-yl)piperazin-1-yl]butan-1-amine (IIa-18) from compound (III-18) MS: 305 [M+H+], yield: 90%.


b) General Procedure for Compounds Wherein in Formula (III) Represents Double Bond.

1.7 Mmol of compound (Ill) was suspended in 40 ml of 40% aqueous solution of methylamine and stirred at room temperature for 16 hours. Then methylamine was evaporated and resulting precipitate was filtered off. Precipitate was washed with water and dried to the constant weight.


Structure of the product was confirmed by mass spectrometry.


According to the above procedure, the following compounds were prepared:

  • 4-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]butan-1-amine (IIa-9) from compound (III-9) MS: 304 [M+H+], yield: 85%;
  • 3-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]propan-1-amine (IIa-10) from compound (III-10) MS: 290 [M+H+], yield: 66%;
  • 2-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]ethan-1-amine (IIa-11) from compound (III-11) MS: 276 [M+H+], yield: 65%;
  • 4-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]butan-1-amine (IIa-12) from compound (III-12) MS: 318 [M+H+], yield: 80%.
  • 4-[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]butyl-1-amine (IIa-19) from compound (III-19) MS: 288 [M+H+], yield: 62%;
  • 3-[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]propyl-1-amine (IIa-20) from compound (III-20) MS: 274 [M+H+], yield: 60%;
  • 2-[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]ethyl-1-amine (IIa-21) from compound (III-21) MS: 260 [M+H+], yield: 67%.
  • 3-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]propyl-1-amine (IIa-22) from compound (III-22) MS: 304 [M+H+], yield: 66%.
  • 2-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]ethyl-1-amine (IIa-23) from compound (III-23) MS: 290 [M+H+], yield: 60%.


EXAMPLE 3
General Procedure for the Preparation of Compounds (I) of the Invention

Compounds of the invention were prepared according to the following scheme.




embedded image


a) General Procedure for Compounds Wherein in Formula (IIa) Represents Single Bond.

0.5 ml Of triethylamine and then 0.5 mmol of suitable arylsulphonyl chloride (IIb) were added to the solution of 0.5 mmol of amine (IIa) in 10 ml of methylene chloride at 10° C. Upon dissolution of chloride (IIb) the reaction mixture was left at room temperature for 3 hours, then the solvent and excess of triethylamine were evaporated. Precipitate thus formed was dissolved in 10 ml of methylene chloride and washed subsequently with 5% solution of sodium hydrogen carbonate (10 ml) and water (10 ml). Organic layer was dried over anhydrous magnesium sulphate, and the solvent was evaporated. Crude sulphonamides were usually purified by crystallization (from methanol), and some of them using column chromatography on silica gel using chloroform:methanol=9:1 as eluent.


Structure of prepared compounds was confirmed by MS data, and purity by HPLC analysis. For selected compounds structure identification was confirmed by 1H-NMR analysis.


Following the general procedure described above and starting from appropriate amine (IIa) and arylsulphonyl chloride (IIb), the following compounds were obtained.


Compound 1
N-(4-(4-(1,2-Benzothiazol-3-yl)piperazin-1-yl)butyl)naphthalene-1-sulphonamide

The title compound was prepared starting from amine (IIa-1) and naphthalene-1-sulphonyl chloride. Yield: 62%. 1H-NMR (300 MHz, DMSO-d6): δ 8.66 (d, 1H, J=8.5 Hz), 8.21 (d, 1H, J=8.1 Hz), 8.13-7.98 (m, 4H), 7.74-7.64 (m, 3H), 7.55 (t, 1H, J=6.9 Hz), 7.42 (t, 1H, J=8.4 Hz), 3.09-3.00 (m, 2H), 2.85-2.78 (m, 4H), 2.42-2.32 (m, 4H), 2.16-2.05 (m, 2H), 1.21-1.32 (m, 4H). MS: 481 [M+H+].


Compound 2
N-(4-(4-(1,2-Benzothiazol-3-yl)piperazin-1-yl)butyl)naphthalene-2-sulphonamide

The title compound was prepared starting from amine (IIa-1) and naphthalene-2-sulphonyl chloride. Yield: 60%. 1H-NMR (300 MHz, DMSO-d6): δ 8.42 (s, 1H), 8.16-8.11 (m, 2H), 8.06-7.98 (m, 3H), 7.81 (d, 1H, J=8.7 Hz), 7.74 (t, 1H, J=6.0 Hz), 7.66-7.62 (m, 1H), 7.54 (t, 1H, J=7.2 Hz), 7.42 (t, 1H, J=7.2 Hz), 2.84-2.78 (m, 4H), 2.48-2.4 (m, 6H), 2.26-2.18 (m, 2H), 1.36-1.41 (m, 4H). MS: 481 [M+H+].


Compound 3
N-(4-(4-(1,2-Benzothiazol-3-yl)piperazin-1-yl)butyl)-3-methylbenzenesulphonamide

The title compound was prepared starting from amine (IIa-1) and 3-methylbenzene-sulphonyl chloride. Yield: 51%. 1H-NMR (300 MHz, DMSO-d6): δ 8.05 (d, 2H, J=7.2 Hz), 7.60-7.41 (m, 6H), 3.40-3.35 (m, 4H), 2.72-2.79 (m, 2H), 2.50-2.48 (m, 4H), 2.38 (s, 3H), 2.28-2.26 (m, 2H), 1.36-1.44 (m, 4H). MS: 445 [M+H+].


Compound 4
N-(4-(4-(1,2-Benzothiazol-3-yl)piperazin-1-yl)butyl)-2-oxo-3H-1,3-benzoxazole-6-sulphonamide

The title compound was prepared starting from amine (IIa-1) and 2-oxo-3H-1,3-benzoxazole-6-sulphonyl chloride. Yield: 47%. MS: 488 [M+H+].


Compound 5
N-(3-(4-(1,2-Benzothiazol-3-yl)piperazin-1-yl)propyl)naphthalene-1-sulphonamide

The title compound was prepared starting from amine (IIa-2) and naphthalene-1-sulphonyl chloride. Yield: 53%. 1H-NMR (300 MHz, DMSO-d6): δ 8.66 (d, 1H, J=8.4 Hz), 8.21 (d, 1H, J=8.1 Hz), 8.14-7.96 (m, 3H), 7.74-7.61 (m, 3H), 7.53 (t, 1H, J=6.9 Hz), 7.41 (t, 1H, J=7.2) Hz), 3.31-3.25 (m, 4H), 2.81-2.88 (m, 2H), 2.29-2.25 (m, 4H), 2.14 (t, 2H, J=7.2 Hz), 1.44 (quintet, 2H, J=6.9 Hz). MS: 467 [M+H+].


Compound 6
N-(3-(4-(1,2-Benzothiazol-3-yl)piperazin-1-yl)propyl)naphthalene-2-sulphonamide

The title compound was prepared starting from amine (IIa-2) and naphthalene-2-sulphonyl chloride. Yield: 56%. 1H-NMR (300 MHz, CD3OD): δ 8.44 (s, 1H), 8.10-8.05 (m, 2H), 8.00-7.85 (m, 4H), 7.70-7.61 (m, 2H), 7.53 (t, 1H, J=6.9 Hz), 7.42 (t, 1H, J=7.2 Hz), 3.46-3.43 (m, 4H), 3.00 (t, 2H, J=6.9 Hz), 2.61-2.58 (m, 4H), 2.46 (t, 2H, J=7.2 Hz), 1.69 (quintet, 2H, J=6.9 Hz). MS: 467 [M+H+].


Compound 7
N-(3-(4-(1,2-Benzothiazol-3-yl)piperazin-1-yl)propyl)-3-methylbenzenesulphonamide

The title compound was prepared starting from amine (IIa-2) and 3-methyl-benzenesulphonyl chloride. Yield: 49%. 1H-NMR (300 MHz, DMSO-d6): δ 8.03 (t, 2H, J=7.2 Hz), 7.60-7.39 (m, 6H), 3.39-3.35 (m, 4H), 2.76-2.82 (m, 2H), 2.50-2.46 (m, 4H), 2.38 (s, 3H), 2.30 (t, 2H, J=7.2 Hz), 1.54 (quintet, 2H, J=6.9 Hz). MS: 431 [M+H+].


Compound 8
N-(3-(4-(1,2-Benzothiazol-3-yl)piperazin-1-yl)propyl)-2-oxo-3H-1,3-benzoxazole-6-sulphonamide

The title compound was prepared starting from amine (IIa-2) and 2-oxo-3H-1,3-benzoxazole-6-sulphonyl chloride. Yield: 31%. 1H-NMR (300 MHz, CDCl3): δ 7.88-7.79 (m, 1H), 7.62 (s, 1H), 7.47 (t, 1H, J=7.4 Hz), 7.35 (t, 1H, J=7.4 Hz), 7.24 (t, 1H, J=8.2 Hz), 6.75 (t, 1H, J=8.2 Hz), 6.59-6.49 (m, 1H), 5.62-5.55 (m, 2H), 3.57-3.52 (m, 4H), 3.09 (t, 2H, J=5.9 Hz), 2.66-2.61 (m, 4H), 2.51 (t, 2H, J=5.9 Hz), 1.69 (quintet, 2H, J=5.9 Hz). MS: 474 [M+H+].


Compound 9
N-(2-(4-(1,2-Benzothiazol-3-yl)piperazin-1-yl)ethyl)naphthalene-1-sulphonamide

The title compound was prepared starting from amine (IIa-3) and naphthalene-1-sulphonyl chloride. Yield: 51%. 1H-NMR (300 MHz, CDCl3): δ 8.68 (d, 1H, J=8.5 Hz), 8.29 (d, 1H, J=7.4 Hz), 8.08 (d, 1H, J=8.2 Hz), 7.95 (d, 1H, J=8.2 Hz), 7.82-7.68 (m, 3H), 7.62-7.54 (m, 2H), 7.46 (t, 1H, J=6.9 Hz), 7.33 (t, 1H, J=6.9) Hz), 3.33-3.27 (m, 4H), 3.03-2.97 (m, 2H), 2.37-2.30 (m, 6H). MS: 453 [M+H+].


Compound 10
N-(2-(4-(1,2-Benzothiazol-3-yl)piperazin-1-yl)ethyl)naphthalene-2-sulphonamide

The title compound was prepared starting from amine (IIa-3) and naphthalene-2-sulphonyl chloride. Yield: 51%. 1H-NMR (300 MHz, CDCl3): δ 8.47 (s, 1H), 8.00-7.79 (m, 6H), 7.68-7.59 (m, 2H), 7.46 (t, 1H, J=6.9 Hz), 7.33 (t, 1H, J=6.9) Hz), 5.39 (s, 1H), 3.47-3.43 (m, 4H), 3.11-3.04 (m, 2H), 2.52-2.44 (m, 6H). MS: 453 [M+H+].


Compound 11
N-(2-(4-(1,2-Benzothiazol-3-yl)piperazin-1-yl)ethyl)-3-methylbenzenesulphonamide

The title compound was prepared starting from amine (IIa-3) and 3-methyl-benzenesulphonyl chloride. Yield: 49%. 1H-NMR (300 MHz, CDCl3): δ 7.86-7.79 (m, 2H), 7.72-7.66 (m, 2H), 7.49-7.31 (m, 4H), 5.28 (s, 1H), 3.48-3.43 (m, 4H), 3.08-3.01 (m, 2H), 2.53-2.46 (m, 6H), 2.43 (5, 3H); MS: 417 [M+H+].


Compound 12
N-(2-(4-(1,2-Benzothiazol-3-yl)piperazin-1-yl)ethyl)-2-oxo-3H-1,3-benzoxazole-6-sulphonamide

The title compound was prepared starting from amine (IIa-3) and 2-oxo-3H-1,3-benzoxazole-6-sulphonyl chloride. Yield: 41%. 1H-NMR (300 MHz, DMSO-d6): δ 8.02 (t, 2H, J=8.2 Hz), 7.62-7.51 (m, 3H), 7.45-7.38 (m, 3H), 3.37-3.24 (m, 4H), 2.93-2.85 (m, 2H), 2.52-2.47 (m, 4H), 2.39 (t, 2H, J=6.7 Hz). MS: 460 [M+H+].


Compound 13
N-(4-(4-(1,2-Benzoxazol-3-yl)piperazin-1-yl)butyl)naphthalene-1-sulphonamide

The title compound was prepared starting from amine (IIa-4) and naphthalene-1-sulphonyl chloride. Yield: 64%. MS: 465 [M+H+].


Compound 14
N-(4-(4-(1,2-Benzoxazol-3-yl)piperazin-1-yl)butyl)naphthalene-2-sulphonamide

The title compound was prepared starting from amine (IIa-4) and naphthalene-2-sulphonyl chloride. Yield: 67%. MS: 465 [M+H+].


Compound 15
N-(4-(4-(1,2-Benzoxazol-3-yl)piperazin-1-yl)butyl)-3-methylbenzenesulphonamide

The title compound was prepared starting from amine (IIa-4) and 3-methylbenzene-sulphonyl chloride. Yield: 59%. MS: 429 [M+H+].


Compound 16
N-(4-(4-(1,2-Benzoxazol-3-yl)piperazin-1-yl)butyl)-2-oxo-3H-1,3-benzoxazole-6-sulphonamide

The title compound was prepared starting from amine (IIa-4) and 2-oxo-3H-1,3-benzoxazole-6-sulphonyl chloride. Yield: 71%. MS: 472 [M+H+].


Compound 17
N-[4-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]naphthalene-1-sulphonamide

The title compound was prepared starting from amine (IIa-5) and naphthalene-1-sulphonyl chloride. Yield: 52%. MS: 483 [M+H+].


Compound 18
N-[4-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]naphthalene-2-sulphonamide

The title compound was prepared starting from amine (IIa-5) and naphthalene-2-sulphonyl chloride. Yield: 44%. MS: 483 [M+H+].


Compound 19
N-[4-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-3-methylbenzene-sulphonamide

The title compound was prepared starting from amine (IIa-5) and 3-methylbenzene-sulphonyl chloride. Yield: 65%. 1H-NMR (300 MHz, CDCl3-d6): δ 7.96-7.91 (m, 1H), 7.69-7.65 (m, 2H), 7.40-7.35 (m, 2H), 7.24 (d, 1H, J=9.0 Hz), 7.05 (t, 1H, J=9 Hz), 3.13-2.96 (m, 4H), 2.41-2.34 (m, 5H), 2.31-2.04 (m, 7H), 1.60-1.58 (m, 4H). MS: 446 [M+H+].


Compound 20
N-[3-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]naphthalene-1-sulphonamide

The title compound was prepared starting from amine (IIa-6) and naphthalene-1-sulphonyl chloride. Yield: 45%. 1H-NMR (300 MHz, CDCl3-d6): δ 8.75-8.70 (m, 1H), 8.28-8.24 (m, 1H), 8.09-8.03 (m, 1H), 7.89-7.83 (m, 1H), 7.68-7.52 (m, 3H), 7.29-7.24 (m, 2H), 7.13-6.98 (m, 1H), 3.32-3.14 (m, 5H), 2.66 (t, 2H, J=6.0 Hz), 2.46-2.17 (m, 6H), 1.78 (quintet, 2H, J=6.0 Hz). MS: 468 [M+H+].


Compound 21
N-[3-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]naphthalene-2-sulphonamide

The title compound was prepared starting from amine (IIa-6) and naphthalene-2-sulphonyl chloride. Yield: 37%. 1H-NMR (300 MHz, CDCl3-d6): δ 8.44 (s, 1H), 7.99-7.83 (m, 5H), 7.67-7.57 (m, 2H), 7.27-7.23 (m, 1H), 7.11 (t, 1H, J=8.9 Hz), 3.14 (t, 3H, J=5.3 Hz), 3.03-3.02 (m, 2H), 2.47 (t, 2H, J=5.6 Hz), 2.19-2.05 (m, 6H), 1.66 (quintet, 2H, J=5.6 Hz). MS: 468 [M+H+].


Compound 22
N-[3-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-3-methylbenzene-sulphonamide

The title compound was prepared starting from amine (IIa-6) and 3-methylbenzene-sulphonyl chloride. Yield: 55%. MS: 432 [M+H+].


Compound 23
N-[2-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]naphthalene-1-sulphonamide

The title compound was prepared starting from amine (IIa-7) and naphthalene-1-sulphonyl chloride. Yield: 58%. 1H-NMR (300 MHz, CDCl3-d6): δ 8.74-8.68 (m, 1H), 8.32-8.27 (m, 1H), 8.09-8.04 (m, 1H), 7.95-7.85 (m, 1H), 7.74-7.51 (m, 3H), 7.29-7.24 (m, 2H), 7.09 (t, 1H, J=9.0 Hz), 5.57-5.30 (m, 1H), 2.98-2.85 (m, 3H), 2.48-2.40 (m, 2H), 2.29-2.22 (m, 2H), 2.00 (t, 2H, 0.1=11.5 Hz), 1.84-1.67 (m, 4H). MS: 454 [M+H+].


Compound 24
N-[2-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]naphthalene-2-sulphonamide

The title compound was prepared starting from amine (IIa-7) and naphthalene-2-sulphonyl chloride. Yield: 33%. 1H-NMR (300 MHz, DMSO-d6): δ 10.54 (s, 1H), 8.50 (s, 1H), 8.20-8.03 (m, 4H), 7.88 (d, 2H, J=6.6 Hz), 7.75-7.72 (m, 3H), 7.34 (t, 1H, J=9.2 Hz), 3.65-3.57 (m, 2H), 3.46-3.37 (m, 1H), 3.26-3.10 (m, 6H), 2.26-2.17 (m, 4H). MS: 454 [M+H+].


Compound 25
N-[2-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-3-methylbenzene-sulphonamide

The title compound was prepared starting from amine (IIa-7) and 3-methylbenzene-sulphonyl chloride. Yield: 41%. 1H-NMR (300 MHz, CDCl3-d6): δ 7.71-7.66 (m, 3H), 7.64-7.38 (m, 2H), 7.36-7.26 (m, 1H), 7.08 (t, 1H, J=9 Hz), 5.27 (s, 1H), 3.08-2.98 (m, 3H), 2.77-2.73 (m, 2H), 2.48-2.42 (m, 5H), 2.16-2.07 (m, 2H), 2.03-1.96 (m, 4H). MS: 418 [M+H+].


Compound 26
N-{4-[4-(1H-Indol-4-yl)piperazin-1-yl]butyl}naphthalene-2-sulphonamide

The title compound was prepared starting from amine (IIa-8) and naphthalene-2-sulphonyl chloride. Yield: 68%. 1H-NMR (300 MHz, CDCl3): δ 8.42 (s, 1H), 8.32 (s, 1H), 7.96-7.82 (m, 4H), 7.64-7.52 (m, 2H), 7.16-7.06 (m, 4H), 6.64-6.58 (m, 1H), 6.58-6.44 (t, 1H, J=2.3 Hz), 3.38-3.26 (m, 4H), 3.06-2.98 (m, 2H), 2.74-2.64 (m, 4H), 2.46-2.38 (m, 2H), 1.68-1.54 (m, 4H). MS: 463 [M+H+].


Compound 27
N-{4-[4-(1H-Indol-4-yl)piperazin-1-yl]butyl}benzenesulphonamide

The title compound was prepared starting from amine (IIa-8) and benzenesulphonyl chloride. Yield: 50%. 1H-NMR (300 MHz, aceton-d6): δ 10.2 (bs, 1H), 7.91-7.86 (m, 2H), 7.64-7.54 (m, 3H), 7.23 (t, 1H, J=2.8 Hz), 7.10-6.98 (m, 2H), 6.54-6.48 (m, 2H), 3.28-3.20 (m 4H), 3.00-2.94 (m, 2H), 2.78-2.64 (m, 4H), 2.50-2.42 (m, 2H), 1.66-1.52 (4H). MS: 413 [M+H+].


Compound 28
3-Fluoro-N-{4-[4-(1H-indol-4-yl)piperazin-1-yl]butyl}benzenesulphonamide

The title compound was prepared starting from amine (IIa-8) and 3-fluorobenzene-sulphonyl chloride. Yield: 61%. 1H-NMR (300 MHz, CDCl3): δ 8.30 (s, 1H), 7.90-7.84 (m, 1H), 7.68-7.62 (m, 1H), 7.58-7.52 (m, 2H), 7.48-7.38 (m, 2H), 7.21-7.18 (m, 2H), 6.66-6.60 (m, 2H), 6.54-6.48 (m, 1H), 3.38-3.30 (m, 4H), 3.06-2.98 (m, 2H), 2.80-2.42 (m, 4H), 2.50-2.48 (m, 2H), 1.68-1.60 (m, 4H). MS: 431 [M+H+].


Compound 29
3,4-Difluoro-N-{4-[4-(1H-indol-4-yl)piperazin-1-yl]butyl}benzenesulphonamide

The title compound was prepared starting from amine (IIa-8) and 3,4-difluorobenzene-sulphonyl chloride Yield: 48%. 1H-NMR (300 MHz, CDCl3): δ 8.26 (s, 1H), 7.72-7.69 (m, 1H), 7.68-7.60 (m, 1H), 7.29-7.20 (m, 2H), 7.18-7.06 (m, 2H), 6.64-6.60 (dd, 1H, J=1.2 Hz and 6.9 Hz), 6.54-6.50 (m, 1H), 3.38-3.30 (m, 4H), 3.06-2.98 (m, 2H), 2.82-2.74 (m, 4H), 2.52-2.44 (m, 2H), 1.70-1.60 (m, 4H). MS: 449 [M+H+]


Compound 30
N-{4-[4-(1H-Indol-4-yl)piperazin-1-yl]butyl}-imidazo[1,2-a]pyridine-3-sulphonamide

The title compound was prepared starting from amine (IIa-8) and imidazo[1,2-a]-pyridine-3-sulphonyl chloride. Yield: 52%. 1H-NMR (300 MHz, CDCl3): δ 8.68-8.62 (m, 1H), 8.24 (s, 1H), 8.12 (s, 1H), 7.74-7.70 (m, 1H), 7.40-7.34 (m, 1H), 7.18-7.08 (m, 3H), 6.98-6.90 (m, 1H), 6.68-6.62 (dd, 1H, J=1.2 and 6.9 Hz), 6.56-6.50 (m, 1H), 3.42-3.32 (m, 4H), 3.02-2.98 (m, 2H), 2.82-2.72 (m, 4H), 2.52-2.46 (m, 2H), 1.68-1.58 (m, 4H). MS: 453 [M+H+].


Compound 31
N-{4-[4-(1H-Indol-4-yl)piperazin-1-yl]butyl}-1H-pyrrolo[2,3-b]pyridine-3-sulphonamide

The title compound was prepared starting from amine (IIa-8) and 1H-pyrrolo-[2,3-b]-pyridine-3-sulphonyl chloride. Yield: 73%. 1H-NMR (300 MHz, CDCl3): δ 10.6 (bs, 1H), 8.38 (dd, 1H, J=1.7 and 4 Hz), 8.30 (dd, 1H, J=1.5 and 7.9 Hz), 8.22 (s, 1H), 7.86 (s, 1H), 7.22-7.08 (m, 4H), 6.62-6.60 (dd, 1H, J=1.2 and 6.9 Hz), 6.50 (t, 1H, J=2.3 Hz), 3.32-3.24 (m, 4H), 3.08-2.98 (m, 2H), 2.70-2.64 (m, 4H), 2.46-2.38 (m, 2H), 1.68-1.58 (m, 4H). MS: 453 [M+H+].


Compound 32
N-{4-[4-(1H-Indol-4-yl)piperazin-1-yl]butyl}-1-benzothiophene-3-sulphonamide

The title compound was prepared starting from amine (IIa-8) and 1-benzo-thiophene-3-sulphonyl chloride. Yield: 81%. 1H-NMR (300 MHz, CDCl3): δ 8.29-8.22 (m, 2H), 8.18 (s, 1H), 7.90-7.84 (m, 1H), 7.46-7.40 (m, 2H), 7.18-7.06 (m, 3H), 6.68-6.62 (dd, 1H, J=1.2 and 6.9 Hz), 6.52 (m, 1H), 3.38-3.32 (m, 4H), 3.06-3.00 (m, 2H), 2.78-2.68 (m, 4H), 2.46-2.40 (m, 2H), 1.60-1.52 (m, 4H). MS: 469 [M+H+].


Compound 33
N-{4-[4-(1H-Indol-4-yl)piperazin-1-yl]butyl}-1-benzothiophene-2-sulphonamide

The title compound was prepared starting from amine (IIa-8) and 1-benzothiophene-2-sulphonyl chloride. Yield: 78%. MS: 469 [M+H+].


Compound 61
N-[4-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]butyl]-6-chloro-naphthalene-2-sulphonamide, hydrochloride

The title compound was prepared starting from amine (IIa-1) and 6-chloro-naphthalene-2-sulphonyl chloride. Yield: 87%. MS: 515 [M+H+].


Compound 62
N-[3-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]propyl]-6-chloro-naphthalene-2-sulphonamide

The title compound was prepared starting from amine (IIa-2) and 6-chloro-naphthalene-2-sulphonyl chloride. Yield: 67%. MS: 501 [M+H+].


Compound 63
N-[4-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]butyl]-3-chloro-4-fluorobenzene-sulphonamide

The title compound was prepared starting from amine (IIa-1) and 3-chloro-4-fluoro-benzenesulphonyl chloride. Yield: 80%. MS: 483 [M+H+].


Compound 64
N-[3-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]propyl]-3-chloro-4-fluorobenzene-sulphonamide

The title compound was prepared starting from amine (IIa-2) and 3-chloro-4-fluoro-benzenesulphonyl chloride. Yield: 76%. MS: 469 [M+H+].


Compound 65
N-[4-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]butyl]-5-fluoro-3-methylbenzothiophene-2-sulphonamide

The title compound was prepared starting from amine (IIa-1) and 5-fluoro-3-methyl-benzothiophene-2-sulphonyl chloride. Yield: 94%. MS: 519 [M+H+].


Compound 66
N-[3-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]propyl]-5-fluoro-3-methylbenzothiophene-2-sulphonamide

The title compound was prepared starting from amine (IIa-2) and 5-fluoro-3-methyl-benzothiophene-2-sulphonyl chloride. Yield: 94%. MS: 505 [M+H+].


Compound 69
N-[4-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]butyl]-3-chlorobenzenesulphonamide

The title compound was prepared starting from amine (IIa-1) and 3-chloro-benzenesulphonyl chloride. Yield: 79%. MS: 465 [M+H+].


Compound 70
N-[3-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]propyl]-3-chlorobenzenesulphonamide

The title compound was prepared starting from amine (IIa-2) and 3-chloro-benzenesulphonyl chloride. Yield: 80%. MS: 451 [M+H+].


Compound 71
N-[4-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]butyl]-3-fluorobenzenesulphonamide

The title compound was prepared starting from amine (IIa-1) and 3-fluoro-benzenesulphonyl chloride. Yield: 81%. MS: 449 [M+H+].


Compound 72
N-[3-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]propyl]-3-fluorobenzenesulphonamide

The title compound was prepared starting from amine (IIa-2) and 3-fluorobenzene-sulphonyl chloride. Yield: 79%. MS: 435 [M+H+].


Compound 73
N-[4-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]butyl]-3-cyanobenzenesulphonamide

The title compound was prepared starting from amine (IIa-1) and 3-cyanobenzene-sulphonyl chloride. Yield: 85%. MS: 456 [M+H+].


Compound 74
N-[3-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]propyl]-3-cyanobenzenesulphonamide

The title compound was prepared starting from amine (IIa-2) and 3-cyanobenzene-sulphonyl chloride. Yield: 91%. 1H-NMR (300 MHz, DMSO-d6): δ 8.03 (dd, 2H, J=8.0 Hz, J=3.6 Hz), 7.79 (d, 2H, J=6.4 Hz), 7.74 (br. s, 1H), 7.26 (d, 2H, J=8.7 Hz), 7.54 (t, 1H, J=7.2 Hz), 7.41 (t, 1H, J=7.2 Hz), 3.38 (br. s, 4H), 2.84-2.78 (m, 2H), 2.49 (br. s, 4H), 2.31 (br.s, 2H), 1.57 (br. s, 2H). MS: 442 [M+H+].


Compound 76
N-[3-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]propyl]imidazo[1,2-a]pyridine-3-sulphonamide

The title compound was prepared starting from amine (IIa-2) and imidazo[1,2-a]-pyridine-3-sulphonyl chloride. Yield: 63%. MS: 457 [M+H+].


Compound 79
N-[4-[4-(1,2-Benzoxazol-3-yl)piperazin-1-yl]butyl]-6-chloro-naphthalene-2-sulphonamide

The title compound was prepared starting from amine (IIa-4) and 6-chloro-naphthalene-2-sulphonyl chloride. Yield: 78%. MS: 499 [M+H+].


Compound 80
N-[3-[4-(1,2-Benzoxazol-3-yl)piperazin-1-yl]propyl]-6-chloro-naphthalene-2-sulphonamide

The title compound was prepared starting from amine (IIa-13) and 6-chloro-naphthalene-2-sulphonyl chloride. Yield: 78%. MS: 485 [M+H+].


Compound 81
N-[4-[4-(1,2-Benzoxazol-3-yl)piperazin-1-yl]butyl]-5-fluoro-3-methylbenzothiophene-2-sulphonamide

The title compound was prepared starting from amine (IIa-4) and 5-fluoro-3-methylbenzothiophene-2-sulphonyl chloride. Yield: 92%. MS: 503 [M+H+].


Compound 82
N-[3-[4-(1,2-Benzoxazol-3-yl)piperazin-1-yl]propyl]-5-fluoro-3-methylbenzothiophene-2-sulphonamide

The title compound was prepared starting from amine (IIa-13) and 5-fluoro-3-methyl-benzothiophene-2-sulphonyl chloride. Yield: 51%. MS: 489 [M+H+].


Compound 85
N-[4-[4-(1,2-Benzoxazol-3-yl)piperazin-1-yl]butyl]-3-chlorobenzenesulphonamide

The title compound was prepared starting from amine (IIa-4) and 3-chlorobenzene-sulphonyl chloride. Yield: 76%. MS: 449 [M+H+].


Compound 86
N-[3-[4-(1,2-Benzoxazol-3-yl)piperazin-1-yl]propyl]-3-chlorobenzenesulphonamide

The title compound was prepared starting from amine (IIa-13) and 3-chlorobenzene-sulphonyl chloride. Yield: 72%. MS: 435 [M+H+].


Compound 87
N-[4-[4-(1,2-Benzoxazol-3-yl)piperazin-1-yl]butyl]-3-fluorobenzenesulphonamide

The title compound was prepared starting from amine (IIa-4) and 3-fluorobenzene-sulphonyl chloride. Yield: 81%. MS: 433 [M+H+].


Compound 89
N-[4-[4-(1,2-Benzoxazol-3-yl)piperazin-1-yl]butyl]-1H-pyrrolo[2,3-b]pyridine-3-sulphonamide

The title compound was prepared starting from amine (IIa-4) and 1H-pyrrolo-[2,3-b]-pyridine-3-sulphonyl chloride. Yield: 65%. MS: 455 [M+H+].


Compound 91
N-[4-[4-(1,2-Benzoxazol-3-yl)piperazin-1-yl]butyl]-3-(trifluoromethyl)benzene-sulphonamide

The title compound was prepared starting from amine (IIa-4) and 3-(trifluoromethyl)-benzenesulphonyl chloride. Yield: 90%. MS: 483 [M+H+].


Compound 92
N-[3-[4-(1,2-Benzoxazol-3-yl)piperazin-1-yl]propyl]-3-(trifluoromethyl)benzene-sulphonamide

The title compound was prepared starting from amine (IIa-13) and 3-(trifluoromethyl)-benzenesulphonyl chloride. Yield: 58%. MS: 469 [M+H+].


Compound 93
N-[4-[4-(1,2-Benzoxazol-3-yl)piperazin-1-yl]butyl]-3,4-dichlorobenzenesulphonamide

The title compound was prepared starting from amine (IIa-4) and 3,4-dichloro-benzenesulphonyl chloride. Yield: 78%. MS: 483 [M+H+].


Compound 94
N-[3-[4-(1,2-Benzoxazol-3-yl)piperazin-1-yl]propyl]-3,4-dichlorobenzenesulphonamide

The title compound was prepared starting from amine (IIa-13) and 3,4-dichloro-benzenesulphonyl chloride. Yield: 61%. 1H-NMR (300 MHz, DMSO-d6): δ 7.96 (d, 1H, J=2.1 Hz), 7.91-7.87 (m, 1H), 7.85-7.80 (m, 1H), 7.74 (d, 1H, J=8.2 Hz), 7.37 (d, 1H, J=7.4 Hz), 7.26 (d, 1H, J=7.7 Hz), 7.12 (t, 1H, J=7.5 Hz), 7.00 (t, 1H, J=7.7 Hz), 3.55 (br. s, 4H), 2.86-2.78 (m, 2H), 2.38 (br. s, 4H), 2.85 (t, 2H, J=6.9 Hz), 1.60-1.48 (m, 2H). MS: 469 [M+H+].


Compound 97
6-Chloro-N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]naphthalene-2-sulphonamide

The title compound was prepared starting from amine (IIa-5) and 6-chloro-naphthalene-2-sulphonyl chloride. Yield: 67%. MS: 516 [M+H+].


Compound 98
6-Chloro-N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]naphthalene-2-sulphonamide

The title compound was prepared starting from amine (IIa-6) and 6-chloro-naphthalene-2-sulphonyl chloride. Yield: 76%. MS: 503 [M+H+].


Compound 101
5-Fluoro-N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-3-methylbenzo-thiophene-2-sulphonamide

The title compound was prepared starting from amine (IIa-5) and 5-fluoro-3-methyl-benzothiophene-2-sulphonyl chloride. Yield: 51%. MS: 520 [M+H+].


Compound 102
5-Fluoro-N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-3-methylbenzothiophene-2-sulphonamide

The title compound was prepared starting from amine (IIa-6) and 5-fluoro-3-methyl-benzothiophene-2-sulphonyl chloride. Yield: 91%. 1H-NMR (300 MHz, DMSO-d6): δ 8.18 (br. s, 1H), 8.07 (dd, 1H, J=8.7 Hz, J=5.1 Hz), 7.93 (dd, 1H, J=8.7 Hz, J=5.1 Hz), 7.78 (dd, 1H, J=9.7 Hz, J=2.3 Hz), 7.66 (dd, 1H, J=9.2 Hz, J=2.3 Hz), 7.39 (td, 1H, J=9.0 Hz, J=2.6 Hz), 7.25 (td, 1H, J=9.5 Hz, J=2.3 Hz), 3.10-2.98 (m, 1H), 2.95 (t, 2H, J=6.3 Hz), 2.82-2.73 (m, 2H), 2.59 (s, 3H), 2.26 (t, 2H, J=7.2 Hz), 2.00-1.85 (m, 4H), 1.76-1.60 (m, 2H), 1.60-1.50 (m, 2H). MS: 506 [M+H+].


Compound 105
3-Chloro-N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]benzene-sulphonamide

The title compound was prepared starting from amine (IIa-5) and 3-chlorobenzene-sulphonyl chloride. Yield: 71%. MS: 466 [M+H+].


Compound 106
3-Chloro-N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]benzene-sulphonamide

The title compound was prepared starting from amine (IIa-6) and 3-chlorobenzene-sulphonyl chloride. Yield: 66%. MS: 453 [M+H+].


Compound 107
3-Fluoro-N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]benzene-sulphonamide

The title compound was prepared starting from amine (IIa-5) and 3-fluorobenzene-sulphonyl chloride. Yield: 68%. MS: 450 [M+H+].


Compound 108
3-Fluoro-N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]benzene-sulphonamide, hydrochloride

The title compound was prepared starting from amine (IIa-6) and 3-fluorobenzene-sulphonyl chloride. Yield: 63%. 1H-NMR (300 MHz, DMSO-d6), hydrochloride: δ 10.40 (br. s, 1H), 8.15 (dd, 1H, J=8.7 Hz, J=5.4 Hz), 7.96 (t, 1H, J=5.9), 7.73-7.49 (m, 4H), 7.33 (td, 1H, J=9.2 Hz, J=2.3 Hz), 3.61-3.50 (m, 2H), 3.50-3.41 (m, 1H), 3.17-2.99 (m, 4H), 2.89-2.80 (m, 2H), 2.34-2.14 (m, 4H), 1.95-1.81 (m, 4H). MS: 436 [M+H+].


Compound 109
3-Bromo-N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]benzene-sulphonamide

The title compound was prepared starting from amine (IIa-5) and 3-bromobenzene-sulphonyl chloride. Yield: 72%. MS: 510 [M+H+].


Compound 110
3-Bromo-N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]benzene-sulphonamide

The title compound was prepared starting from amine (IIa-6) and 3-bromobenzene-sulphonyl chloride. Yield: 59%. MS: 497 [M+H+].


Compound 111
N-[4-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-4-phenylbenzene-sulphonamide

The title compound was prepared starting from amine (IIa-5) and 4-phenylbenzene-sulphonyl chloride. Yield: 80%. MS: 508 [M+H+].


Compound 112
N-[3-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-4-phenylbenzene-sulphonamide

The title compound was prepared starting from amine (IIa-6) and 4-phenylbenzene-sulphonyl chloride. Yield: 53%. MS: 494 [M+H+].


Compound 113
N-[4-[4-(1H-Indol-4-yl)piperazin-1-yl]butyl]-3-chlorobenzenesulphonamide

The title compound was prepared starting from amine (IIa-8) and 3-chlorobenzene-sulphonyl chloride. Yield: 71%. 1H-NMR (300 MHz, CDCl3): δ 8.23 (s, 1H), 7.84 (t, 1H, J=1.8 Hz), 7.74 (dt, 1H, J=1.3 and 7.9 Hz), 7.52-7.46 (m, 1H), 7.40 (m, 1H, J=7.7 Hz), 7.16-7.08 (m, 3H), 6.64 (dd, 1H, J=1.3 and 6.9 Hz), 6.52 (t, 1H, J=2.3 Hz), 3.36-3.28 (m, 4H), 3.04-2.96 (m, 2H), 2.76-2.68 (m, 4H), 2.50-2.46 (m, 2H), 1.66-1.60 (m, 4H). MS: 447 [M+H+].


Compound 165
5-Chloro-3-methyl-N-[4-[4-(2-oxo-1,3-dihydrobenzimidazol-4-yl)piperazin-1-yl]butyl]-1-benzothiophene-2-sulfonamid

The title compound was prepared starting from amine (IIa-16) and 5-chloro-3-methyl-1-benzothiophene-2-sulphonyl chloride. Yield: 55%. MS: 534 [M+H+].


Compound 173
3-Chloro-N-[4-[4-(2-oxo-1,3-dihydrobenzimidazol-4-yl)piperazin-1-yl]butyl]benzenesulphonamide

The title compound was prepared starting from amine (IIa-16) and 3-chlorobenzene-sulphonyl chloride. Yield: 61%. MS: 464 [M+H+].


Compound 174
3-Chloro-N-[3-[4-(2-oxo-1,3-dihydrobenzimidazol-4-yl)piperazin-1-yl]propyl]benzenesulphonamide

The title compound was prepared starting from amine (IIa-17) and 3-chlorobenzene-sulphonyl chloride. Yield: 53%. MS: 450 [M+H+].


Compound 175
3-Fluoro-N-[4-[4-(2-oxo-1,3-dihydrobenzimidazol-4-yl)piperazin-1-yl]butyl]benzenesulphonamide

The title compound was prepared starting from amine (IIa-16) and 3-fluorobenzene-sulphonyl chloride. Yield: 71%. MS: 448 [M+H+].


Compound 176
3-Fluoro-N-[3-[4-(2-oxo-1,3-dihydrobenzimidazol-4-yl)piperazin-1-yl]propyl]benzenesulphonamide

The title compound was prepared starting from amine (IIa-17) and 3-fluorobenzene-sulphonyl chloride. Yield: 62%. MS: 434 [M+H+].


Compound 195
N-[4-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]butyl]-5-chloro-thiophene-2-sulphonamide

The title compound was prepared starting from amine (IIa-1) and 5-chloro-thiophene-2-sulphonyl chloride. Yield: 76%. MS: 471 [M+H+].


Compound 196
N-[3-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]propyl]-5-chloro-thiophene-2-sulphonamide

The title compound was prepared starting from amine (IIa-2) and 5-chloro-thiophene-2-sulphonyl chloride. Yield: 76%. MS: 457 [M+H+].


Compound 209
3-Chloro-N-[4-[4-(3-oxo-4H-1,4-benzoxazin-8-yl)piperazin-1-yl]butyl]benzenesulphonamide

The title compound was prepared starting from amine (IIa-18) and 3-chlorobenzene-sulphonyl chloride. Yield: 81%. 1H-NMR (300 MHz, CDCl3): 8.39 (s, 1H), 7.38 (t, 1H, J=1.7 Hz), 7.72 (dt, 1H, J=1.3 and 7.7 Hz), 7.52-7.48 (m, 1H), 7.42 (t, 1H, J=7.7 Hz), 6.91 (t, 1H, J=7.7 Hz), 6.70 (dd, 1H, J=1.5 and 8.2 Hz), 6.52 (dd, 1H, J=1.3 and 7.9 Hz), 3.22-3.10 (m, 4H), 3.02-2.92 (m, 2H), 2.72-2.64 (m, 4H), 2.48-2.38 (m, 2H), 1.68-1.58 (m, 4H). MS: 479 [M+H+].


Compound 211
3-Fluoro-N-[4-[4-(3-oxo-4H-1,4-benzoxazin-8-yl)piperazin-1-yl]butyl]benzenesulphonamide

The title compound was prepared starting from amine (IIa-18) and 3-fluorobenzene-sulphonyl chloride. Yield: 82%. 1H-NMR (300 MHz, CDCl3): 8.40 (s, 1H), 7.66-7.62 (m, 1H), 7.58-7.52 (m, 1H), 7.50-7.42 (m, 1H), 7.28-7.20 (m, 1H), 6.91 (t, 1H, J=7.9 Hz), 6.67 (dd, 1H, J=8.2 and 1.2 Hz), 6.52 (dd, 1H, J=7.7 and 1.2 Hz), 4.60 (s, 2H), 3.22-3.12 (m, 4H), 3.02-2.94 (m, 2H), 2.74-2.64 (m, 4H), 2.48-2.40 (m, 2H), 1.68-1.58 (m, 4H). MS: 463 [M+H+].


Compound 225
N-[4-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]butyl]-4-fluorobenzenesulphonamide

The title compound was prepared starting from amine (IIa-1) and 4-fluorobenzene-sulphonyl chloride. Yield: 90%. MS: 449 [M+H+].


Compound 226
N-[4-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]butyl]-3,4-difluorobenzenesulphonamide

The title compound was prepared starting from amine (IIa-1) and 3,4-difluorobenzene-sulphonyl chloride. Yield: 80%. MS: 467 [M+H+].


Compound 227
N-[4-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]butyl]-4-chlorobenzenesulphonamide

The title compound was prepared starting from amine (IIa-1) and 4-chlorobenzene-sulphonyl chloride. Yield: 84%. MS: 465 [M+H+].


Compound 228
N-[4-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]butyl]-3,4-dichlorobenzenesulphonamide

The title compound was prepared starting from amine (IIa-1) and 3,4-dichlorobenzene-sulphonyl chloride. Yield: 82%. MS: 499 [M+H+].


Compound 229
N-[4-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]butyl]-4-bromobenzenesulphonamide

The title compound was prepared starting from amine (IIa-1) and 4-bromobenzene-sulphonyl chloride. Yield: 81%. MS: 509 [M+H+].


Compound 230
N-[4-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]butyl]-3-bromobenzenesulphonamide

The title compound was prepared starting from amine (IIa-1) and 3-bromobenzene-sulphonyl chloride. Yield: 77%. MS: 509 [M+H+].


Compound 231
N-[4-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]butyl]-3-hydroxybenzenesulphonamide

The title compound was prepared starting from amine (IIa-1) and 3-hydroxybenzene-sulphonyl chloride. Yield: 41%. MS: 447 [M+H+].


Compound 232
N-[4-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]butyl]-3-methoxybenzenesulphonamide

The title compound was prepared starting from amine (IIa-1) and 3-methoxybenzene-sulphonyl chloride. Yield: 76%. MS: 461 [M+H+].


Compound 233
N-[4-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]butyl]-4-tert-butyl-benzenesulphonamide

The title compound was prepared starting from amine (IIa-1) and 4-tert-butyl-benzene-sulphonyl chloride. Yield: 65%. MS: 487 [M+H+].


Compound 234
N-[4-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]butyl]-4-(trifluoromethyl)benzenesulphonamide

The title compound was prepared starting from amine (IIa-1) and 4-trifluoromethyl-benzenesulphonyl chloride. Yield: 82%. MS: 499 [M+H+].


Compound 235
N-[4-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]butyl]-3-(trifluoromethyl)benzenesulphonamide

The title compound was prepared starting from amine (IIa-1) and 3-trifluoromethyl-benzenesulphonyl chloride. Yield: 79%. MS: 499 [M+H+].


Compound 236
N-[4-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]butyl]-4-(trifluoromethoxy)benzenesulphonamide

The title compound was prepared starting from amine (IIa-1) and 4-trifluoromethoxy-benzenesulphonyl chloride. Yield: 71%. MS: 515 [M+H+].


Compound 237
N-[4-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]butyl]-4-phenylbenzenesulphonamide

The title compound was prepared starting from amine (IIa-1) and 4-phenylbenzene-sulphonyl chloride. Yield: 94%. MS: 507 [M+H+].


Compound 238
N-[4-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]butyl]thiophene-2-sulphonamide

The title compound was prepared starting from amine (IIa-1) and thiophene-2-sulphonyl chloride. Yield: 88%. MS: 437 [M+H+].


Compound 239
N-[4-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]butyl]benzothiophene-2-sulphonamide

The title compound was prepared starting from amine (IIa-1) and benzothiophene-2-sulphonyl chloride. Yield: 71%. MS: 487 [M+H+].


Compound 240
N-[4-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]butyl]benzothiophene-3-sulphonamide

The title compound was prepared starting from amine (IIa-1) and benzothiophene-3-sulphonyl chloride. Yield: 66%. 1H-NMR (300 MHz, DMSO-d6): δ 8.43 (s, 1H), 8.19 (d, 1H, J=7.0 Hz), 8.09 (d, 1H, J=7.0 Hz), 8.02 (t, 2H, J=8.7 Hz), 7.92 (t, 1H, J=5.4 Hz), 7.57-7.39 (m, 4H), 3.36-3.31 (m, 4H), 2.88-2.81 (m, 2H), 2.42-2.36 (m, 4H), 2.14 (t, 2H, J=6.4 Hz), 1.34-1.27 (m, 4H). MS: 487 [M+H+].


Compound 241
N-[4-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]butyl]-6-chlorobenzothiophene-2-sulphonamide

The title compound was prepared starting from amine (IIa-1) and 6-chlorobenzo-thiophene-2-sulphonyl chloride. Yield: 93%. MS: 521 [M+H+].


Compound 242
N-[4-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]butyl]-2,3-dihydrobenzofuran-5-sulphonamide

The title compound was prepared starting from amine (IIa-1) and 2,3-dihydro-benzofuran-5-sulphonyl chloride. Yield: 78%. MS: 473 [M+H+].


Compound 243
N-[4-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]butyl]-1,3-benzothiazole-4-sulphonamide

The title compound was prepared starting from amine (IIa-1) and 1,3-benzothiazole-4-sulphonyl chloride. Yield: 72%. MS: 488 [M+H+].


Compound 244
N-[4-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]butyl]-1H-indazole-6-sulphonamide

The title compound was prepared starting from amine (IIa-1) and 1H-indazole-6-sulphonyl chloride. Yield: 56%. MS: 471 [M+H+].


Compound 245
N-[4-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]butyl]-1,3-benzodioxole-5-sulphonamide

The title compound was prepared starting from amine (IIa-1) and 1,3-benzodioxole-5-sulphonyl chloride. Yield: 80%. 1H-NMR (300 MHz, DMSO-d6): δ 8.03 (dd, 2H, J=8.2 Hz, J=3.6 Hz), 7.57-7.39 (m, 3H), 7.31 (d, 1H, J=8.2 Hz), 7.23 (s, 1H), 7.06 (d, 1H, J=8.2 Hz), 6.56 (s, 2H), 3.40 (br.s, 4H), 2.77-2.71 (m, 2H), 2.53 (br. s, 4H), 2.28 (br. s, 2H), 1.39 (br. s, 4H). MS: 475 [M+H+].


Compound 246
N-[4-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]butyl]imidazo[1,2-a]pyridine-3-sulphonamide

The title compound was prepared starting from amine (IIa-1) and imidazo[1,2-a]-pyridine-3-sulphonyl chloride. Yield: 60%. MS: 471 [M+H+].


Compound 247
N-[4-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]butyl]-1H-pyrrolo[2,3-b]pyridine-3-sulphonamide

The title compound was prepared starting from amine (IIa-1) and 1H-pyrrolo-[2,3-b]-pyridine-3-sulphonyl chloride. Yield: 65%. MS: 471 [M+H+].


Compound 248
N-[3-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]propyl]-4-fluorobenzenesulphonamide

The title compound was prepared starting from amine (IIa-2) and 4-fluorobenzene-sulphonyl chloride. Yield: 75%. MS: 435 [M+H+].


Compound 249
N-[3-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]propyl]-3,4-difluorobenzenesulphonamide

The title compound was prepared starting from amine (IIa-2) and 3,4-difluorobenzene-sulphonyl chloride. Yield: 89%. MS: 453 [M+H+].


Compound 250
N-[3-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]propyl]-4-chlorobenzenesulphonamide

The title compound was prepared starting from amine (IIa-2) and 4-chlorobenzene-sulphonyl chloride. Yield: 90%. MS: 452 [M+H+].


Compound 251
N-[3-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]propyl]-3,4-dichlorobenzenesulphonamide

The title compound was prepared starting from amine (IIa-2) and 3,4-dichlorobenzene-sulphonyl chloride. Yield: 87%. MS: 485 [M+H+].


Compound 252
N-[3-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]propyl]-4-bromobenzenesulphonamide

The title compound was prepared starting from amine (IIa-2) and 4-bromobenzene-sulphonyl chloride. Yield: 92%. MS: 495 [M+H+].


Compound 253
N-[3-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]propyl]-3-bromobenzenesulphonamide

The title compound was prepared starting from amine (IIa-2) and 3-bromobenzene-sulphonyl chloride. Yield: 88%. MS: 495 [M+H+].


Compound 254
N-[3-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]propyl]-3-hydroxybenzenesulphonamide

The title compound was prepared starting from amine (IIa-2) and 3-hydroxybenzene-sulphonyl chloride. Yield: 45%. MS: 433 [M+H+].


Compound 255
N-[3-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]propyl]-3-methoxybenzenesulphonamide

The title compound was prepared starting from amine (IIa-2) and 3-methoxybenzene-sulphonyl chloride. Yield: 79%. MS: 447 [M+H+].


Compound 256
N-[3-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]propyl]-4-tert-butylbenzenesulphonamide

The title compound was prepared starting from amine (IIa-2) and 4-tert-butyl-benzene-sulphonyl chloride. Yield: 93%. MS: 473 [M+H+].


Compound 257
N-[3-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]propyl]-4-(trifluoromethyl)benzenesulphonamide

The title compound was prepared starting from amine (IIa-2) and 4-(trifluoromethyl)-benzenesulphonyl chloride. Yield: 85%. MS: 485 [M+H+].


Compound 258
N-[3-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]propyl]-3-(trifluoromethyl)benzenesulphonamide

The title compound was prepared starting from amine (IIa-2) and 3-(trifluoromethyl)-benzenesulphonyl chloride. Yield: 90%. MS: 485 [M+H+].


Compound 259
N-[3-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]propyl]-4-(trifluoromethoxy)benzenesulphonamide

The title compound was prepared starting from amine (IIa-2) and 4-(trifluoromethoxy)-benzenesulphonyl chloride. Yield: 76%. MS: 501 [M+H+].


Compound 260
N-[3-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]propyl]-4-phenylbenzenesulphonamide

The title compound was prepared starting from amine (IIa-2) and 4-phenylbenzene-sulphonyl chloride. Yield: 93%. MS: 493 [M+H+].


Compound 261
N-[3-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]propyl]thiophene-2-sulphonamide

The title compound was prepared starting from amine (IIa-2) and thiophene-2-sulphonyl chloride. Yield: 86%. MS: 423 [M+H+].


Compound 262
N-[3-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]propyl]benzothiophene-2-sulphonamide

The title compound was prepared starting from amine (IIa-2) and benzothiophene-2-sulphonyl chloride. Yield: 73%. MS: 473 [M+H+].


Compound 263
N-[3-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]propyl]benzothiophene-3-sulphonamide

The title compound was prepared starting from amine (IIa-2) and benzothiophene-3-sulphonyl chloride. Yield: 77%. MS: 473 [M+H+].


Compound 264
N-[3-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]propyl]-6-chlorobenzothiophene-2-sulphonamide

The title compound was prepared starting from amine (IIa-2) and 6-chloro-benzothiophene-2-sulphonyl chloride. Yield: 86%. MS: 507 [M+H+].


Compound 265
N-[3-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]propyl]-2,3-dihydrobenzofuran-5-sulphonamide

The title compound was prepared starting from amine (IIa-2) and 2,3-dihydro-benzofuran-5-sulphonyl chloride. Yield: 92%. MS: 459 [M+H+].


Compound 266
N-[3-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]propyl]-1,2-benzoxazole-5-sulphonamide

The title compound was prepared starting from amine (IIa-2) and 1,2-benzoxazole-5-sulphonyl chloride. Yield: 75%. MS: 458 [M+H+].


Compound 267
N-[3-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]propyl]-1,3-benzothiazole-4-sulphonamide

The title compound was prepared starting from amine (IIa-2) and 1,3-benzothiazole-4-sulphonyl chloride. Yield: 83%. MS: 474 [M+H+].


Compound 268
N-[3-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]propyl]-1H-indazole-6-sulphonamide

The title compound was prepared starting from amine (IIa-2) and 1H-indazole-6-sulphonyl chloride. Yield: 57%. MS: 457 [M+H+].


Compound 269
N-[3-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]propyl]-1,3-benzodioxole-5-sulphonamide

The title compound was prepared starting from amine (IIa-2) and 1,3-benzodioxole-5-sulphonyl chloride. Yield: 84%. MS: 461 [M+H+].


Compound 270
N-[3-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]propyl]-1H-pyrrolo[2,3-b]pyridine-3-sulphonamide

The title compound was prepared starting from amine (IIa-2) and 1H-pyrrolo-[2,3-b]-pyridine-3-sulphonyl chloride. Yield: 68%. MS: 457 [M+H+].


Compound 271
N-[4-[4-(1,2-Benzoxazol-3-yl)piperazin-1-yl]butyl]-4-fluorobenzenesulphonamide

The title compound was prepared starting from amine (IIa-4) and 4-fluorobenzene-sulphonyl chloride. Yield: 89%. 1H-NMR (300 MHz, DMSO-d6): δ 7.86-7.81 (m, 2H), 7.64 (t, 1H, J=5.9 Hz), 7.48-7.35 (m, 3H), 7.26 (d, 1H, J=7.7 Hz), 7.13 (t, 1H, J=7.4 Hz), 6.99 (t, 1H, J=7.7 Hz), 3.56 (br. s, 4H), 2.79-2.72 (m, 2H), 2.41 (br. s, 4H), 2.23 (br. s, 2H), 1.37 (br. s, 4H). MS: 433 [M+H+].


Compound 272
N-[4-[4-(1,2-Benzoxazol-3-yl)piperazin-1-yl]butyl]-3,4-difluorobenzenesulphonamide

The title compound was prepared starting from amine (IIa-4) and 3,4-difluorobenzene-sulphonyl chloride. Yield: 84%. MS: 451 [M+H+].


Compound 273
N-[4-[4-(1,2-Benzoxazol-3-yl)piperazin-1-yl]butyl]-4-chlorobenzenesulphonamide

The title compound was prepared starting from amine (IIa-4) and 4-chlorobenzene-sulphonyl chloride. Yield: 93%. MS: 449 [M+H+].


Compound 274
N-[4-[4-(1,2-Benzoxazol-3-yl)piperazin-1-yl]butyl]-4-bromobenzenesulphonamide

The title compound was prepared starting from amine (IIa-4) and 4-bromobenzene-sulphonyl chloride. Yield: 91%. MS: 493 [M+H+].


Compound 275
N-[4-[4-(1,2-Benzoxazol-3-yl)piperazin-1-yl]butyl]-3-bromobenzenesulphonamide

The title compound was prepared starting from amine (IIa-4) and 3-bromobenzene-sulphonyl chloride. Yield: 71%. MS: 493 [M+H+].


Compound 276
N-[4-[4-(1,2-Benzoxazol-3-yl)piperazin-1-yl]butyl]-3-chloro-4-fluorobenzenesulphonamide

The title compound was prepared starting from amine (IIa-4) and 3-chloro-4-fluoro-benzenesulphonyl chloride. Yield: 83%. MS: 467 [M+H+].


Compound 277
N-[4-[4-(1,2-Benzoxazol-3-yl)piperazin-1-yl]butyl]-3-hydroxybenzenesulphonamide

The title compound was prepared starting from amine (IIa-4) and 3-hydroxy-benzenesulphonyl chloride. Yield: 38%. MS: 431 [M+H+].


Compound 278
N-[4-[4-(1,2-Benzoxazol-3-yl)piperazin-1-yl]butyl]-3-methoxybenzenesulphonamide

The title compound was prepared starting from amine (IIa-4) and 3-methoxy-benzenesulphonyl chloride. Yield: 89%. MS: 445 [M+H+].


Compound 279
N-[4-[4-(1,2-Benzoxazol-3-yl)piperazin-1-yl]butyl]-4-tert-butylbenzenesulphonamide, hydrochloride

The title compound was prepared starting from amine (IIa-4) and 4-tert-butyl-benzenesulphonyl chloride. Yield: 80%. MS: 471 [M+H+].


Compound 280
N-[4-[4-(1,2-Benzoxazol-3-yl)piperazin-1-yl]butyl]-4-(trifluoromethyl)benzenesulphonamide

The title compound was prepared starting from amine (IIa-4) and 4-(trifluoromethyl)-benzenesulphonyl chloride. Yield: 74%. MS: 483 [M+H+].


Compound 281
N-[4-[4-(1,2-Benzoxazol-3-yl)piperazin-1-yl]butyl]-4-(trifluoromethoxy)benzenesulphonamide

The title compound was prepared starting from amine (IIa-4) and 4-(trifluoromethoxy)-benzenesulphonyl chloride. Yield: 72%. 1H-NMR (300 MHz, DMSO-d6): δ 7.93-7.88 (m, 2H), 7.76 (t, 1H, J=5.6 Hz), 7.58 (d, 2H, J=9.0 Hz), 7.37 (d, 1H, J=7.4 Hz), 7.26 (d, 1H, J=7.6 Hz), 7.13 (d, 1H, J=7.4 Hz), 7.00 (d, 1H, J=7.5 Hz), 3.54 (br. s, 4H), 2.82-2.77 (m, 2H), 2.40 (br. s, 4H), 2.22 (br. s, 2H), 1.37 (br. s, 4H). MS: 499 [M+H+].


Compound 282
N-[4-[4-(1,2-Benzoxazol-3-yl)piperazin-1-yl]butyl]-3-cyanobenzenesulphonamide

The title compound was prepared starting from amine (IIa-4) and 3-cyanobenzene-sulphonyl chloride. Yield: 87%. MS: 440 [M+H+].


Compound 283
N-[4-[4-(1,2-Benzoxazol-3-yl)piperazin-1-yl]butyl]-4-phenylbenzenesulphonamide

The title compound was prepared starting from amine (IIa-4) and 4-phenylbenzene-sulphonyl chloride. Yield: 90%. MS: 491 [M+H+].


Compound 284
N-[4-[4-(1,2-Benzoxazol-3-yl)piperazin-1-yl]butyl]thiophene-2-sulphonamide

The title compound was prepared starting from amine (IIa-4) and thiophene-2-sulphonyl chloride. Yield: 83%. MS: 421 [M+H+].


Compound 285
N-[4-[4-(1,2-Benzoxazol-3-yl)piperazin-1-yl]butyl]-5-chloro-thiophene-2-sulphonamide

The title compound was prepared starting from amine (IIa-4) and 5-chloro-thiophene-2-sulphonyl chloride. Yield: 77%. MS: 455 [M+H+].


Compound 286
N-[4-[4-(1,2-Benzoxazol-3-yl)piperazin-1-yl]butyl]benzothiophene-2-sulphonamide

The title compound was prepared starting from amine (IIa-4) and benzothiophene-2-sulphonyl chloride. Yield: 79%. MS: 471 [M+H+].


Compound 287
N-[4-[4-(1,2-Benzoxazol-3-yl)piperazin-1-yl]butyl]benzothiophene-3-sulphonamide

The title compound was prepared starting from amine (IIa-4) and benzothiophene-3-sulphonyl chloride. Yield: 75%. MS: 471 [M+H+].


Compound 288
N-[4-[4-(1,2-Benzoxazol-3-yl)piperazin-1-yl]butyl]-6-chlorobenzothiophene-2-sulphonamide

The title compound was prepared starting from amine (IIa-4) and 6-chlorobenzo-thiophene-2-sulphonyl chloride. Yield: 69%. MS: 505 [M+H+].


Compound 289
N-[4-[4-(1,2-Benzoxazol-3-yl)piperazin-1-yl]butyl]-2,3-dihydrobenzofuran-5-sulphonamide

The title compound was prepared starting from amine (IIa-4) and 2,3-dihydro-benzofuran-5-sulphonyl chloride. Yield: 80%. MS: 457 [M+H+].


Compound 290
N-[4-[4-(1,2-Benzoxazol-3-yl)piperazin-1-yl]butyl]-1,3-benzothiazole-4-sulphonamide

The title compound was prepared starting from amine (IIa-4) and 1,3-benzothiazole-4-sulphonyl chloride. Yield: 72%. MS: 472 [M+H+].


Compound 291
N-[4-[4-(1,2-Benzoxazol-3-yl)piperazin-1-yl]butyl]-1H-indazole-6-sulphonamide

The title compound was prepared starting from amine (IIa-4) and 1H-indazole-6-sulphonyl chloride. Yield: 74%. MS: 455 [M+H+].


Compound 292
N-[4-[4-(1,2-Benzoxazol-3-yl)piperazin-1-yl]butyl]-1,3-benzodioxole-5-sulphonamide

The title compound was prepared starting from amine (IIa-4) and 1,3-benzodioxole-5-sulphonyl chloride. Yield: 88%. MS: 459 [M+H+].


Compound 293
N-[4-[4-(1,2-Benzoxazol-3-yl)piperazin-1-yl]butyl]imidazo[1,2-a]pyridine-3-sulphonamide

The title compound was prepared starting from amine (IIa-4) and imidazo[1,2-a]-pyridine-3-sulphonyl chloride. Yield: 64%. MS: 455 [M+H+].


Compound 294
4-Fluoro-N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]benzenesulphonamide

The title compound was prepared starting from amine (IIa-5) and 4-fluorobenzene-sulphonyl chloride. Yield: 79%. MS: 450 [M+H+].


Compound 295
3,4-Difluoro-N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]benzenesulphonamide

The title compound was prepared starting from amine (IIa-5) and 3,4-difluoro-benzenesulphonyl chloride. Yield: 70%. MS: 468 [M+H+].


Compound 296
4-Chloro-N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]benzenesulphonamide

The title compound was prepared starting from amine (IIa-5) and 4-chlorobenzene-sulphonyl chloride. Yield: 71%. MS: 466 [M+H+].


Compound 297
3,4-Dichloro-N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]benzenesulphonamide

The title compound was prepared starting from amine (IIa-5) and 3,4-dichlorobenzene-sulphonyl chloride. Yield: 65%. MS: 500 [M+H+].


Compound 298
4-Bromo-N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]benzenesulphonamide

The title compound was prepared starting from amine (IIa-5) and 4-bromobenzene-sulphonyl chloride. Yield: 82%. MS: 510 [M+H+].


Compound 299
3-Chloro-4-fluoro-N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]benzenesulphonamide

The title compound was prepared starting from amine (IIa-5) and 3-chloro-4-fluoro-benzenesulphonyl chloride. Yield: 70%. MS: 484 [M+H+].


Compound 300
N-[4-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-3-methoxybenzene-sulphonamide

The title compound was prepared starting from amine (IIa-5) and 3-methoxybenzene-sulphonyl chloride. Yield: 68%. MS: 462 [M+H+].


Compound 301
4-tert-Butyl-N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]benzenesulphonamide

The title compound was prepared starting from amine (IIa-5) and 4-tert-butyl-benzene-sulphonyl chloride. Yield: 69%. MS: 488 [M+H+].


Compound 302
N-[4-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-4-(trifluoromethyl)benzene-sulphonamide

The title compound was prepared starting from amine (IIa-5) and 4-(trifluoromethyl)-benzenesulphonyl chloride. Yield: 58%. MS: 500 [M+H+].


Compound 303
N-[4-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-3-(trifluoromethyl)-benzenesulphonamide

The title compound was prepared starting from amine (IIa-5) and 3-(trifluoromethyl)-benzenesulphonyl chloride. Yield: 64%. MS: 500 [M+H+].


Compound 304
N-[4-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-4-(trifluoromethoxy)-benzenesulphonamide

The title compound was prepared starting from amine (IIa-5) and 4-(trifluoromethoxy)-benzenesulphonyl chloride. Yield: 65%. MS: 516 [M+H+].


Compound 305
4-Cyano-N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]benzenesulphonamide

The title compound was prepared starting from amine (IIa-5) and 4-cyanobenzene-sulphonyl chloride. Yield: 76%. MS: 457 [M+H+].


Compound 306
3-Cyano-N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]benzenesulphonamide

The title compound was prepared starting from amine (IIa-5) and 3-cyanobenzene-sulphonyl chloride. Yield: 61%. MS: 457 [M+H+].


Compound 307
N-[4-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]thiophene-3-sulphonamide

The title compound was prepared starting from amine (IIa-5) and thiophene-3-sulphonyl chloride. Yield: 50%. MS: 438 [M+H+].


Compound 308
5-Chloro-N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]thiophene-2-sulphonamide

The title compound was prepared starting from amine (IIa-5) and 5-chloro-thiophene-2-sulphonyl chloride. Yield: 51%. MS: 472 [M+H+].


Compound 309
N-[4-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-2,5-dimethyl-thiophene-3-sulphonamide

The title compound was prepared starting from amine (IIa-5) and 2,5-dimethyl-thiophene-3-sulphonyl chloride. Yield: 67%. MS: 466 [M+H+].


Compound 310
N-[4-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-1-methyl-indole-4-sulphonamide

The title compound was prepared starting from amine (IIa-5) and 1-methyl-indole-4-sulphonyl chloride. Yield: 57%. MS: 485 [M+H+].


Compound 311
N-[4-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-1-methyl-indole-6-sulphonamide

The title compound was prepared starting from amine (IIa-5) and 1-methyl-indole-6-sulphonyl chloride. Yield: 78%. MS: 485 [M+H+].


Compound 312
N-[4-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]benzothiophene-2-sulphonamide

The title compound was prepared starting from amine (IIa-5) and benzothiophene-2-sulphonyl chloride. Yield: 51%. MS: 488 [M+H+].


Compound 313
N-[4-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]benzothiophene-3-sulphonamide

The title compound was prepared starting from amine (IIa-5) and benzothiophene-3-sulphonyl chloride. Yield: 62%. MS: 488 [M+H+].


Compound 314
6-Chloro-N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]benzothiophene-2-sulphonamide

The title compound was prepared starting from amine (IIa-5) and 6-chloro-benzothiophene-2-sulphonyl chloride. Yield: 53%. MS: 522 [M+H+].


Compound 315
5-Chloro-N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-3-methylbenzo-thiophene-2-sulphonamide

The title compound was prepared starting from amine (IIa-5) and 5-chloro-3-methyl-benzothiophene-2-sulphonyl chloride. Yield: 61%. MS: 536 [M+H+].


Compound 316
N-[4-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]benzofuran-2-sulphonamide

The title compound was prepared starting from amine (IIa-5) and benzofuran-2-sulphonyl chloride. Yield: 71%. MS: 472 [M+H+].


Compound 317
N-[4-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-2,3-dihydrobenzofuran-5-sulphonamide

The title compound was prepared starting from amine (IIa-5) and 2,3-dihydro-benzofuran-5-sulphonyl chloride. Yield: 54%. MS: 474 [M+H+].


Compound 318
N-[4-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-1,3-benzothiazole-4-sulphonamide

The title compound was prepared starting from amine (IIa-5) and 1,3-benzothiazole-4-sulphonyl chloride. Yield: 47%. MS: 489 [M+H+].


Compound 319
N-[4-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-1H-indazole-6-sulphonamide

The title compound was prepared starting from amine (IIa-5) and 1H-indazole-6-sulphonyl chloride. Yield: 58%. MS: 472 [M+H+].


Compound 320
N-[4-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-1,3-benzodioxole-5-sulphonamide, hydrochloride

The title compound was prepared starting from amine (IIa-5) and 1,3-benzodioxole-5-sulphonyl chloride. Yield: 65%. MS: 476 [M+H+].


Compound 321
N-[4-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-2,3-dihydro-1,4-benzodioxine-6-sulphonamide

The title compound was prepared starting from amine (IIa-5) and 2,3-dihydro-1,4-benzodioxine-6-sulphonyl chloride. Yield: 78%. MS: 490 [M+H+].


Compound 322
N-[4-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]imidazo[1,2-a]pyridine-3-sulphonamide

The title compound was prepared starting from amine (IIa-5) and imidazo[1,2-a]-pyridine-3-sulphonyl chloride. Yield: 47%. MS: 472 [M+H+].


Compound 323
N-[4-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-1H-pyrrolo[2,3-b]pyridine-3-sulphonamide

The title compound was prepared starting from amine (IIa-5) and 1H-pyrrolo-[2,3-b]-pyridine-3-sulphonyl chloride. Yield: 63%. MS: 472 [M+H+].


Compound 324
N-[4-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-2-oxo-indoline-5-sulphonamide

The title compound was prepared starting from amine (IIa-5) and 2-oxo-indoline-5-sulphonyl chloride. Yield: 48%. 1H-NMR (300 MHz, DMSO-d6): δ 7.98 (dd, 1H, J=8.7 Hz, J=5.4 Hz), 7.66 (dd, 1H, J=9.0 Hz, J=2.3 Hz), 7.59-7.53 (m, 2H), 7.29-7.17 (m, 2H), 3.35 (s, 2H), 3.18-3.09 (m, 1H), 2.95-2.88 (m, 2H), 2.74 (s, 2H), 2.27 (s, 2H), 2.12-1.95 (m, 6H), 1.86-1.75 (m, 2H), 1.42-1.34 (m, 4H). MS: 487 [M+H+].


Compound 325
N-[4-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]thiophene-2-sulphonamide

The title compound was prepared starting from amine (IIa-5) and thiophene-2-sulphonyl chloride. Yield: 70%. MS: 438 [M+H+].


Compound 326
4-Fluoro-N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]benzenesulphonamide

The title compound was prepared starting from amine (IIa-6) and 4-fluorobenzene-sulphonyl chloride. Yield: 56%. MS: 436 [M+H+].


Compound 327
3,4-Difluoro-N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]benzenesulphonamide

The title compound was prepared starting from amine (IIa-6) and 3,4-difluorobenzene-sulphonyl chloride. Yield: 69%. MS: 454 [M+H+].


Compound 328
4-Chloro-N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]benzenesulphonamide

The title compound was prepared starting from amine (IIa-6) and 4-chlorobenzene-sulphonyl chloride. Yield: 56%. MS: 453 [M+H+].


Compound 329
3,4-Dichloro-N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]benzenesulphonamide

The title compound was prepared starting from amine (IIa-6) and 3,4-dichlorobenzene-sulphonyl chloride. Yield: 87%. MS: 486 [M+H+].


Compound 330
4-Bromo-N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]benzenesulphonamide

The title compound was prepared starting from amine (IIa-6) and 4-bromobenzene-sulphonyl chloride. Yield: 48%. MS: 497 [M+H+].


Compound 331
3-Chloro-4-fluoro-N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]benzenesulphonamide

The title compound was prepared starting from amine (IIa-6) and 3-chloro-4-fluoro-benzenesulphonyl chloride. Yield: 83%. MS: 471 [M+H+].


Compound 332
N-[3-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-3-methoxybenzene-sulphonamide

The title compound was prepared starting from amine (IIa-6) and 3-methoxybenzene-chloride. Yield: 81%. MS: 448 [M+H+].


Compound 333
4-tert-Butyl-N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]benzenesulphonamide

The title compound was prepared starting from amine (IIa-6) and 4-tert-butyl-benzene-sulphonyl chloride. Yield: 51%. MS: 474 [M+H+].


Compound 334
N-[3-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-4-(trifluoromethyl)-benzenesulphonamide

The title compound was prepared starting from amine (IIa-6) and 4-(trifluoromethyl)-benzenesulphonyl chloride. Yield: 73%. MS: 486 [M+H+].


Compound 335
N-[3-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-3-(trifluoromethyl)-benzenesulphonamide

The title compound was prepared starting from amine (IIa-6) and 3-(trifluoromethyl)-benzenesulphonyl chloride. Yield: 48%. MS: 486 [M+H+].


Compound 336
N-[3-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-4-(trifluoromethoxy)-benzenesulphonamide

The title compound was prepared starting from amine (IIa-6) and 4-(trifluoromethoxy)-benzenesulphonyl chloride. Yield: 53%. MS: 502 [M+H+]


Compound 337
4-Cyano-N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]benzenesulphonamide

The title compound was prepared starting from amine (IIa-6) and 4-cyanobenzene-so chloride. Yield: 85%. MS: 443 [M+H+].


Compound 338
3-cyano-N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]benzenesulphonamide

The title compound was prepared starting from amine (IIa-6) and 3-cyanobenzene-chloride. Yield: 84%. MS: 443 [M+H+].


Compound 339
N-[3-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]thiophene-2-sulphonamide

The title compound was prepared starting from amine (IIa-6) and thiophene-2-sulphonyl chloride. Yield: 68%. MS: 424 [M+H+].


Compound 340
N-[3-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]thiophene-3-sulphonamide

The title compound was prepared starting from amine (IIa-6) and thiophene-3-sulphonyl chloride. Yield: 66%. MS: 424 [M+H+].


Compound 341
5-Chloro-N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]thiophene-2-sulphonamide

The title compound was prepared starting from amine (IIa-6) and 5-chloro-thiophene-2-sulphonyl chloride. Yield: 81%. MS: 459 [M+H+].


Compound 342
N-[3-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-2,5-dimethyl-thiophene-3-sulphonamide

The title compound was prepared starting from amine (IIa-6) and 2,5-dimethyl-thiophene-3-sulphonyl chloride. Yield: 58%. MS: 452 [M+H+].


Compound 343
N-[3-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-1-methyl-indole-4-sulphonamide

The title compound was prepared starting from amine (IIa-6) and 1-methyl-indole-4-sulphonyl chloride. Yield: 62%. MS: 471 [M+H+].


Compound 344
N-[3-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-1-methyl-indole-5-sulphonamide

The title compound was prepared starting from amine (IIa-6) and 1-methyl-indole-5-sulphonyl chloride. Yield: 55%. MS: 471 [M+H+].


Compound 345
N-[3-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]benzothiophene-2-sulphonamide

The title compound was prepared starting from amine (IIa-6) and benzothiophene-2-sulphonyl chloride. Yield: 57%. MS: 474 [M+H+].


Compound 346
N-[3-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]benzothiophene-3-sulphonamide

The title compound was prepared starting from amine (IIa-6) and benzothiophene-3-sulphonyl chloride. Yield: 63%. MS: 474 [M+H+].


Compound 347
6-Chloro-N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]benzothiophene-2-sulphonamide

The title compound was prepared starting from amine (IIa-6) and 6-chlorobenzo-thiophene-2-sulphonyl chloride. Yield: 66%. MS: 509 [M+H+].


Compound 348
5-Chloro-N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-3-methyl-benzothiophene-2-sulphonamide

The title compound was prepared starting from amine (IIa-6) and 5-chloro-3-methyl-benzothiophene-2-sulphonyl chloride. Yield: 88%. 1H-NMR (300 MHz, DMSO-d6): δ 8.20 (br. s, 1H), 8.08-8.02 (m, 2H), 7.93 (dd, 1H, J=8.7 Hz, J=5.4 Hz), 7.68 (dd, 1H, J=9.2 Hz, J=2.1 Hz), 7.53 (dd, 1H, J=8.5 Hz, J=2.1 Hz), 7.25 (td, 1H, J=9.0 Hz, J=2.1 Hz), 3.10-3.00 (m, 1H), 2.96 (t, 2H, J=6.7 Hz), 2.77 (br. s, 2H), 2.61 (s, 3H), 2.28 (br. s, 2H), 2.02-1.86 (m, 4H), 1.76-1.64 (m, 2H), 1.60-1.50 (m, 2H). MS: 523 [M+H+].


Compound 349
N-[3-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]benzofuran-2-sulphonamide

The title compound was prepared starting from amine (IIa-6) and benzofuran-2-sulphonyl chloride. Yield: 48%. MS: 458 [M+H+].


Compound 350
N-[3-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-2,3-dihydrobenzofuran-5-sulphonamide

The title compound was prepared starting from amine (IIa-6) and 2,3-dihydro-benzofuran-5-sulphonyl chloride. Yield: 29%. MS: 460 [M+H+].


Compound 351
N-[3-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-1,3-benzothiazole-4-sulphonamide

The title compound was prepared starting from amine (IIa-6) and 1,3-benzothiazole-4-sulphonyl chloride. Yield: 57%. MS: 475 [M+H+].


Compound 352
N-[3-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-1H-indazole-6-sulphonamide

The title compound was prepared starting from amine (IIa-6) and 1H-indazole-6-sulphonyl chloride. Yield: 80%. MS: 458 [M+H+].


Compound 353
N-[3-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-2-oxo-3H-1,3-benzoxazole-6-sulphonamide

The title compound was prepared starting from amine (IIa-6) and 2-oxo-3H-1,3-benzoxazole-6-sulphonyl chloride. Yield: 57%. MS: 475 [M+H+].


Compound 354
N-[3-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-1,3-benzodioxole-5-sulphonamide

The title compound was prepared starting from amine (IIa-6) and 1,3-benzodioxole-5-sulphonyl chloride. Yield: 65%. MS: 462 [M+H+].


Compound 355
N-[3-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-2,3-dihydro-1,4-benzo-dioxine-6-sulphonamide

The title compound was prepared starting from amine (IIa-6) and 2,3-dihydro-1,4-benzodioxine-6-sulphonyl chloride. Yield: 64%. MS: 476 [M+H+].


Compound 356
N-[3-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]imidazo[1,2-a]pyridine-3-sulphonamide

The title compound was prepared starting from amine (IIa-6) and imidazo[1,2-a]-pyridine-3-sulphonyl chloride. Yield: 62%. MS: 458 [M+H+].


Compound 357
N-[3-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-1H-pyrrolo[2,3-b]pyridine-2-sulphonamide

The title compound was prepared starting from amine (IIa-6) and 1H-pyrrolo-[2,3-b]-pyridine-2-sulphonyl chloride. Yield: 64%. MS: 458 [M+H+].


Compound 358
6-Chloro-N-[4-[4-(1H-indol-4-yl)piperazin-1-yl]butyl]naphthalene-2-sulphonamide

The title compound was prepared starting from amine (IIa-8) and 6-chloro-naphthalene-2-sulphonyl chloride. Yield: 72%. 1H-NMR (300 MHz, CDCl3): δ 8.39 (s, 1H), 8.20 (s, 1H), 7.88-7.82 (m, 3H), 7.78 (d, 1H, J=8.9 Hz), 7.49 (dd, 1H, J=2.0 and 8.7 Hz), 7.18-7.14 (m, 2H), 7.13-7.10 (m, 1H), 6.62 (dd, 1H, J=1.6 and 6.8 Hz), 6.51 (t, 1H, J=2.3 Hz), 3.35-3.30 (m, 4H), 3.09-3.00 (m, 2H), 2.75-2.70 (m, 4H), 2.49-2.42 (m, 2H), 1.65-1.60 (m, 4H). MS: 497 [M+H+].


Compound 359
4-Fluoro-N-[4-[4-(1H-indol-4-yl)piperazin-1-yl]butyl]benzenesulphonamide

The title compound was prepared starting from amine (IIa-8) and 4-fluorobenzene-sulphonyl chloride. Yield: 75%. 1H-NMR (300 MHz, CDCl3): δ 8.22 (s, 1H), 7.90-7.82 (m, 2H), 7.18-7.00 (m, 5H), 6.62 (dd, 1H, J=1.2 and 7.1 Hz), 6.52 (t, 1H, J=2.3 Hz), 3.58-3.36 (m, 4H), 3.02-2.96 (m, 2H), 2.78-2.70 (m, 4H), 2.48-2.40 (m, 2H), 1.66-1.58 (m, 4H). MS: 431 [M+H+].


Compound 360
N-[4-[4-(1H-Indol-4-yl)piperazin-1-yl]butyl]-4-(trifluoromethyl)benzenesulphonamide

The title compound was prepared starting from amine (IIa-8) and 4-(trifluoromethyl)-benzenesulphonyl chloride. Yield: 60%. 1H-NMR (300 MHz, CDCl3): δ 8.18 (s, 1H), 8.76 (d, 2H, J=7.9 Hz), 7.72 (d, 2H, J=8.2 Hz), 7.18-7.04 (m, 3H), 6.61 (dd, 1H, J=1.2 and 6.9 Hz), 6.52 (t, 1H, J=2.3 Hz), 3.36-3.18 (m, 4H), 3.08-2.96 (m, 2H), 2.78-2.70 (m, 4H), 2.48-2.40 (m, 2H), 1.68-1.60 (m, 4H). MS: 481 [M+H+].


Compound 361
N-[4-[4-(1H-Indol-4-yl)piperazin-1-yl]butyl]-3-(trifluoromethyl)benzenesulphonamide

The title compound was prepared starting from amine (IIa-8) and 3-(trifluoromethyl)-benzenesulphonyl chloride. Yield: 75%. 1H-NMR (300 MHz, CDCl3): 8.45 (s, 1H), 8.15-8.00 (m, 2H), 7.82-7.78 (m, 2H), 7.50-7.46 (d, 1H, J=6.9 Hz), 7.31-7.20 (m, 2H), 6.62-6.58 (m, 1H), 6.52-6.46 (m, 1H), 3.62-3.42 (m, 4H), 3.48-3.40 (m, 2H), 3.38-3.30 (m, 2H), 3.02-2.88 (m, 1H), 2.75-2.60 (m, 2H), 2.50-2.40 (m, 1H), 2.22-2.14 (m, 2H), 1.68-1.54 (m, 2H). MS: 481 [M+H+].


Compound 362
3-Cyano-N-[4-[4-(1H-indol-4-yl)piperazin-1-yl]butyl]benzenesulphonamide

The title compound was prepared starting from amine (IIa-8) and 3-cyanobenzene-sulphonyl chloride. Yield: 68%. 1H-NMR (300 MHz, CDCl3): δ 8.32 (s, 1H), 8.12 (t, 1H, J=1.7 Hz), 8.06 (dt, 1H, J=1.0 and 7.9 Hz), 7.78 (dd, 1H, J=1.4 and 7.9 Hz), 7.18-7.06 (m, 3H), 6.62 (dd, 1H, J=1.3 and 6.9 Hz), 6.50 (t, 1H, J=2.3 Hz), 3.36-3.28 (m, 4H), 3.04-2.96 (m, 2H), 2.80-2.72 (m, 4H), 2.50-2.42 (m, 2H), 1.70-1.60 (m, 4H). MS: 438 [M+H+].


Compound 363
6-Chloro-N-[4-[4-(1H-indol-4-yl)piperazin-1-yl]butyl]benzothiophene-2-sulphonamide

The title compound was prepared starting from amine (IIa-8) and 6-chlorobenzo-thiophene-2-sulphonyl chloride. Yield: 68%. 1H-NMR (300 MHz, CDCl3): δ 8.26 (s, 1H), 7.80 (d, 1H, J=1.8 Hz), 7.76 (d, 1H, J=0.7 Hz), 7.70 (d, 1H, J=8.4 Hz), 7.38 (dd, 1H, J=1.6 and 8.7 Hz), 7.18-7.10 (m, 4H), 6.61 (dd, 1H, J=1.6 and 6.7 Hz), 6.51 (t, 1H, J=2.3 Hz), 3.40-3.32 (m, 4H), 3.12-3.08 (m, 2H), 2.80-2.72 (m, 4H), 2.50-2.42 (m, 2H), 1.70-1.16 (m, 4H). MS: 503 [M+H+].


Compound 364
5-Fluoro-N-[4-[4-(1H-indol-4-yl)piperazin-1-yl]butyl]-3-methylbenzothiophene-2-sulphonamide

The title compound was prepared starting from amine (IIa-8) and 5-fluoro-3-methyl-benzothiophene-2-sulphonyl chloride. Yield: 75%. 1H-NMR (300 MHz, CDCl3): δ 8.24 (s, 1H), 7.78-7.68 (m, 1H), 7.50-7.39 (m, 1H), 7.28-7.20 (m, 1H), 7.16-7.04 (m, 3H), 6.60-6.58 (m, 1H), 6.56-6.50 (m, 1H), 3.38-3.32 (m, 2H), 3.28-3.19 (m, 3H), 3.16-3.10 (m, 1H), 2.78-2.68 (m, 4H), 2.68 (s, 3H), 2.50-2.44 (m, 2H), 1.68-1.60 (m, 4H). MS: 501 [M+H+].


Compound 365
N-[4-[4-(1H-Indol-4-yl)piperazin-1-yl]butyl]-1,3-benzodioxole-5-sulphonamide

The title compound was prepared starting from amine (IIa-8) and 1,3-benzodioxole-5-sulphonyl chloride. Yield: 70%. MS: 378 [M+H+].


Compound 371
N-[3-[4-(1,2-Benzoxazol-3-yl)piperazin-1-yl]propyl]naphthalene-1-sulphonamide

The title compound was prepared starting from amine (IIa-13) and naphthalene-1-sulphonyl chloride. Yield: 87%. MS: 451 [M+H+].


Compound 372
N-[3-[4-(1,2-Benzoxazol-3-yl)piperazin-1-yl]propyl]naphthalene-2-sulphonamide, hydrochloride

The title compound was prepared starting from amine (IIa-13) and naphthalene-2-sulphonyl chloride. Yield: 80%. MS: 451 [M+H+].


Compound 373
N-[3-[4-(1,2-Benzoxazol-3-yl)piperazin-1-yl]propyl]-4-fluorobenzenesulphonamide

The title compound was prepared starting from amine (IIa-13) and 4-fluorobenzene-sulphonyl chloride. Yield: 65%. MS: 419 [M+H+].


Compound 374
N-[3-[4-(1,2-Benzoxazol-3-yl)piperazin-1-yl]propyl]-3,4-difluorobenzenesulphonamide

The title compound was prepared starting from amine (IIa-13) and 3,4-difluorobenzene-sulphonyl chloride. Yield: 70%. MS: 437 [M+H+].


Compound 375
N-[3-[4-(1,2-Benzoxazol-3-yl)piperazin-1-yl]propyl]-4-chlorobenzenesulphonamide

The title compound was prepared starting from amine (IIa-13) and 4-chlorobenzene-sulphonyl chloride. Yield: 70%. MS: 435 [M+H+].


Compound 376
N-[3-[4-(1,2-Benzoxazol-3-yl)piperazin-1-yl]propyl]-4-bromobenzenesulphonamide

The title compound was prepared starting from amine (IIa-13) and 4-bromobenzene-sulphonyl chloride. Yield: 78%. MS: 479 [M+H+].


Compound 377
N-[3-[4-(1,2-Benzoxazol-3-yl)piperazin-1-yl]propyl]-3-bromobenzenesulphonamide

The title compound was prepared starting from amine (IIa-13) and 3-bromobenzene-sulphonyl chloride. Yield: 74%. MS: 479 [M+H+].


Compound 378
N-[3-[4-(1,2-Benzoxazol-3-yl)piperazin-1-yl]propyl]-3-chloro-4-fluorobenzene-sulphonamide

The title compound was prepared starting from amine (IIa-13) and 3-chloro-4-fluoro-benzenesulphonyl chloride. Yield: 60%. MS: 453 [M+H+].


Compound 379
N-[3-[4-(1,2-Benzoxazol-3-yl)piperazin-1-yl]propyl]-4-tert-butyl-benzenesulphonamide

The title compound was prepared starting from amine (IIa-13) and 4-tert-butyl-benzene-sulphonyl chloride. Yield: 59%. MS: 457 [M+H+]


Compound 380
N-[3-[4-(1,2-Benzoxazol-3-yl)piperazin-1-yl]propyl]-4-(trifluoromethyl)benzene-sulphonamide

The title compound was prepared starting from amine (IIa-13) and 4-(trifluoromethyl)-benzenesulphonyl chloride. Yield: 56%. MS: 469 [M+H+].


Compound 381
N-[3-[4-(1,2-Benzoxazol-3-yl)piperazin-1-yl]propyl]-3-cyanobenzenesulphonamide

The title compound was prepared starting from amine (IIa-13) and 3-cyanobenzene-sulphonyl chloride. Yield: 62%. MS: 426 [M+H+].


Compound 382
N-[3-[4-(1,2-Benzoxazol-3-yl)piperazin-1-yl]propyl]-4-phenylbenzenesulphonamide

The title compound was prepared starting from amine (IIa-13) and 4-phenylbenzene-so sulphonyl chloride. Yield: 78%. MS: 477 [M+H+].


Compound 383
N-[3-[4-(1,2-Benzoxazol-3-yl)piperazin-1-yl]propyl]-2,3-dihydrobenzofuran-5-sulphonamide

The title compound was prepared starting from amine (IIa-13) and 2,3-dihydro-benzofuran-5-sulphonyl chloride. Yield: 67%. MS: 443 [M+H+].


Compound 384
N-[3-[4-(1,2-Benzoxazol-3-yl)piperazin-1-yl]propyl]-1,3-benzothiazole-4-sulphonamide

The title compound was prepared starting from amine (IIa-13) and 1,3-benzothiazole-4-sulphonyl chloride. Yield: 56%. MS: 458 [M+H+].


Compound 385
N-[4-[4-(2,3-Dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]naphthalene-1-sulphonamide

The title compound was prepared starting from amine (IIa-14) and naphthalene-1-sulphonyl chloride. Yield: 81%. MS: 482 [M+H+].


Compound 386
N-[4-[4-(2,3-Dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]naphthalene-2-sulphonamide

The title compound was prepared starting from amine (IIa-14) and naphthalene-2-sulphonyl chloride. Yield: 88%. MS: 482 [M+H+].


Compound 387
6-Chloro-N-[4-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]naphthalene-2-sulphonamide

The title compound was prepared starting from amine (IIa-14) and 6-chloro-naphthalene-2-sulphonyl chloride. Yield: 74%. MS: 516 [M+H+].


Compound 388
N-[4-[4-(2,3-Dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]-3-fluorobenzene-sulphonamide

The title compound was prepared starting from amine (IIa-14) and 3-fluorobenzene-sulphonyl chloride. Yield: 70%. MS: 450 [M+H+].


Compound 389
N-[4-[4-(2,3-Dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]-3,4-difluorobenzene-sulphonamide

The title compound was prepared starting from amine (IIa-14) and 3,4-difluorobenzene-sulphonyl chloride. Yield: 77%. MS: 468 [M+H+].


Compound 390
3-Chloro-N-[4-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]benzenesulphonamide

The title compound was prepared starting from amine (IIa-14) and 3-chlorobenzene-sulphonyl chloride. Yield: 67%. MS: 466 [M+H+].


Compound 391
3-Bromo-N-[4-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]benzenesulphonamide

The title compound was prepared starting from amine (IIa-14) and 3-bromobenzene-sulphonyl chloride. Yield: 73%. 1H-NMR (300 MHz, DMSO-d6): δ 7.91 (s, 1H), 7.86-7.78 (m, 3H), 7.55 (t, 1H, J=8.0 Hz), 6.69 (t, 1H, J=8.0 Hz), 6.49-6.41 (m, 2H), 4.21-4.17 (m, 4H), 2.90 (br. s, 4H), 2.81-2.75 (m, 2H), 2.41 (br. s, 4H), 2.21 (br. s, 2H), 1.37 (br. s, 4H). MS: 510 [M+H+].


Compound 392
3-Chloro-N-[4-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]-4-fluoro-benzenesulphonamide

The title compound was prepared starting from amine (IIa-14) and 3-chloro-4-fluoro-benzenesulphonyl chloride. Yield: 68%. MS: 484 [M+H+].


Compound 393
N-[4-[4-(2,3-Dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]-3-hydroxybenzene-sulphonamide

The title compound was prepared starting from amine (IIa-14) and 3-hydroxybenzene-sulphonyl chloride. Yield: 45%. MS: 448 [M+H+].


Compound 394
N-[4-[4-(2,3-Dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]-3-methoxybenzene-sulphonamide

The title compound was prepared starting from amine (IIa-14) and 3-methoxybenzene-sulphonyl chloride. Yield: 70%. MS: 462 [M+H+].


Compound 395
N-[4-[4-(2,3-Dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]-3-methylbenzenesulphonamide

The title compound was prepared starting from amine (IIa-14) and 3-methylbenzene-sulphonyl chloride. Yield: 63%. MS: 446 [M+H+].


Compound 396
N-[4-[4-(2,3-Dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]-4-phenylbenzene-sulphonamide

The title compound was prepared starting from amine (IIa-14) and 4-phenylbenzene-sulphonyl chloride. Yield: 76%. MS: 508 [M+H+].


Compound 397
N-[4-[4-(2,3-Dihydro-1,4-benzodioxin-8-yl)piperazin-1-yl]butyl]thiophene-2-sulphonamide

The title compound was prepared starting from amine (IIa-14) and thiophene-2-sulphonyl chloride. Yield: 73%. 1H-NMR (300 MHz, DMSO-d6): δ 7.91 (d, 1H, J=5.1 Hz), 7.85 (t, 1H, J=5.7 Hz), 7.56 (d, 1H, J=3.9 Hz), 7.18-7.15 (m, 1H), 6.69 (t, 1H, J=8.2 Hz), 6.49-6.41 (m, 2H), 4.21-4.17 (m, 4H), 2.92 (br. s, 4H), 2.85-2.82 (m, 2H), 2.48 (br. s, 4H), 2.25 (br. s, 2H), 1.40 (br. s, 4H). MS: 438 [M+H+].


Compound 398
5-Chloro-N-[4-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]thiophene-2-sulphonamide

The title compound was prepared starting from amine (IIa-14) and 5-chloro-thiophene-2-sulphonyl chloride. Yield: 64%. MS: 472 [M+H+].


Compound 399
N-[4-[4-(2,3-Dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]benzothiophene-2-sulphonamide

The title compound was prepared starting from amine (IIa-14) and benzothiophene-2-sulphonyl chloride. Yield: 66%. MS: 488 [M+H+].


Compound 400
N-[4-[4-(2,3-Dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]benzothiophene-3-sulphonamide

The title compound was prepared starting from amine (IIa-14) and benzothiophene-3-sulphonyl chloride. Yield: 68%. MS: 488 [M+H+].


Compound 401
6-Chloro-N-[4-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]benzothiophene-2-sulphonamide

The title compound was prepared starting from amine (IIa-14) and 6-chlorobenzo-thiophene-2-sulphonyl chloride. Yield: 70%. MS: 522 [M+H+].


Compound 402
N-[4-[4-(2,3-Dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]-1H-indazole-6-sulphonamide

The title compound was prepared starting from amine (IIa-14) and 1H-indazole-6-sulphonyl chloride. Yield: 50%. MS: 472 [M+H+].


Compound 403
N-[4-[4-(2,3-Dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]-2-oxo-3H-1,3-benzoxazole-6-sulphonamide

The title compound was prepared starting from amine (IIa-14) and 2-oxo-3H-1,3-benzoxazole-6-sulphonyl chloride. Yield: 67%. MS: 489 [M+H+].


Compound 404
N-[4-[4-(2,3-Dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]-1,3-benzodioxole-5-sulphonamide

The title compound was prepared starting from amine (IIa-14) and 1,3-benzodioxole-5-sulphonyl chloride. Yield: 68%. MS: 476 [M+H+].


Compound 405
N-[3-[4-(2,3-Dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]naphthalene-1-sulphonamide, hydrochloride

The title compound was prepared starting from amine (IIa-15) and naphthalene-1-sulphonyl chloride. Yield: 69%. MS: 468 [M+H+].


Compound 406
N-[3-[4-(2,3-Dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]naphthalene-2-sulphonamide, hydrochloride

The title compound was prepared starting from amine (IIa-15) and naphthalene-2-sulphonyl chloride. Yield: 69%. MS: 468 [M+H+].


Compound 407
6-Chloro-N-[3-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]naphthalene-2-sulphonamide, hydrochloride

The title compound was prepared starting from amine (IIa-15) and 6-chloro-naphthalene-2-sulphonyl chloride. Yield: 80%. MS: 502 [M+H+].


Compound 408
N-[3-[4-(2,3-Dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]-4-fluorobenzene-sulphonamide, hydrochloride

The title compound was prepared starting from amine (IIa-15) and 4-fluorobenzene-sulphonyl chloride. Yield: 68%. MS: 436 [M+H+].


Compound 409
N-[3-[4-(2,3-Dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]-3-fluorobenzene-sulphonamide, hydrochloride

The title compound was prepared starting from amine (IIa-15) and 3-fluorobenzene-sulphonyl chloride. Yield: 83%. MS: 436 [M+H+].


Compound 410
N-[3-[4-(2,3-Dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]-3,4-difluorobenzene-sulphonamide

The title compound was prepared starting from amine (IIa-15) and 3,4-difluorobenzene-sulphonyl chloride. Yield: 62%. 1H-NMR (300 MHz, DMSO-d6): δ 7.86-7.63 (m, 4H), 6.69 (t, 1H, J=8.2 Hz), 6.51-6.40 (m, 2H), 4.21-4.15 (m, 4H), 2.88 (br. s, 4H), 2.82-2.75 (m, 2H), 2.39 (br. s, 4H), 2.26 (br. s, 2H), 1.51-1.47 (m, 2H). MS: 454 [M+H+].


Compound 411
3-Chloro-N-[3-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]benzenesulphonamide

The title compound was prepared starting from amine (IIa-15) and 3-chlorobenzene-sulphonyl chloride. Yield: 70%. MS: 452 [M+H+].


Compound 412
4-Bromo-N-[3-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]benzenesulphonamide, hydrochloride

The title compound was prepared starting from amine (IIa-15) and 4-bromobenzene-sulphonyl chloride. Yield: 76%. MS: 496 [M+H+].


Compound 413
3-Bromo-N-[3-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]benzenesulphonamide

The title compound was prepared starting from amine (IIa-15) and 3-bromobenzene-sulphonyl chloride. Yield: 70%. 1H-NMR (300 MHz, DMSO-d6): δ 7.93-7.74 (m, 4H), 7.58-7.52 (m, 1H), 6.68 (t, 1H, J=8.2 Hz), 6.49-6.39 (m, 2H), 4.21-4.15 (m, 4H), 2.88 (br. s, 4H), 2.81-2.70 (m, 2H), 2.37 (br. s, 4H), 2.25 (br. s, 2H), 1.54-1.49 (m, 2H). MS: 496 [M+H+].


Compound 414
N-[3-[4-(2,3-Dihydro-1,4-benzodioxin-8-yl)piperazin-1-yl]propyl]-3-methylbenzene-sulphonamide

The title compound was prepared starting from amine (IIa-15) and 3-methylbenzene-sulphonyl chloride. Yield: 78%. MS: 432 [M+H+].


Compound 415
N-[3-[4-(2,3-Dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]-4-phenylbenzene-sulphonamide, hydrochloride

The title compound was prepared starting from amine (IIa-15) and 4-phenylbenzene-sulphonyl chloride. Yield: 70%. MS: 494 [M+H+].


Compound 416
N-[3-[4-(2,3-Dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]benzothiophene-3-sulphonamide

The title compound was prepared starting from amine (IIa-15) and benzothiophene-3-sulphonyl chloride. Yield: 46%. MS: 474 [M+H+].


Compound 417
N-[3-[4-(2,3-Dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]-2,3-dihydrobenzofuran-5-sulphonamide, hydrochloride

The title compound was prepared starting from amine (IIa-15) and 2,3-dihydro-chloride. Yield: 62%. MS: 460 [M+H+].


Compound 418

N-[4-[4-(2-oxo-1,3-dihydrobenzimidazol-4-yl)piperazin-1-yl]butyl]naphthalene-1-sulphonamide


The title compound was prepared starting from amine (IIa-16) and naphthalene-1-sulphonyl chloride. Yield: 52%. MS: 480 [M+H+].


Compound 419
N-[4-[4-(2-oxo-1,3-dihydrobenzimidazol-4-yl)piperazin-1-yl]butyl]naphthalene-2-sulphonamide

The title compound was prepared starting from amine (IIa-16) and naphthalene-2-sulphonyl chloride. Yield: 76%. MS: 480 [M+H+].


Compound 420
4-Fluoro-N-[4-[4-(2-oxo-1,3-dihydrobenzimidazol-4-yl)piperazin-1-yl]butyl]benzenesulphonamide

The title compound was prepared starting from amine (IIa-16) and 4-fluorobenzene-sulphonyl chloride. Yield: 64%. MS: 448 [M+H+].


Compound 421
4-Chloro-N-[4-[4-(2-oxo-1,3-dihydrobenzimidazol-4-yl)piperazin-1-yl]butyl]benzenesulphonamide

The title compound was prepared starting from amine (IIa-16) and 4-chlorobenzene-sulphonyl chloride. Yield: 55%. MS: 464 [M+H+].


Compound 422
3-Methyl-N-[4-[4-(2-oxo-1,3-dihydrobenzimidazol-4-yl)piperazin-1-yl]butyl]benzenesulphonamide

The title compound was prepared starting from amine (IIa-16) and 3-methylbenzene-so sulphonyl chloride. Yield: 71%. MS: 444 [M+H+].


Compound 423
N-[3-[4-(2-oxo-1,3-dihydrobenzimidazol-4-yl)piperazin-1-yl]propyl]naphthalene-1-sulphonamide

The title compound was prepared starting from amine (IIa-17) and naphthalene-1-sulphonyl chloride. Yield: 56%. MS: 466 [M+H+].


Compound 424
N-[3-[4-(2-oxo-1,3-dihydrobenzimidazol-4-yl)piperazin-1-yl]propyl]naphthalene-2-sulphonamide

The title compound was prepared starting from amine (IIa-17) and naphthalene-2-sulphonyl chloride. Yield: 75%. MS: 466 [M+H+].


Compound 425
4-chloro-N-[3-[4-(2-oxo-1,3-dihydrobenzimidazol-4-yl)piperazin-1-yl]propyl]-benzenesulphonamide

The title compound was prepared starting from amine (IIa-17) and 4-chlorobenzene-sulphonyl chloride. Yield: 65%. MS: 449 [M+H+].


Compound 426
3-Methyl-N-[3-[4-(2-oxo-1,3-dihydrobenzimidazol-4-yl)piperazin-1-yl]propyl]benzenesulphonamide

The title compound was prepared starting from amine (IIa-17) and 3-methylbenzene-sulphonyl chloride. Yield: 57%. M5: 430[M+H+].


Compound 427
N-[4-[4-(3-oxo-4H-1,4-benzoxazin-8-yl)piperazin-1-yl]butyl]naphthalene-2-sulphonamide

The title compound was prepared starting from amine (IIa-18) and naphthalene-2-sulphonyl chloride. Yield: 72%. 1H-NMR (300 MHz, CDCl3): 8.40 (s, 1H), 8.39 (s, 1H), 7.96-7.70 (m, 4H), 7.64-7.54 (m, 2H), 6.91 (t, 1H, J=7.9 Hz), 6.66 (dd, 1H, J=8.2 and 1.2 Hz), 6.52 (dd, 1H, J=7.7 and 1.2 Hz), 4.60 (s, 2H), 3.20-3.12 (m, 4H), 3.08-2.98 (m, 2H), 2.70-2.60 (m, 4H), 2.42-2.38 (m, 2H), 1.62-1.54 (m, 4H). MS: 495 [M+H+].


Compound 428
4-Fluoro-N-[4-[4-(3-oxo-4H-1,4-benzoxazin-8-yl)piperazin-1-yl]butyl]benzenesulphonamide

The title compound was prepared starting from amine (IIa-18) and 4-fluorobenzene-sulphonyl chloride. Yield: 80%. 1H-NMR (300 MHz, CDCl3): 8.05 (s, 1H), 7.85-7.80 (m, 2H), 7.18-7.06 (m, 2H), 6.82 (t, 1H, J=7.9 Hz), 6.62 (dd, 1H, J=8.2 and 1.2 Hz), 6.45 (d, 1H, J=7.7 and 1.2 Hz), 4.60 (m, 2H), 3.20-3.16 (m, 4H), 3.00-2.88 (m, 2H), 2.75-2.60 (m, 4H), 2.47-2.40 (m, 2H), 1.65-1.58 (m, 4H). MS: 463 [M+H+].


Compound 429
N-[4-[4-(3-oxo-4H-1,4-benzoxazin-8-yl)piperazin-1-yl]butyl]-4-(trifluoromethyl)benzenesulphonamide

The title compound was prepared starting from amine (IIa-18) and 4-(trifluoromethyl)-benzenesulphonyl chloride. Yield: 76%. 1H-NMR (300 MHz, CDCl3): 0.90 (d, 2H, J=8.2 Hz), 7.70 (d, 2H, J=8.2 Hz), 6.84 (t, 1H, J=7.9 Hz), 6.58 (dd, 1H, J=8.2 and 1.2 Hz), 6.50 (dd, 1H, J=7.7 and 1.2 Hz), 4.60 (s, 2H), 3.10-3.00 (m, 4H), 2.92-2.88 (m, 2H), 2.62-2.58 (m, 4H), 2.38-2.28 (m, 2H), 1.58-1.50 (m, 4H). MS: 513 [M+H+].


Compound 430
N-[4-[4-(3-oxo-4H-1,4-benzoxazin-8-yl)piperazin-1-yl]butyl]-3-(trifluoromethyl)benzenesulphonamide

The title compound was prepared starting from amine (IIa-18) and 3-(trifluoromethyl)-benzenesulphonyl chloride. Yield: 65%. 1H-NMR (300 MHz, CDCl3): 7.60-7.54 (m, 1H), 7.50-7.42 (m, 1H), 7.28-7.24 (m, 1H), 7.12-6.68 (m, 1H), 7.00-7.68 (m, 1H), 6.62 (d, 1H, so J=6.6 Hz), 6.52 (d, 1H, J=3.0 Hz), 5.20 (s, 2H), 3.40-3.37 (m, 4H), 3.37-3.30 (m, 1H), 3.04-2.98 (m, 2H), 2.86-2.78 (m, 4H), 2.76-2.70 (m, 1H), 1.68-1.60 (m, 4H). MS: 513 [M+H+].


Compound 431
5-Chloro-N-[4-[4-(3-oxo-4H-1,4-benzoxazin-8-yl)piperazin-1-yl]butyl]thiophene-2-sulphonamide

The title compound was prepared starting from amine (IIa-18) and 5-chloro-thiophene-2-sulphonyl chloride. Yield: 85%. 1H-NMR (300 MHz, CDCl3): 8.70 (s, 1H), 7.33 (d, 1H, J=3.8 Hz), 6.93-6.88 (m, 2H), 6.67 (dd, 1H, J=8.2 and 1.2 Hz), 6.52 (dd, 1H, J=7.7 and 1.2 Hz), 4.60 (s, 2H), 3.20-3.12 (m, 4H), 3.08-3.00 (m, 2H), 2.72-2.64 (m, 4H), 2.46-2.40 (m, 2H), 1.68-1.60 (m, 4H). MS: 485 [M+H+].


b) General Procedure for Compounds Wherein in Formula (IIa) Represents Double Bond.

0.2 Mmol of amine (IIa) was dissolved in 5 ml of anhydrous N,N-dimethylformamide, and then 4 mmol of N,N-diisopropylethylamine was added. The mixture was purged with argon, and 0.24 mmol of appropriate arylsulphonyl chloride was subsequently added (IIb). After 30 minutes of stirring at room temperature the mixture was poured into is about 20 ml of ice water. The mixture was extracted with ethyl acetate or methylene chloride. Organic layer was washed with brine, dried over anhydrous sodium sulphate, and then concentrated under reduced pressure. Crude sulphonamides were usually purified by means of crystallization (from methanol), and some of them using column chromatography on silica gel with using methylene chloride/methanol 20:1 as eluent. Structure of prepared compounds was confirmed by MS data, and purity by HPLC analysis. For selected compounds structure identification was further confirmed by 1H-NMR analysis.


Following the general procedure described above and starting from appropriate compounds amine (IIa) and arylsulphonyl chloride (IIb), the following compounds were obtained.


Compound 34
N-{4-[4-(5-Chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]butyl}naphthalene-1-sulphonamide

The title compound was prepared starting from amine (IIa-9) and naphthalene-1-sulphonyl chloride. Yield: 42%. MS: 494 [M+H+].


Compound 35
N-{4-[4-(5-Chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]butyl}naphthalene-2-sulphonamide

The title compound was prepared starting from amine (IIa-9) and naphthalene-2-sulphonyl chloride. Yield: 40%. MS: 494 [M+H+].


Compound 36
4-Fluoro-N-{4-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]butyl}benzenesulphonamide

The title compound was prepared starting from amine (IIa-9) and 4-fluorobenzene-sulphonyl chloride. Yield: 42%. MS: 462 [M+H+].


Compound 37
3-Fluoro-N-{4-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]butyl}benzenesulphonamide

The title compound was prepared starting from amine (IIa-9) and 3-fluorobenzene-sulphonyl chloride. Yield: 60%. MS: 462 [M+H+].


Compound 38
4-Chloro-N-{4-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]butyl}benzenesulphonamide

The title compound was prepared starting from amine (IIa-9) and 4-chlorobenzene-sulphonyl chloride. Yield: 55%. MS: 478 [M+H+].


Compound 39
3-Chloro-N-{4-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]butyl}benzenesulphonamide

The title compound was prepared starting from amine (IIa-9) and 3-chlorobenzene-sulphonyl chloride. Yield: 30%. MS: 478 [M+H+].


Compound 40
3-Methyl-N-{4-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]butyl}benzenesulphonamide

The title compound was prepared starting from amine (IIa-9) and 3-methylbenzene-sulphonyl chloride. Yield: 55%. MS: 458 [M+H+].


Compound 41
3-Hydroxy-N-{4-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]butyl}-benzenesulphonamide

The title compound was prepared starting from amine (IIa-9) and 3-hydroxybenzene-sulphonyl chloride. Yield: 20%. MS: 460 [M+H+].


Compound 42
4-Methoxy-N{4-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]butyl}benzenesulphonamide

The title compound was prepared starting from amine (IIa-9) and 4-methoxybenzene-sulphonyl chloride. Yield: 52%. MS: 474 [M+H+].


Compound 43
N-{3-[4-(5-Chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]propyl}naphthalene-1-sulphonamide

The title compound was prepared starting from amine (IIa-10) and naphthalene-1-sulphonyl chloride. Yield: 99%. MS: 480 [M+H+].


Compound 44
N-{3-[4-(5-Chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]propyl}naphthalene-2-sulphonamide

The title compound was prepared starting from amine (IIa-10) and naphthalene-2-sulphonyl chloride. Yield: 76%. MS: 480 [M+H+].


Compound 45
4-Fluoro-N-{3-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]propyl}benzenesulphonamide

The title compound was prepared starting from amine (IIa-10) and 4-fluoro-benzenesulphonyl chloride. Yield: 99%. MS: 448 [M+H+].


Compound 46
3-Fluoro-N-{3-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]propyl}benzenesulphonamide

The title compound was prepared starting from amine (IIa-10) and 3-fluorobenzene-sulphonyl chloride. Yield: 98%. MS: 448 [M+H+].


Compound 47
4-Chloro-N-{3-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]propyl}benzenesulphonamide

The title compound was prepared starting from amine (IIa-10) and 4-chlorobenzene-sulphonyl chloride. Yield: 72%.


Compound 48
3-Chloro-N-{3-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]propyl}-benzenesulphonamide

The title compound was prepared starting from amine (IIa-10) and 3-chlorobenzene-sulphonyl chloride. Yield: 98%. MS: 464 [M+H+].


Compound 49
3-Hydroxy-N-[3-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]propyl]-benzenesulphonamide

The title compound was prepared starting from amine (IIa-10) and 3-hydroxybenzene-sulphonyl chloride. Yield: 29%. MS: 446 [M+H+].


Compound 50
N-{2-[4-(5-Chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]ethyl}naphthalene-1-sulphonamide

The title compound was prepared starting from amine (IIa-11) and naphthalene-1-sulphonyl chloride. Yield: 99%. MS: 466 [M+H+].


Compound 51
N-{2-[4-(5-Chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]ethyl}naphthalene-2-sulphonamide

The title compound was prepared starting from amine (IIa-11) and naphthalene-2-sulphonyl chloride. Yield: 99%. MS: 466 [M+H+].


Compound 52
N-{2-[4-(5-Chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]ethyl}-4-fluorobenzene-sulphonamide

The title compound was prepared starting from amine (IIa-11) and 4-fluorobenzene-sulphonyl chloride. Yield: 98%. MS: 434 [M+H+].


Compound 53
3-Fluoro-N-{2-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]ethyl}benzene-sulphonamide

The title compound was prepared starting from amine (IIa-11) and 3-fluorobenzene-sulphonyl chloride. Yield: 52%. MS: 434 [M+H+].


Compound 54
4-Chloro-N-{2-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]ethyl}benzenesulphonamide

The title compound was prepared starting from amine (IIa-11) and 4-chlorobenzene-sulphonyl chloride. Yield: 98%. MS: 450 [M+H+].


Compound 55
3-Chloro-N-{2-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]ethyl}benzenesulphonamide

The title compound was prepared starting from amine (IIa-11) and 3-chlorobenzene-sulphonyl chloride. Yield: 89%. MS: 450 [M+H+].


Compound 56
3-Methyl-N-{2-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]ethyl}benzenesulphonamide

The title compound was prepared starting from amine (IIa-11) and 3-methylbenzene-sulphonyl chloride. Yield: 48%. MS: 430 [M+H+].


Compound 57
3-Hydroxy-N-{2-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]ethyl}-benzenesulphonamide

The title compound was prepared starting from amine (IIa-11) and 3-hydroxybenzene-sulphonyl chloride. Yield: 12%. MS: 432 [M+H+].


Compound 58
4-Chloro-N-{4-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]butyl}benzenesulphonamide

The title compound was prepared starting from amine (IIa-12) and 4-chlorobenzene-sulphonyl chloride. Yield: 10%. MS: 492 [M+H+].


Compound 137
N-[4-[4-(5-Chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]butyl]-3-chloro-benzenesulphonamide

The title compound was prepared starting from amine (IIa-12) and 3-chlorobenzene-sulphonyl chloride. Yield: 95%. MS: 492 [M+H+].


Compound 138
N-[3-[4-(5-Chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]propyl]-3-chlorobenzenesulphonamide

The title compound was prepared starting from amine (IIa-22) and 3-chlorobenzene-sulphonyl chloride. Yield: 89%. MS: 478 [M+H+].


Compound 139
N-[4-[4-(5-Chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]butyl]-3-fluorobenzenesulphonamide

The title compound was prepared starting from amine (IIa-12) and 3-fluorobenzene-sulphonyl chloride. Yield: 86%. MS: 476 [M+H+].


Compound 140
N-[3-[4-(5-Chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]propyl]-3-fluorobenzenesulphonamide

The title compound was prepared starting from amine (IIa-22) and 3-fluorobenzene-sulphonyl chloride. Yield: 85%. MS: 462 [M+H+].


Compound 141
N-[4-[4-(5-Chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]butyl]-4-tert-butyl-benzenesulphonamide

The title compound was prepared starting from amine (IIa-12) and 4-tert-butyl-benzenesulphonyl chloride. Yield: 67%. MS: 514 [M+H+].


Compound 366
N-[4-[4-(5-Chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]butyl]-naphthalene-1-sulphonamide

The title compound was prepared starting from amine (IIa-12) and naphthalene-1-sulphonyl chloride. Yield: 60%. MS: 508 [M+H+].


Compound 367
N-[4-[4-(5-Chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]butyl]-naphthalene-2-sulphonamide

The title compound was prepared starting from amine (IIa-12) and naphthalene-2-sulphonyl chloride. Yield: 82%. MS: 508 [M+H+].


Compound 368
N-[4-[4-(5-Chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]butyl]-4-fluorobenzenesulphonamide

The title compound was prepared starting from amine (IIa-12) and 4-fluorobenzenesulphonyl chloride. Yield: 93%. MS: 376 [M+H+].


Compound 369
N-[4-[4-(5-Chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]butyl]-3-hydroxybenzenesulphonamide

The title compound was prepared starting from amine (IIa-12) and 3-hydroxybenzene-sulphonyl chloride. Yield: 43%. MS: 474 [M+H+].


Compound 370
N-[4-[4-(5-Chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]butyl]-3-methylbenzenesulphonamide

The title compound was prepared starting from amine (IIa-12) and 3-methylbenzene-sulphonyl chloride. Yield: 84%. MS: 472 [M+H+].


Compound 432
N-[4-[4-(5-Fluoro-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]butyl]naphthalene-2-sulphonamide

The title compound was prepared starting from amine (IIa-19) and naphthalene-2-sulphonyl chloride. Yield: 65%. 1H-NMR (300 MHz, CDCl3): 8.40 (s, 1H), 8.20 (s, 1H), 6.98 (t, 1H, J=3.4 Hz), 6.02 (s, 1H), 3.15-3.10 (m, 2H), 2.98-2.90 (m, 2H), 2.80-2.72 (m, 4H), 2.56-2.52 (m, 2H), 1.65-1.48 (m, 4H). MS: 478 [M+H+].


Compound 433
3-Fluoro-N-[4-[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]butyl]benzenesulphonamide

The title compound was prepared starting from amine (IIa-19) and 3-fluorobenzene-sulphonyl chloride. Yield: 78%. 1H-NMR (300 MHz, CD3OD): 8.01 (q, 1H, J=4.6 Hz), 7.88 (d, 1H, J=3.6 Hz), 7.78-7.62 (m, 2H), 7.58-7.48 (m, 2H), 7.38-7.32 (dt, 1H, J=8.9 and 2.5 Hz), 6.04-5.98 (m, 1H), 3.20-3.18 (m, 2H), 2.92 (t, 2H, J=6.4 Hz), 2.78 (t, 2H, J=6.1 Hz), 2.64-2.58 (m, 2H), 2.46 (t, 2H, J=6.9 Hz), 1.62-1.50 (m, 4H). MS: 446 [M+H+].


Compound 434
N-[4-[4-(5-Fluoro-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]butyl]-3-hydroxybenzenesulphonamide

The title compound was prepared starting from amine (IIa-19) and 3-hydroxybenzene-sulphonyl chloride. Yield: 67%. MS: 444 [M+H+].


Compound 435
N-[4-[4-(5-Fluoro-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]butyl]-3-methylbenzene-sulphonamide

The title compound was prepared starting from amine (IIa-19) and 3-methylbenzene-sulphonyl chloride. Yield: 76%. 1H-NMR (300 MHz, CD3OD): 7.54-7.46 (m, 3H), 7.30-7.18 (m, 4H), 6.90 (dt, 1H, J=8.9 and 2.5 Hz), 6.04-5.98 (m, 1H), 3.38-3.30 (m, 2H), 2.87 (t, 2H, J=5.9 Hz), 2.80-2.60 (m, 4H), 2.48 (t, 2H, J=6.6 Hz), 1.58-1.52 (m, 4H). MS: 442 [M+H+].


Compound 436
3-Fluoro-N-[3-[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]propyl]benzenesulphonamide

The title compound was prepared starting from amine (IIa-20) and 3-fluorobenzene-sulphonyl chloride. Yield: 70%. 1H-NMR (300 MHz, CD3OD): 7.54-7.46 (m, 3H), 7.30-7.18 (m, 4H), 6.90 (dt, 1H, J=8.9 and 2.5 Hz), 6.04-5.98 (m, 1H), 3.38-3.30 (m, 2H), 2.87 (t, 2H, J=5.9 Hz), 2.80-2.60 (m, 4H), 2.48 (t, 2H, J=6.6 Hz), 1.58-1.52 (m, 4H). MS: 432 [M+H+].


Compound 437
N-[3-[4-(5-Fluoro-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]propyl]-3-hydroxybenzene-sulphonamide

The title compound was prepared starting from amine (IIa-20) and 3-hydroxybenzene-sulphonyl chloride. Yield: 62%. M5: 430[M+H+].


Compound 438
N-[2-[4-(5-Fluoro-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]ethyl]naphthalene-2-sulphonamide

The title compound was prepared starting from amine (IIa-21) and naphthalene-2-sulphonyl chloride. Yield: 54%. MS: 450 [M+H+].


Compound 439
3-Fluoro-N-[2-[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]ethyl]benzenesulphonamide

The title compound was prepared starting from amine (IIa-21) and 3-fluorobenzene-sulphonyl chloride. Yield: 70%. 1H-NMR (300 MHz, CDCl3): 8.17 (s, 1H), 7.70-7.46 (m, 4H), 7.32-7.20 (m, 3H), 7.00-6.94 (m, 1H), 6.02-5.98 (m, 1H), 3.12 (t, 2H, J=5.3 Hz), 3.06-3.02 (m, 2H), 2.62-2.48 (m, 4H), 1.76-1.62 (m, 2H). MS: 418 [M+H+].


Compound 440
N-[2-[4-(5-Fluoro-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]ethyl]-3-methylbenzenesulphonamide

The title compound was prepared starting from amine (IIa-21) and 3-methylbenzene-sulphonyl chloride. Yield: 83%. 1H-NMR (300 MHz, CD3OD): 7.71-7.62 (m, 2H), 7.48-7.40 is (m, 3H), 7.32-7.28 (m, 2H), 6.86 (dt, 1H, J=8.9 and 2.5 Hz), 6.12-6.10 (m, 1H), 3.38 (s, 3H), 3.18-3.14 (m, 2H), 3.10-3.06 (m, 2H), 2.72-2.68 (m, 2H), 2.60-2.54 (m, 2H), 2.38-2.34 (m, 2H). MS: 414 [M+H+].


Compound 441
N-[3-[4-(5-Chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]propyl]-naphthalene-1-sulphonamide

The title compound was prepared starting from amine (IIa-22) and naphthalene-1-sulphonyl chloride. Yield: 74%. MS: 494 [M+H+].


Compound 442
N-[3-[4-(5-Chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]propyl]-naphthalene-2-sulphonamide

The title compound was prepared starting from amine (IIa-22) and naphthalene-2-sulphonyl chloride. Yield: 67%. MS: 494 [M+H+].


Compound 443
N-[3-[4-(5-Chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]propyl]-4-fluorobenzenesulphonamide

The title compound was prepared starting from amine (IIa-22) and 4-fluorobenzene-sulphonyl chloride. Yield: 50%. MS: 462 [M+H+].


Compound 444
4-Chloro-N-[3-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]propyl]-benzenesulphonamide

The title compound was prepared starting from amine (IIa-22) and 4-chlorobenzene-sulphonyl chloride. Yield: 69%. MS: 478 [M+H+].


Compound 445
N-[3-[4-(5-Chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]propyl]-3-hydroxybenzenesulphonamide

The title compound was prepared starting from amine (IIa-22) and 3-hydroxybenzene-sulphonyl chloride. Yield: 40%. MS: 460 [M+H+].


Compound 446
N-[3-[4-(5-Chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]propyl]-3-methylbenzenesulphonamide

The title compound was prepared starting from amine (IIa-22) and 3-methylbenzene-sulphonyl chloride. Yield: 82%. MS: 458 [M+H+].


Compound 447
N-[2-[4-(5-Chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]ethyl]-naphthalene-1-sulphonamide

The title compound was prepared starting from amine (IIa-23) and naphthalene-1-sulphonyl chloride. Yield: 89%. MS: 480 [M+H+].


Compound 448
N-[2-[4-(5-Chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]ethyl]-naphthalene-2-sulphonamide

The title compound was prepared starting from amine (IIa-23) and naphthalene-2-sulphonyl chloride. Yield: 61%. MS: 480 [M+H+].


Compound 449
N-[2-[4-(5-Chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]ethyl]-4-fluorobenzenesulphonamide

The title compound was prepared starting from amine (IIa-23) and 4-fluorobenzene-sulphonyl chloride. Yield: 45%. MS: 448 [M+H+].


Compound 450
N-[2-[4-(5-Chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]ethyl]-3-fluorobenzenesulphonamide

The title compound was prepared starting from amine (IIa-23) and 3-fluorobenzene-sulphonyl chloride. Yield: 56%. MS: 448 [M+H+].


Compound 451
4-Chloro-N-[2-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]ethyl]-benzensulphonamide

The title compound was prepared starting from amine (IIa-23) and 4-chlorobenzene-sulphonyl chloride. Yield: 88%. MS: 464 [M+H+].


Compound 452
3-Chloro-N-[2-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]ethyl]-benzenesulphonamide

The title compound was prepared starting from amine (IIa-23) and 3-chlorobenzene-sulphonyl chloride. Yield: 63%. MS: 464 [M+H+].


Compound 453
N-[2-[4-(5-Chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]ethyl]-3-hydroxybenzenesulphonamide

The title compound was prepared starting from amine (IIa-23) and 3-hydroxybenzene-sulphonyl chloride. Yield: 46%. MS: 446 [M+H+].


Compound 454
N-[2-[4-(5-Chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]ethyl]-3-methylbenzenesulphonamide

The title compound was prepared starting from amine (IIa-23) and 3-methylbenzene-sulphonyl chloride. Yield: 51%. MS: 444 [M+H+].


Tests In Vitro
EXAMPLE 4
In Vitro Pharmacology: Binding Assays

The affinity of compounds of the present invention to dopaminergic, serotoninergic, adrenergic, muscarinic M3, histaminergic H1, sigma and serotonin transporter receptors was tested using the methods as described below, consisting in measuring their binding to these receptors using radioreceptors methods.


The specific ligand binding to the receptors is defined as the difference between the total binding and the nonspecific binding determined in the presence of an excess of so unlabelled ligand.


The results are expressed as a percent of control specific binding ((measured specific binding/control specific binding)×100) and as a percent inhibition of control specific binding (100−((measured specific binding/control specific binding)×100)) obtained in the presence of the test compounds. The specific Ligand binding to the receptor is is defined as the difference between total and non-specific binding determined in the presence of an excess of unlabelled ligand. The compounds were tested at a concentration of 1×10−6 M, and scintillation counting was the method of detection of ligand binding. Conditions and methodology (by reference to the literature) of in vitro tests are given in Table 1 and the tests results for representative compounds are given in Table 2 (dopaminergic receptor D2), in Table 3 (dopaminergic receptor D3), in Table 4 (serotoninergic receptors 5-HT1A and 5-HT2A), in Table 5 (serotoninergic receptors 5-HT6 and 5-HT7), in Table 6 (serotonine transporter (SERT) receptor), in Table 7 (sigma receptor σ), in Table 8 (adrenergic α1 receptor), in Table 9 (adrenergic α2C receptor), in Table 10 (histaminergic H1 receptor), in Table 11 (muscarinic M3 receptor) and in Table 12 (serotoninergic receptor 5-HT2C).









TABLE 1







Conditions and methodology of in vitro tests for binding assays














Assay
Origin
Radioligand
Concentration
Kd
Non Specific
Incubation
Ref.





a1 (non-selective)
rat cerebral cortex
[3H]prazosin
0.25 nM
 0.09 nM
prazosin (0.5 μM)
 60 min 22° C.
 1


a2C (h)
human recombinant
[3H]RX 821002
  2 nM
 0.95 nM
(−)epinephrine (100 μM)
 60 min 22° C.
 2



(CHO cells)








D2S (h)
human recombinant
[3H]methyl-
 0.3 nM
 0.15 nM
(+)butaclamol (10 μM)
 60 min 22° C.
 3



(HEK-293 cells)
spiperone







D3 (h)
human recombinant
[3H]methyl-
 0.3 nM
0.085 nM
(+)butaclamol (10 μM)
 60 min 22° C.
 4



(CHO cells)
spiperone







H1 (h)
human recombinant
[3H]pyrilamine
  1 nM
 1.7 nM
pyrilamine (1 μM)
 60 min 22° C.
 5



(HEK-293 cells)








M3 (h)
human recombinant
[3H]4-DAMP
 0.2 nM
 0.5 nM
atropine (1 μM)
 60 min 22° C.
 6



(CHO cells)








5-HT1A (h)
human recombinant
[3H]8-OH-DPAT
 0.3 nM
 0.5 nM
8-OH-DPAT (10 μM)
 60 min 22° C.
 7



(HEK-293 cells)








5-HT2A (h)
human recombinant
[3H]ketanserin
 0.5 nM
 0.6 nM
ketanserin (1 μM)
 60 min 22° C.
 8



(HEK-293 cells)








5-HT2C (h)
human recombinant
[3H]mesulergine
  1 nM
 0.5 nM
RS 102221 (10 μM)
120 min 37° C.
 9



(HEK-293 cells)








5-HT6 (h)
human recombinant
[3H]LSD
  2 nM
 1.8 nM
serotonin (100 μM)
120 min 37° C.
10



(CHO cells)








5-HT7 (h)
human recombinant
[3H]LSD
  4 nM
 2.3 nM
serotonin (10 μM)
120 min 22° C.
11



(CHO cells)








σ (non-selective)
rat cerebral cortex
[3H]DTG
  8 nM
  29 nM
haloperidol (10 μM)
120 min 22° C.
12


SERT (h)
human recombinant
[3H]imipramine
  2 nM
 1.7 nM
imipramine (10 μM)
 60 min 22° C.
13



(CHO cells)
















TABLE 2







Results of dopaminergic receptor D2 affinity test for representative compounds




















Cpd.
D2 [%]
Cpd.
D2 [%]
Cpd.
D2 [%]
Cpd.
D2 [%]
Cpd.
D2 [%]
Cpd.
D2 [%]
Cpd.
D2 [%]























1
97
43
100
107
104
249
98
307
88
349
93
406
59


2
98
44
100
108
106
250
97
308
96
350
102
407
58


3
96
45
100
109
100
251
97
309
84
351
101
408
40


4
96
46
100
110
109
252
97
310
96
352
100
409
79


5
96
47
100
111
108
253
99
311
105
353
91
411
40


6
96
48
99
112
103
254
87
312
99
354
83
414
48


7
95
49
99
113
98
255
98
313
101
355
99
415
58


8
98
50
97
137
65
256
97
314
99
356
98
416
59


9
91
51
97
138
40
257
99
315
99
357
99
417
68


10
94
52
99
139
52
258
95
316
98
358
96
418
97


11
89
53
99
140
47
259
93
317
105
359
96
419
93


12
93
54
98
165
64
260
99
318
67
360
99
423
97


13
99
55
98
174
91
261
97
319
109
361
99
424
97


14
99
56
100
176
89
262
98
320
100
362
101
425
91


15
90
57
100
195
99
263
98
321
98
363
99
426
28


16
99
58
97
196
98
264
87
322
96
364
100
427
83


17
98
61
100
209
82
267
100
323
105
365
99
428
78


18
98
62
92
211
81
268
98
324
105
366
54
429
61


19
97
63
99
225
77
269
99
325
96
367
49
430
69


20
98
64
98
226
87
270
74
326
109
368
41
431
68


21
99
65
99
227
104
273
88
327
89
369
67
435
78


22
96
66
101
228
103
274
96
328
108
370
58
437
57


23
97
69
106
229
101
276
95
329
109
385
75
438
97


24
99
70
99
230
105
282
97
330
108
386
70
439
97


25
96
71
103
231
99
283
99
331
100
1387
90
440
44


26
97
72
99
232
92
288
103
332
83
388
50
441
77


27
90
73
102
233
83
289
99
333
92
389
50
442
22


28
98
74
93
234
85
291
99
334
75
390
61
443
22


29
94
76
94
235
103
293
85
335
105
391
76
1444
40


30
98
79
99
236
99
294
105
336
97
392
57
445
98


31
38
81
90
237
62
295
95
337
59
393
46
446
44


32
101
85
100
238
87
296
105
338
98
394
72
447
3


33
97
87
87
239
102
297
93
339
96
395
61
449
31


34
99
89
89
240
101
298
99
340
101
396
68
450
15


35
99
91
92
241
100
299
87
341
98
398
73
451
46


36
100
93
98
242
105
300
96
342
106
399
79
452
42


37
100
97
100
243
100
301
96
343
101
400
83
453
48


38
100
98
101
244
105
302
90
344
107
401
84
454
−5


38
101
101
99
245
97
303
108
345
109
402
68




40
100
102
100
246
98
304
94
346
100
403
85




41
93
105
107
247
104
305
88
347
103
404
60




42
74
106
108
248
99
306
106
348
104
405
68
















TABLE 3







Results of dopaminergic receptor D3 affinity test for representative compounds




















Compd.
D3 [%]
Compd.
D3 [%]
Compd.
D3 [%]
Compd.
D3 [%]
Compd.
D3 [%]
Compd.
D3 [%]
Compd.
D3 [%]























1
96
45
100
110
97
251
97
310
97
353
97
414
81


2
100
46
100
111
93
252
98
311
101
354
88
415
76


3
98
47
101
112
98
253
99
312
97
355
97
416
56


4
98
48
97
113
99
254
98
313
99
356
96
417
67


5
98
49
99
137
92
255
82
314
100
357
94
418
99


6
97
50
95
138
57
256
96
315
97
358
99
419
97


7
97
51
87
139
92
257
100
316
95
359
100
420
97


8
97
52
99
140
73
258
97
317
97
360
100
421
94


9
90
53
99
165
89
259
85
318
95
361
98
422
98


10
97
54
98
173
98
260
98
319
90
362
102
423
98


11
91
55
96
174
96
261
98
320
99
363
101
424
98


12
92
56
99
175
87
262
98
321
98
364
100
425
104


13
92
57
98
176
95
263
98
322
93
365
100
426
94


14
97
58
100
195
89
264
65
323
96
366
81
427
104


15
88
61
96
196
97
267
99
324
103
367
87
428
104


16
99
62
63
209
103
268
98
325
95
368
94
429
104


17
93
63
103
211
102
269
100
326
99
369
97
430
101


18
98
64
98
225
76
270
82
327
97
370
91
431
103


19
90
65
74
226
90
273
85
328
99
385
89
434
98


20
96
66
101
227
90
274
91
329
99
386
88
435
95


21
97
69
77
228
92
276
69
330
99
387
93
436
96


22
96
70
101
229
95
282
87
331
100
388
83
437
100


23
93
71
91
230
87
283
101
332
96
389
85
438
98


24
98
72
95
231
97
288
102
333
89
390
81
439
95


25
94
73
94
232
89
289
79
334
96
391
85
440
92


26
98
74
92
233
76
291
85
335
93
392
93
441
72


27
96
76
71
234
91
293
65
336
96
393
92
442
53


28
99
79
96
235
87
294
95
337
79
394
86
443
71


29
98
81
97
236
85
295
98
338
100
395
87
444
74


30
98
85
77
237
85
296
100
339
100
396
86
445
97


31
96
87
77
238
85
297
100
340
101
398
90
446
66


33
101
89
95
239
102
298
98
341
98
399
92
447
−17


34
100
91
70
240
99
299
98
342
99
400
88
449
34


35
101
93
86
241
97
300
96
343
96
401
95
450
39


36
100
97
100
242
89
301
96
344
101
402
89
451
30


37
101
98
104
243
93
302
99
345
100
403
99
452
14


38
100
101
92
244
91
303
97
346
93
404
92
453
56


38
101
102
103
245
97
304
87
347
103
405
62
454
58


40
100
105
88
246
86
305
103
348
102
406
54




41
100
106
97
247
83
306
99
349
100
407
84




42
101
107
97
248
100
307
95
350
95
408
70




43
99
108
98
249
100
308
95
351
103
409
85




44
98
109
99
250
85
309
90
352
97
411
52
















TABLE 4







Results of serotoninergic receptors 5-HT1A and 5-HT2A affinity tests for representative compounds





















Compd.
5-HT1A
5-HT2A
Compd.
5-HT1A
5-HT2A
Compd.
5-HT1A
5-HT2A
Compd.
5-HT1A
5-HT2A
Compd.
5-HT1A
5-HT2A
























1
96
99
62
46
101
240
98
101
314
75
102
386
96
65


2
99
100
63
97
100
241
98
101
315
70
102
387
100
90


3
98
100
64
99
101
242
92
94
316
84
102
388
92
19


4
99
99
65
100
101
243
98
100
317
45
98
389
118
56


5
99
99
66
98
101
244
69
96
318
96
89
390
101
59


6
99
100
69
80
92
245
99
99
319
55
88
391
97
68


7
99
100
70
99
101
246
91
88
320
69
101
392
100
64


8
100
100
71
89
94
247
78
88
321
78
100
393
93
47


9
98
99
72
95
94
248
97
101
322
43
94
394
95
71


10
97
99
74
99
102
249
100
101
323
45
96
395
75
61


11
99
99
73
92
81
250
98
92
324
56
104
396
85
58


12
99
99
76
90
81
251
99
101
325
62
102
397
95
13


13
89
100
79
84
91
252
99
101
326
59
96
398
107
38


14
88
100
81
92
101
253
99
101
327
67
91
399
99
82


15
86
99
85
54
88
254
94
90
328
58
90
400
100
66


16
93
100
87
41
89
255
93
84
329
69
91
401
103
79


17
84
100
89
71
99
256
96
102
330
67
93
402
102
76


18
81
100
91
40
95
257
99
101
331
82
102
403
98
64


19
64
100
93
48
90
258
100
101
332
71
97
404
97
55


20
71
100
97
75
100
259
97
56
333
42
99
405
97
74


21
77
100
98
80
102
260
96
102
334
86
90
406
99
28


22
75
99
101
82
100
261
98
102
335
54
97
407
88
50


23
85
100
102
92
101
262
99
102
336
61
100
408
101
−50


24
80
100
105
41
91
263
98
102
337
41
102
409
81
66


25
92
100
106
63
97
264
54
105
338
80
102
410
96
42


26
100
98
107
38
95
267
98
101
339
76
82
411
95
4


27
99
62
108
48
88
268
98
102
340
45
104
413
88
40


28
100
89
109
86
93
269
99
101
341
74
102
414
98
76


29
99
64
110
55
99
270
75
89
342
74
106
415
96
25


30
100
67
111
39
96
273
46
95
343
32
105
416
101
58


31
82
36
112
20
93
274
73
97
344
42
105
417
100
−48


33
100
95
113
100
69
276
51
87
345
45
93
418
98
36


34
100
50
137
39
47
282
50
78
346
51
97
419
98
52


35
99
60
138
54
62
283
89
103
347
92
101
423
99
30


36
97
54
139
57
41
288
86
95
348
36
107
424
99
66


37
99
48
140
56
68
289
68
94
349
49
108
425
98
25


38
98
46
165
70
37
291
38
83
350
57
95
426
79
20


38
100
55
174
98
−24
293
57
89
351
71
103
427
84
49


40
99
49
176
97
7
294
23
95
352
89
101
428
90
30


41
77
84
195
89
91
295
68
99
353
48
101
429
88
35


42
90
77
196
99
102
296
34
93
354
59
86
430
86
87


43
99
36
209
92
29
297
31
95
355
60
103
431
101
31


44
94
55
211
86
32
298
67
100
356
95
99
435
83
57


45
98
59
225
87
84
299
45
89
357
63
101
436
85
56


46
98
57
226
90
100
300
80
102
358
100
99
437
24
74


47
98
49
227
89
90
301
77
101
359
100
79
438
97
63


48
98
45
228
81
91
302
50
95
360
83
67
439
99
83


49
99
88
229
92
80
303
35
96
361
95
49
440
76
37


50
99
45
230
85
87
304
60
76
362
91
41
441
54
57


51
97
48
232
89
100
305
58
96
363
101
98
442
14
61


52
99
88
231
97
101
306
44
97
364
92
89
443
59
67


53
100
74
233
53
100
307
73
99
365
90
55
444
51
65


54
94
74
234
95
92
308
81
102
366
34
49
445
93
78


55
98
53
235
86
80
309
64
88
367
49
51
446
73
66


56
99
85
236
76
89
310
91
99
368
−7
64
447
42
19


57
99
89
237
51
24
311
49
105
369
62
79
449
57
76


58
94
51
238
90
95
312
86
99
370
57
65





61
94
100
239
98
101
313
72
101
385
103
77
















TABLE 5







Results of serotoninergic receptors 5-HT6 and 5-HT7


affinity tests for representative compounds









Compd.
5-HT6
5-HT7












1
95
96


2
97
97


3
83
97


4
87
97


5
84
98


6
88
98


7
98
97


8
91
97


9
22
98


10
37
99


11
54
99


12
80
89


13
96
100


14
99
99


15
71
100


16
94
99


17
99
99


18
100
98


19
69
100


20
85
101


21
93
99


22
99
99


23
69
96


24
76
95


25
71
98


26
51
98


27
34
92


28
98
92


29
37
91


30
5
96


31
18
87


32
23


33
42
99


34
87
87


35
88
88


36
81
90


37
80
89


38
86
90


38
88
93


40
82
92


41
89
76


42
96
76


43
83
97


44
83
97


45
90
96


46
84
97


47
83
98


48
91
98


49
93
99


50
95
95


51
94
94


52
99
98


53
98
99


54
97
95


55
98
97


56
99
100


57
98
102


58
84
46


61
96
100


62
69
78


63
89
99


64
99
99


65
97
98


66
95
101


69
88
96


70
99
100


71
76
99


72
78
101


73
82
91


74
95
97


76
70
86


79
97
97


81
98
99


85
77
99


87
67
90


89
94
98


91
83
99


93
92
88


97
98
93


98
98
98


101
98
98


102
97
97


105
87
85


106
93
91


107
75
91


108
86
90


109
84
92


110
96
91


111
95
93


112
94
95


113
74
97


137
91
33


138
95
52


139
96
56


140
92
81


165
−16
86


174
4
92


176
29
80


195
60
98


196
92
100


209
70
85


211
32
81


225
74
92


226
78
92


227
76
94


228
87
98


229
75
89


230
85
101


231
95
99


232
76
89


233
76
93


234
62
97


235
82
93


236
67
91


237
89
64


238
74
88


239
96
98


240
98
97


241
96
99


242
73
101


243
73
99


244
81
98


245
82
98


246
49
86


247
93
93


248
98
98


249
101
100


250
73
88


251
99
99


252
93
99


253
101
99


254
76
93


255
68
91


256
95
100


257
94
101


258
98
100


259
74
96


260
92
100


261
83
100


262
93
99


263
96
98


264
63
75


267
95
100


268
93
99


269
98
101


270
70
82


273
74
97


274
81
83


276
78
87


282
64
98


283
96
99


288
98
100


289
78
91


291
83
99


293
44
93


294
72
94


295
93
99


296
83
91


297
87
88


298
98
100


299
84
75


300
89
99


301
94
98


302
72
101


303
90
98


304
78
93


305
78
85


306
81
89


307
76
85


308
83
99


309
79
87


310
89
89


311
99
95


312
98
97


313
100
100


314
100
99


315
98
98


316
93
97


317
78
89


318
76
92


319
87
90


320
82
99


321
89
100


322
62
95


323
92
93


324
78
78


325
72
98


326
94
94


327
99
86


328
87
92


329
97
95


330
83
90


331
97
99


332
95
64


333
93
92


334
98
85


335
93
88


336
92
92


337
76
87


338
94
98


339
89
89


340
72
90


341
93
78


342
100
96


343
77
92


344
91
95


345
91
91


346
95
87


347
99
100


348
96
87


349
87
91


350
96
87


351
89
94


352
95
100


353
58
83


354
86
96


355
75
84


356
78
99


357
94
99


358
70
94


359
42
95


360
67
100


361
70
86


362
69
88


363
84
98


364
80
91


365
67
95


366
98
53


367
86
23


368
96
42


369
99
7


370
88
42


385
10
99


386
1
82


387
26
96


388
−20
90


389
19
93


390
26
66


391
19
92


392
7
91


393
9
91


394
18
98


395
−35
83


396
31
88


398
3
97


399
23
96


400
9
95


401
27
91


402
1
100


403
−21
95


404
4
96


405
53
93


406
54
92


407
37
102


408
35
83


409
−9
91


411
41
89


414
−15
94


415
15
92


416
55
99


417
24
62


418
5
89


419
12
86


423
16
88


424
69
95


425
5
95


426
−4
85


427
36
98


428
33
78


429
−57
83


430
94
84


431
35
67


435
58
64


437
47
83


438
96
92


439
92
78


440
86
68


441
84
82


442
87
61


443
92
54


444
87
59


445
84
98


446
96
21


447
106
34


449
93
81


450
96
50


451
97
25


452
108
41


453
107
76


454
102
68
















TABLE 6







Results of serotonine transporter (SERT) receptor


affinity tests for representative compounds










Compd.
SERT [%]














1
49



2
69



3
57



4
26



5
84



6
95



7
88



8
63



9
29



10
50



11
1



12
7



13
7



14
3



15
−3



16
−3



17
44



18
39



19
8



20
85



21
46



22
44



23
68



24
53



25
20



26
14



27
−3



28
53



29
12



30
14



31
−2



33
−4



34
101



35
99



36
101



37
101



38
101



38
101



40
101



41
94



42
96



43
100



44
100



45
98



46
102



47
101



48
101



49
101



50
98



51
100



52
100



53
99



54
99



55
98



56
99



57
100



58
78



61
55



62
15



63
53



64
80



65
57



66
93



69
6



70
82



71
41



72
44



73
37



74
79



76
15



79
3



81
28



85
2



87
2



89
2



91
2



93
0



97
61



98
54



101
47



102
38



105
−11



106
2



107
−12



108
−9



109
15



110
8



111
−14



112
−17



113
28



137
38



138
25



139
17



140
14



165
4



174
11



176
−3



195
−3



196
75



209
−1



211
33



225
−4



226
4



227
2



228
16



229
9



230
13



231
59



232
13



233
5



234
32



235
8



236
−15



237
−7



238
13



239
64



240
46



241
50



242
12



243
63



244
19



245
38



246
31



247
14



248
80



249
77



250
23



251
87



252
94



253
79



254
9



255
29



256
93



257
93



258
80



259
16



260
90



261
60



262
87



263
87



264
−18



267
91



268
86



269
96



270
12



273
22



274
30



276
3



282
12



283
24



288
−14



289
9



291
8



293
3



294
−14



295
16



296
49



297
23



298
35



299
14



300
30



301
45



302
19



303
9



304
4



305
−18



306
−10



307
−3



308
28



309
−5



310
57



311
34



312
35



313
23



314
50



315
68



316
47



317
−17



318
45



319
8



320
13



321
61



322
16



323
41



324
37



325
20



326
19



327
−1



328
7



329
−2



330
−2



331
31



332
18



333
5



334
30



335
−25



336
41



337
35



338
21



339
3



340
9



341
8



342
26



343
4



344
31



345
−10



346
17



347
33



348
6



349
0



350
−5



351
31



352
56



353
−1



354
6



355
45



356
11



357
41



358
40



359
33



360
8



361
6



362
37



363
32



364
35



365
25



366
8



367
4



368
14



369
29



370
30



385
6



386
−5



387
−14



388
−28



389
44



390
−15



391
−28



392
−11



393
−7



394
12



395
69



396
16



398
−7



399
−22



400
30



401
−8



402
16



403
−9



404
−9



405
−5



406
10



407
−2



408
−18



409
2



411
12



414
18



415
−5



416
−4



417
−11



418
5



419
−21



423
25



424
−3



425
10



426
−18



427
13



428
23



429
22



430
19



431
12



435
81



437
105



438
97



439
93



440
70



441
1



442
4



443
−9



444
44



445
68



446
20



447
23



449
21



450
54



451
32



452
18



453
23



454
14

















TABLE 7







Results of sigma σ receptor affinity tests for representative compounds










Compd.
σ [%]














1
54



2
65



3
66



4
1



5
72



6
59



7
61



8
17



9
23



10
31



11
21



12
4



13
87



14
40



15
47



16
2



17
83



18
70



19
92



20
81



21
82



22
92



23
82



24
80



25
76



26
99



27
78



28
84



29
93



30
42



33
94



34
51



35
42



36
57



37
66



38
46



38
57



40
68



43
58



44
45



45
74



46
79



47
53



48
67



49
61



50
61



51
55



52
80



53
79



54
66



55
79



56
78



57
75



58
34



61
46



63
54



64
54



65
62



66
61



70
64



74
34



79
37



81
59



89
−1



97
55



98
50



101
70



102
74



113
92



174
−16



176
−25



196
66



231
62



239
69



240
44



241
51



243
29



245
52



248
64



249
68



251
61



252
59



253
64



256
41



257
57



258
61



260
41



261
57



262
51



263
49



267
50



268
30



269
49



283
34



288
45



295
63



298
68



300
83



301
73



308
86



312
71



313
83



314
49



315
72



316
81



320
80



321
74



325
85



331
79



338
72



347
57



352
76



356
70



357
64



358
84



359
85



363
96



418
6



419
−14



423
9



424
−3



425
−3



438
79



439
80



445
67

















TABLE 8







Results of adrenergic α1 receptor affinity tests for


representative compounds










Compd.
α1 [%]














1
99



2
97



3
100



4
96



5
98



6
95



7
98



8
94



9
74



10
79



11
85



12
67



13
102



14
102



15
102



16
101



17
100



18
101



19
99



20
99



21
97



22
100



23
97



24
97



25
98



26
98



27
96



28
92



29
99



30
96



31
101



33
100



34
81



35
70



36
84



37
82



38
77



38
84



40
86



41
87



42
77



43
70



44
54



45
84



46
78



47
68



48
71



49
84



50
50



51
40



52
57



53
61



54
43



55
46



56
61



57
65



58
76



61
94



62
61



63
99



64
93



65
95



66
93



69
94



70
96



71
99



72
93



73
98



74
94



76
95



79
88



81
96



85
98



87
98



89
98



91
99



93
97



97
98



98
97



101
99



102
99



105
96



106
101



107
100



108
100



109
101



110
103



111
100



112
99



113
99



137
10



138
8



139
20



140
17



165
47



173
89



174
86



175
82



176
77



195
96



196
93



209
90



211
80



225
94



226
94



227
92



228
92



229
96



230
98



231
96



232
94



233
94



234
91



235
95



236
92



237
87



238
103



239
99



240
96



241
93



242
98



243
97



244
98



245
96



246
99



247
98



248
91



249
99



250
95



251
95



252
27



253
97



254
96



255
92



256
87



257
94



258
97



259
88



260
91



261
−90



262
95



263
90



264
53



267
97



268
90



269
97



270
88



273
101



274
99



276
95



282
102



283
92



288
94



289
100



291
99



293
98



294
101



295
96



296
101



297
100



298
103



299
98



300
96



301
96



302
100



303
97



304
101



305
99



306
99



307
105



308
91



309
103



310
107



311
107



312
100



313
100



314
100



315
−13



316
90



317
99



318
98



319
94



320
98



321
98



322
103



323
103



324
103



325
95



326
101



327
109



328
101



329
102



330
102



331
101



332
107



333
106



334
105



335
101



336
107



337
93



338
99



339
108



340
110



341
108



342
103



343
86



344
106



345
102



346
103



347
99



348
90



349
98



350
102



351
97



352
99



353
103



354
103



355
105



356
101



357
99



358
88



359
97



360
93



361
98



362
96



363
92



364
87



365
100



366
8



367
9



368
34



369
50



370
38



385
96



386
96



387
86



388
91



389
93



390
73



391
90



392
99



393
91



394
92



395
92



396
84



397
92



398
97



399
99



400
94



401
90



402
94



403
98



404
93



405
82



406
77



407
72



408
70



409
81



410
84



411
87



413
90



414
88



415
78



416
81



417
73



418
98



419
86



420
82



421
88



422
86



423
91



424
93



425
93



426
67



427
86



428
72



429
78



430
46



431
88



435
48



437
52



438
44



439
27



440
14



441
16



442
1



443
41



444
26



445
50



446
29



447
1



449
12



450
−1



451
−4



452
14



453
23



454
7

















TABLE 9







Results of adrenergic α2C receptor affinity tests for


representative compounds










Compd.
α2C [%]














1
100



2
101



3
99



4
96



5
99



6
93



7
96



8
93



9
98



10
98



11
94



12
83



13
99



14
100



15
98



16
101



17
100



18
100



19
100



20
99



21
98



22
100



23
99



24
99



25
98



26
100



27
100



28
92



29
98



30
99



33
100



34
98



35
96



36
92



37
93



38
93



39
98



40
97



43
94



44
86



45
88



46
87



47
92



48
88



49
86



50
97



51
94



52
88



53
87



54
91



55
82



56
90



57
78



58
80



61
101



63
98



64
100



65
104



66
103



70
100



74
92



79
106



81
106



89
98



97
100



98
108



101
106



102
101



113
99



174
55



176
44



196
95



231
99



239
105



240
100



241
98



243
96



245
101



248
93



249
98



251
96



252
95



253
102



256
92



257
99



258
98



260
99



261
92



262
94



263
93



267
99



268
99



269
101



283
109



288
109



295
97



298
98



300
94



301
98



308
96



312
92



313
100



314
108



315
93



316
94



320
101



321
100



325
93



331
104



338
104



347
110



352
100



356
96



357
94



358
101



359
99



363
101



418
94



419
93



423
69



424
67



425
59



438
94



439
68



445
69

















TABLE 10







Results of histaminergic H1 receptor affinity tests for representative


compounds










Compd.
H1 [%]














1
91



2
94



3
94



4
100



5
92



6
93



7
93



8
97



9
77



10
81



11
74



12
79



13
84



14
88



15
84



16
97



17
80



18
79



19
79



20
78



21
90



22
88



23
67



24
56



25
62



26
52



27
27



28
57



29
74



30
40



33
56



34
67



35
51



36
66



37
56



38
67



39
69



40
56



43
41



44
41



45
62



46
60



47
56



48
57



49
74



50
10



51
17



52
45



53
38



54
28



55
18



56
96



57
35



58
75



61
97



63
99



64
98



65
95



66
99



70
97



74
90



79
96



81
93



89
85



97
91



98
100



101
97



102
94



113
60



174
25



176
8



196
93



231
97



239
98



240
92



241
97



243
93



245
98



248
97



249
97



251
−220



252
−77



253
98



256
94



257
91



258
97



260
95



261
92



262
95



263
93



267
92



268
95



269
92



283
96



288
94



295
95



298
90



300
87



301
88



308
92



312
86



313
90



314
93



315
90



316
85



320
84



321
95



325
83



331
97



338
95



347
98



352
97



356
80



357
84



358
74



359
60



363
70



418
55



419
12



423
16



424
28



425
6



438
67



439
18



445
60

















TABLE 11







Results of muscarinic M3 receptor affinity tests for


representative compounds










Compd.
M3 [%]














1
13



2
17



3
13



4
3



5
7



6
−1



7
13



8
−11



9
−2



10
−2



11
−6



12
−9



13
−1



14
−6



15
−9



16
−1



17
7



18
6



19
9



20
−9



21
2



22
12



23
−2



24
10



25
6



26
17



27
46



28
50



29
25



30
66



33
5



34
9



35
4



36
−3



37
11



38
9



39
11



40
10



43
−7



44
11



45
9



46
8



47
3



48
8



49
10



50
10



51
1



52
5



53
8



54
8



55
8



56
3



57
10



58
11



61
5



63
11



64
7



65
8



66
10



70
25



74
17



79
12



81
6



89
22



97
16



98
16



101
14



102
18



113
29



174
15



176
6



196
18



231
11



239
9



240
15



241
4



243
10



245
25



248
13



249
9



251
8



252
16



253
24



256
15



257
12



258
15



260
11



261
15



262
19



263
7



267
13



268
14



269
20



283
−4



288
3



295
19



298
19



300
18



301
18



308
30



312
19



313
25



314
13



315
24



316
28



320
24



321
14



325
26



331
10



338
1



347
12



352
12



356
2



357
25



358
17



359
63



363
15



418
4



419
−8



423
−1



424
7



425
2



438
15



439
16



445
27

















TABLE 12







Results of serotoninergic 5-HT2C receptor affinity tests for representative


compounds










Cpd.
5-HT2C [%]














1
80



2
89



3
77



4
91



5
81



6
88



7
89



8
90



9
24



10
54



11
40



12
17



13
34



14
51



15
23



16
53



17
62



18
73



19
56



20
75



21
87



22
73



23
44



24
65



25
32



26
19



27
−1



28
6



29
11



30
11



33
27



34
51



35
30



36
34



37
35



38
31



39
50



40
50



43
67



44
56



45
70



46
73



47
60



48
64



49
92



50
18



51
14



52
36



53
28



54
24



55
26



56
50



57
58



58
21



61
95



63
95



64
v



65
95



66
86



70
88



74
78



79
72



81
50



89
34



97
89



98
91



101
80



102
76



113
10



174
0



176
9



196
89



231
87



239
88



240
78



241
96



243
81



245
72



248
84



249
89



251
83



252
84



253
89



256
94



257
83



258
86



260
90



261
87



262
84



263
87



267
78



268
78



269
92



283
80



288
32



295
51



298
52



300
49



301
79



308
57



312
80



313
59



314
85



315
78



316
66



320
46



321
65



325
49



331
82



338
76



347
99



352
78



356
83



357
83



358
62



359
12



363
57



418
19



419
7



423
9



424
8



425
24



438
59



439
41



445
67










EXAMPLE 5
In Vitro Pharmacology: Cellular Functional Assays

The results are expressed as a percent of control specific agonist response ((measured specific response/control specific agonist response)×100) for agonist effect and as a percent inhibition of control specific agonist response (100−((measured specific response/control specific agonist response)×100)) for antagonist effect obtained in the presence of the test compounds. The compounds were tested at the concentration of 1×10−6M.


Conditions and methodology (by reference to the literature) of cellular functional assays are given in Table 13 and the tests results for representative compounds are given in Table 14 (dopaminergic receptor D2), in Table 15 (dopaminergic receptor D3), in Table 16 (serotoninergic receptor 5-HT1A), in Table 17 (serotoninergic receptor 5-HT2A), in Table 18 (serotoninergic receptor 5-HT6), in Table 19 (serotoninergic receptor 5-HT7), in Table 20 (adrenergic α1 receptor), in Table 21 (adrenergic α2C receptor), in Table 22 (histaminergic H1 receptor) and in Table 23 (serotoninergic 5-HT2C receptor). In the Tables ag refers to agonism, and antag to antagonism).









TABLE 13







Conditions and methodology of in vitro tests for cellular functional assays

















Reaction
Method of



Assay
Origin
Stimulus
Incubation
Product
Detection
Ref.





M3 (h)
human recombinant
none
22° C.
intracellular
Fluorimetry
14


(agonist effect)
(CHO cells)
(1 μM acetylcholine for control)

[Ca2+]


M3 (h)
human recombinant
acetylcholine
22° C.
intracellular
Fluorimetry
14


(antagonist effect)
(CHO cells)
(10 nM)

[Ca2+]


5-HT7 (h)
human recombinant
none

45 min

cAMP
HTRF
15


(agonist effect)
(CHO cells)
(10 μM serotonin for control)
37° C.


5-HT7 (h)
human recombinant
serotonin

45 min

cAMP
HTRF
15


(antagonist effect)
(CHO cells)
(300 nM)
37° C.


5-HT6 (h)
human recombinant
none

45 min

cAMP
HTRF
16


(agonist effect)
(CHO cells)
(10 μM serotonin for control)
37° C.


5-HT6 (h)
human recombinant
serotonin

45 min

cAMP
HTRF
16


(antagonist effect)
(CHO cells)
(100 nM)
37° C.


D2S (h)
human recombinant
none
28° C.
impedance
cellular dielectric
17


(agonist effect)
(HEK-293 cells)
(3 μM dopamine for control)


spectroscopy


D2S (h)
human recombinant
dopamine
28° C.
impedance
cellular dielectric
17


(antagonist effect)
(HEK-293 cells)
(30 nM)


spectroscopy


5-HT2C (h)
human recombinant
none

30 min

IP1
HTRF
18


(agonist effect)
(HEK-293 cells)
(1 μM serotonin for control)
37° C.


5-HT2C (h)
human recombinant
serotonin

30 min

IP1
HTRF
18


(antagonist effect)
(HEK-293 cells)
(10 nM)
37° C.


H1 (h)
human recombinant
none
22° C.
intracellular
Fluorimetry
19


(agonist effect)
(HEK-293 cells)
(10 μM histamine for control)

[Ca2+]


H1 (h)
human recombinant
histamine
22° C.
intracellular
Fluorimetry
19


(antagonist effect)
(HEK-293 cells)
(300 nM)

[Ca2+]


α1A (h)
human recombinant
none
22° C.
intracellular
Fluorimetry
20


(agonist effect)
(CHO cells)
(30 nM epinephrine for control)

[Ca2+]
1
1


α1A (h)
human recombinant
epinephrine
22° C.
intracellular
Fluorimetry
20


(antagonist effect)
(CHO cells)
(3 nM)

[Ca2+]


5-HT2A (h)
human recombinant
none

30 min

IP1
HTRF
18


(agonist effect)
(HEK-293 cells)
(100 nM serotonin for control)
37° C.


5-HT2A (h)
human recombinant
serotonin

30 min

IP1
HTRF
18


(antagonist effect)
(HEK-293 cells)
(100 nM)
37° C.


D3 (h)
human recombinant
none

10 min

cAMP
HTRF
21


(agonist effect)
(CHO cells)
(300 nM dopamine for control)
37° C.


D3 (h)
human recombinant
dopamine

10 min

cAMP
HTRF
21


(antagonist effect)
(CHO cells)
(10 nM)
37° C.


5-HT1A (h)
human recombinant
none

15 min

cAMP
HTRF
22


(agonist effect)
(CHO cells)
(100 nM 8-OH-DPAT for control)
22° C.


5-HT1A (h)
human recombinant
8-OH-DPAT

15 min

cAMP
HTRF
22


(antagonist effect)
(CHO cells)
(10 nM)
22° C.


α2C (h)
human recombinant
none

10 min

cAMP
HTRF
23


(agonist effect)
(CHO cells)
(1 μM epinephrine for control)
37° C.


α2C (h)
human recombinant
epinephrine

10 min

cAMP
HTRF
23


(antagonist effect)
(CHO cells)
(100 nM)
37° C.
















TABLE 14







Results of cellular functional assays for dopaminergic D2 receptor


for representative compounds











D2-antag.


Cpd.
D2-ag [%]
[%]












1
−1
95


2
2
97


7
0
91


8
7
85


13
2
95


14
4
98


15
2
88


16
4
98


18
−1
98


22
2
99


26
29
99


27
40
100


28
49
105


29
45
99


30
43
97


32
35
89


33
37
98


34
21
66


35
27
65


36
28
92


37
21
82


38
31
84


39
30
90


40
36
94


43
20
55


44
16
45


45
20
82


46
23
80


47
26
66


48
22
53


49
11
100


50
15
26


51
10
37


53
5
60


56
42
106


57
10
100


61
4
77


65
10
74


79
3
77


81
4
73


97
4
95


98
4
80


101
6
85


102
1
85


113
42
94


239
13
84


240
3
83


241
6
82


288
5
79


298
12
84


312
4
90


313
−5
85


314
9
86


331
4
87


338
3
88


352
12
88


358
30
84


359
39
96


363
50
94


423
41
96


424
44
97


452
24
53
















TABLE 15







Results of cellular functional assays for dopaminergic D3 receptor


for representative compounds











D3-antag.


Compd.
D3-ag [%]
[%]












1
−17
49


2
−15
81


7
−21
66


8
−24
73


14
−15
92


18
−27
114


22
−25
81


26
64
−8


28
59
−2


30
52
35


33
60
−1


36
29
53


40
33
59


45
18


46
18
48


48
14
54


49
−3
71


53
5
48


56
34
45


57
24
41


61
4
45


79
−9
77


81
−10
76


89
−18
69


97
−23
87


98
−10
109


101
−18
112


102
4
83


113
39
30


239
6
84


240
8
72


241
7
78


283
−10
58


288
0
72


298
−8
99


312
10
97


313
8
81


314
−30
110


331
−15
114


338
−10
109


352
−18
113


358
47
35


359
25
79


363
65
−3


423
70
22


424
70
18
















TABLE 16







Results of cellular functional assays for serotoninergic 5-HT1A


receptor for representative compounds










5-HT1A-ag
5-HT1A-


Compd.
[%]
antag. [%]












2
47
18


7
59
51


8
14
81


16
−14
91


22
0
99


26
67
22


27
56
48


28
63
27


29
71
26


30
22
86


33
63
24


34
97
−31


35
102
−37


36
99
−33


37
92
−28


38
94
−33


39
86
−25


40
102
−37


43
87
−27


44
90
−29


45
99
−27


46
92
−20


47
90
−31


48
90
−24


49
82
7


50
98
−34


51
86
−27


53
90
−6


56
92
−6


57
92
−8


61
75
20


65
9
35


81
5
22


97
13
38


102
1
35


113
32
92


239
7
58


240
9
50


241
5
42


358
22
70


359
22
94


363
78
27


423
35
73


424
23
75


452
30
7
















TABLE 17







Results of cellular functional assays for serotoninergic 5-HT2A


receptor for representative compounds












5-HT2A -ag
5-HT2A -antag



Compd.
[%]
[%]















1
0
99



2
2
102



7
0
100



8
−2
99



13
2
100



14
1
100



15
−1
100



16
−1
98



18
−1
102



22
−1
102



26
−1
77



33
−1
41



61
0
97



65
−2
98



79
−2
97



81
−1
95



89
−2
94



97
−3
102



98
−2
97



101
−1
100



102
−2
99



239
−2
94



240
−3
93



241
−2
99



283
0
99



288
−2
97



298
−1
99



312
−2
98



313
−3
98



314
−2
99



331
−1
98



338
−1
100



352
−1
100



358
−1
57



363
−1
62

















TABLE 18







Results of cellular functional assays for serotoninergic 5-HT6


receptor for representative compounds









Cpd.
5-HT6-ag [%]
5-HT6-antag. [%]












1
1
39


2
2
28


3

22


4
−1
37


5

18


6

26


7
1
65


8
−1
64


9
0
−4


10
1
−16


11
−1
−10


12
−1
−2


13
1
56


14
1
69


15
2
21


16
0
50


17
2
69


18
1
87


19
−1
23


20
−2
23


21
−2
39


22
1
82


23
0
1


24
2
9


25
0
6


28
0
53


36
1
7


49
2
71


53
1
87


56
2
92


57
3
86


61
−2
72


65
−1
81


79
1
76


81
1
88


89
0
83


97
−2
95


98
−2
79


101
−2
103


102
−1
82


239
0
70


240
−2
71


241
0
69


283
0
64


288
0
74


298
0
89


312
−1
76


313
−3
91


314
0
91


331
−1
98


338
0
88


352
−2
75
















TABLE 19







Results of cellular functional assays for serotoninergic 5-HT7


receptor for representative compounds










5-HT7-ag
5-HT7-


Cpd.
[%]
antag. [%]












1
−1
97


2
−1
80


3
−2
93


4
−1
81


5
−1
85


6
0
66


7
−1
98


8
−1
82


9
0
48


10
0
85


11
0
85


12
−1
68


13
1
95


14
−1
85


15
0
96


16
−1
80


17

95


18
−1
89


19
−1
99


20
−1
101


21
0
98


22
−1
100


23
0
88


24
0
99


25
−1
97


26
14
13


27
5
8


28
4
23


29
5
9


30
5
73


33
19
20


36
0
16


40
−1
30


49
−1
85


53
1
25


56
1
36


57
1
91


61
−1
78


65
−2
91


79
−2
97


81
−2
98


89
−2
91


97
−2
100


98
−2
92


101
−2
101


102
−2
94


113
9
45


239
−2
81


240
−2
98


241
−2
83


283
−2
93


288
−2
92


298
−3
98


312
−2
97


313
−2
100


314
−3
95


331
−2
102


338
−3
100


352
−2
102


358
10
28


359
8
43


363
6
24


424
18
43
















TABLE 20







Results of cellular functional assays for adrenergic α1A receptor for


representative compounds









Compd.
α1A -ag [%]
α1A -antag. [%]












1
0
100


2
0
100


7
0
100


8
0
100


13
0
100


14
0
100


16
0
100


18
0
99


22
0
100


26
0
100


27
1
100


30
0
97


33
0
100


61
0
100


65
0
98


81
1
100


89
−1
100


97
0
99


98
0
99


101
0
100


102
0
100


113
1
100


239
−1
100


240
0
100


241
0
95


283
0
100


288
0
97


298
1
100


312
0
100


313
0
100


314
1
100


331
1
100


338
2
100


352
1
100


359
1
100


363
0
100


423
16
70


424
39
76
















TABLE 21







Results of cellular functional assays for adrenergic α2C receptor for


representative compounds









Compd.
α2C −ag [%]
α2C −antag. [%]












1
−9
7


2
−8
30


7
−6
2


8
−16
1


13
−7
18


14
−3
12


16
−7
9


18
−10
28


22
−8
12


26
25
53


27
3
31


28
4
27


30
18
35


33
−1
6


36
−2
4


40
−9
9


56
20
4


61
1
18


65
8
20


79
7
22


81
9
20


89
−10
7


97
−4
36


98
−1
16


101
1
46


102
−7
14


113
13
53


239
3
33


240
13
35


241
−1
14


283
2
25


288
1
13


298
−4
39


312
61
39


313
−11
46


314
−2
30


331
−14
7


338
−3
9


352
−16
16


358
28
48


359
13
38


363
17
42
















TABLE 22







Results of cellular functional assays for histaminergic H1 receptor


for representative compounds









Cpd.
H1 -ag [%]
H1 -antag. [%]












1
0
51


2
−1
48


7
1
70


8
1
98


56
0
68


61
1
76


65
0
60


79
0
57


81
1
38


97
3
57


98
−1
78


101
33
94


102
0
48


239
0
54


240
0
69


241
1
47


283
0
41


288
0
57


298
30
90


313
4
47


314
5
50


331
2
85


338
1
51


352
1
60
















TABLE 23







Results of cellular functional assays for serotoninergic 5-HT2C


receptor for representative compounds











Cpd.
5-HT2C -ag [%]
5-HT2C -antag. [%]















65
0
18



98
−5
35



241
−4
52










EXAMPLE 6

Ability to block hERG potassium channels was determined using the electrophysiological method and cloned hERG potassium channels (KCNH2 gene, expressed in CHO cells) as biological material. The effects were evaluated using IonWorks™ Quattro system (MDS-AT).


hERG Test Procedures


hERG current was elicited using a pulse pattern with fixed amplitudes (conditioning pre-pulse: −80 mV for 25 ms; test pulse: +40 mV for 80 ms) from a holding potential of 0 mV. hERG current was measured as a difference between the peak current at 1 ms after the test step to +40 mV and the steady-state current at the end of the step to +40 mV.


Data Analysis

Data acquisition and analyses was performed using the IonWorks Quattro™ system operation software (version 2.0.2; Molecular Devices Corporation, Union City, Calif.). Data were corrected for leak current.


The hERG block was calculated as: % Block=(1−I TA/(Control)×100%, where IControl and ITA were the currents elicited by the test pulse in control and in the presence of a test compound, respectively. Results are presented in Table 24.









TABLE 24







Results of hERG potassium channels affinity tests for


representative compounds










Cpd.
hERG [%]














1
16



2
14



3
17



5
17



6
13



7
14



14
−1.4



17
24



18
30



22
52



30
−3



31
2



36
2.4



50
6



53
12



55
8



56
9



57
0



61
12



97
1



101
14



113
16



331
32



338
40.5



358
0



359
9



360
5



363
0



445
2










EXAMPLE 7
Guinea-Pig Ileum Test

Ileum was prepared from male guinea-pigs with 300-350 g of body weight, fasted for 24 h before experiment with free access to drinking water. Terminal ileum was dissected and placed into a Krebs solution (NaCl 120 mM, KCl 5.6 mM, MgCl2 2.2 mM, CaCl2 2.4 mM, NaHCO3 19 mM, glucose 10 mM) and 2 cm-long fragments were cut. Each segment of the gut was placed in 30 ml chamber filled with the Krebs solution at 37 C, pH 7.4, with constant oxygenation (O2/CO2, 19:1), fixed by the lower end to a glass rod and by the upper end to the force-displacement transducer FDT 10-A (Biopac Systems, COMMAT, Ltd., Turkey). The preparation was allowed to stabilize in organ baths for 60 min under a resting tension of 0.5 g, washing every 15 min with fresh Krebs solution. All responses were recorded using software Biopac Systems Inc MP-35 Data Acquisition, Turkey.


Stock solutions of test and reference compounds were prepared in concentration 10−3 M. About 1 mg of each tested compound was weighed and dissolved in appropriate volume of dimethyl sulfoxide, ethanol or water or in a mixture of them (depending on the solubility). In next step, stock solutions were diluted 10× in water.


The equilibration period a cumulative concentration-response curve was constructed in so each tissue for respective agonist—carbachol (3×10−9−3×10−6 M) or histamine (10−8-10−5 M) by the method of van Rossum (Ref. 24). Following the first agonist curve, tissues were incubated with one of the concentrations of tested compounds for 15 min and the next cumulative concentration curve to agonist was obtained. Only one concentration of the antagonist was tested in each piece of tissue. Experiments were repeated three to eight times.


After the equilibration period a cumulative concentration-response curve was constructed in each tissue for histamine (10−8-10−5 M) by the method of van Rossum. Following the first histamine curve, tissues were incubated with one of the concentrations of tested compounds for 15 min and the next cumulative concentration curve to histamine was obtained. Only one concentration of the antagonist was tested in each piece of tissue. Experiments were repeated three to seven times.


Concentration-response curves were analysed using GraphPad Prism 4.0 (GraphPad Software Inc., San Diego, Calif., USA). Contractile responses to carbachol (in the presence or absence of tested compounds) are expressed as a percentage of maximal carbachol effect (Emax=100%), reached in the concentration-response curves obtained before incubation with the tested compounds. The data are expressed as the mean±SEM of at least four separate experiments. The affinity was estimated with the equation pKB=log(concentration ratio-1)−log(molar antagonist concentration), where the concentration ratio is the ratio of equieffective agonist concentrations in the absence and in the presence of the antagonist.









TABLE 25







Results of Guinea-pig ileum test for representative compounds











Compound
M ant*(pKb)
H ant** (pKb)















1
5.102
6.303



2
5.54
6.34



3
4.74
6.83







*antagonistic activity towards muscarinic receptor



**antagonistic activity towards histaminergic receptor






Results of in vitro tests as described in Examples 4-7 show that compounds of the invention display high affinity for dopamine and serotonin receptors, especially D2, D3, 5-HT1A, 5-HT2A, 5-HT6 and 5-HT7 subtypes, adrenergic alpha2C and alpha1A as well as sigma receptors and serotonin transporter. Most of the tested compounds possess antagonistic profile for all of the receptors they have affinity for, with some of them ie showing partially agonistic properties for D2 and/or D3 receptors as well as fully or partially agonistic activity towards 5-HT1A receptors. This confirms their potential usefulness in the treatment of diseases connected with disturbances in dopaminergic, serotoninergic and noradrenergic transmission, e.g. psychoses, depression as well as anxiety disorders etc. It should be stressed that some of the compounds possess parallel (simultaneous) affinity for D2,5-HT6 and 5-HT7 receptors, displaying efficient antagonistic properties for all of them, which particularly differentiates them from the compounds currently used for treatment of abovementioned diseases. Such a pharmacological profile suggests possible efficacy in the treatment of psychoses as well as precognitive and antidepressant activity. In the same time compounds of the invention possess weak affinity for potassium hERG channel and muscarine receptors as well as moderate affinity for H1 and 5-HT2C receptors, what may potentially contribute to reduced side effects such as, arrhythmia, vegetative disorders, weight gain and metabolic disorders, which are frequently caused by many of the currently used drugs for treatment of the abovementioned diseases.


Tests In Vivo
EXAMPLE 8
Activity Testing in Mice

Male CD-1 mice weighing 20-22 g derived from accredited animal facility localized at Medical College of Jagiellonian University, male C57BL/6J mice weighing 20-21 g and male Swiss Albino mice weighing 21-22 g derived from the licensed dealer (Staniszewska; Ilkowice, Poland) were group-housed for 3-4 day period in polycarbonate Makrolon type 3 cages (dimensions 26.5×15×42 cm) in an environmentally controlled, experimental room (ambient temperature 22-20C.; relative humidity 50-60%; 12:12 light:dark cycle, lights on at 8:00), in groups of 15. Male Wistar rats weighing 205-225 g upon arrival from accredited animal facility Charles River (Sulzfeld, Germany) were group-housed for 6 day period in polycarbonate Makrolon type 3 cages (dimensions 26.5×15×42 cm) in an environmentally controlled room (ambient temperature 20-22′C; relative humidity 50-60%; 12:12 light:dark cycle, lights on at 8:00), in groups of 4. Standard laboratory food (LSM-B) and filtered water were freely available. Standard laboratory food (Ssniff M-Z) and filtered water were freely available. On the day before experiments the equipment produces “white noise” was turned on for 30 minutes and mice or rats were weighted exact to 1 g. Animals were assigned randomly to treatment groups. All the experiments were performed by two observers unaware of the treatment applied between 9:00 and 14:00 on separate groups of animals. All animals were used only once and were killed immediately after the experiment. All the experimental procedures were approved by the IV Local Bioethics Commission in Warszawa.


d-Amphetamine-Induced Locomotor Hyperactivity


The locomotor activity was recorded with an Opto M3 multi-channel activity monitor (MultiDevice Software v. 1.3, Columbus Instruments). The mice were individually placed in plastic cages (22×12×13 cm) for 30 minutes habituation period, and then the crossings of each channel (ambulation) were counted during 1 h with data recording every 5 minutes. The cages were cleaned up with 70% ethanol after each mouse. Drugs were administered to 10 mice per treatment group. d-Amphetamine was administered 30 minutes before the test. Compound 22 was given 30 minutes before the experiment, and other compounds were given 60 minutes before the experiment.









TABLE 26







Results of d-amphetamine-induced locomotor hyperactivity test










Compound
MED* [mg/kg]














2
5



7
2



18
2.5



22
2.5



97
2.5







*minimum effective dose [mg of compound/kg of body weight]






MK-801-Induced Locomotor Hyperactivity

The locomotor activity was recorded according to method described above. Instead of d-Amphetamine, MK-801 was administered 15 min before the test. Compound 22 was given 30 minutes before the experiment.









TABLE 27







Results of MK-801-induced locomotor hyperactivity test










Compound
MED* [mg/kg]







22
1.25










Tail Suspension Test in C57BL/6J Mice

The testing procedure was based on a method of Steru et al. (The tail suspension test: a new method for screening antidepressants in mice, Psychopharmacology 85, 367-370, 1985). An automated device (Kinder Scientific) was used. Mice were suspended by the tail with tape to an aluminum hook connected to a strain gauge. Mice were positioned such that the base of their tail was aligned with the bottom of the hook. This positioning was found to decrease the propensity for mice to climb their tail during the test. A strain gauge connected to computer software detected any movements by the mouse in order to record the number of times (events) each subject enters into an escape behavior (struggling episodes), the duration of the event, and the average strength of each event during a 6-min test session. The total duration of immobility was calculated as the time the force of the mouse's movements was below a preset threshold. An optimum threshold was determined by comparing manually scored videotapes with automated scores. The following settings were used in all experiments: threshold 0, 20 Newtons, off delay 30 msec. Drugs were administered to 7-8 mice per treatment group. Compound 22 was given 30 minutes, while Compound 36 was given 60 minutes before the experiment.









TABLE 28







Results of tail suspension test in C57BL/6J mice










Compound
MED [mg/kg]







22
0.156



36
0.312










Four-Plate Test in Swiss Mice

The four-plate test (BIOSEB, France) was performed in a cage (25×18×16 cm) floored by four identical rectangular metal plates (8×11 cm) separated from one another by a gap of 4 mm. The top of the cage was covered by a transparent Perspex lid that prevented escape behaviour. The plates were connected to a device that can generated electric shocks. Following a 15-s habituation period, the animal's motivation to explore a novel environment was suppressed by an electric foot shock (0.8 mA, 0.5 s) every time it moved from one plate to another during a 1-minute test session (Aron et al., Evaluation of a rapid technique for detecting minor tranquilizers, Neuropharmacology 10, 459-469, 1971). This action is referred to as a ‘punished crossing’, and was followed by a 3 s shock interval, during which the animal could move across plates without receiving a shock. Drugs were administered to 8-10 mice per treatment group. Compound 22 was given 30 minutes, while Compound 36 was given 60 minutes before the experiment.









TABLE 29







Results of four-plate test in mice










Compound
MED [mg/kg]







22
0.312



36
0.312










EXAMPLE 9
Activity Testing in Rats

Drug-naive male Wistar rats (Charles River, Sulzfeld, Germany) weighing 250-400 g were used in all experiments. Rats were housed two per standard plastic cage and kept in a room with constant environmental conditions (21-22′C, relative humidity 60%, a 12:12 light-dark cycle with lights on at 7:00 a.m.). Animals were supplied by the breeder two weeks before the onset of behavioral procedures. During this time, the subjects were weighed and handled several times. Tap water and standard lab chow (Labofeed H, WPIK, Kcynia, Poland) was available ad libitum.


Test Compounds

Compounds 22 and 36 were prepared as a suspension in 1% aqueous solution of Tween 80, whereas d-amphetamine and MK-801 were dissolved in distilled water immediately before administration. An injection volume of 10 ml/kg (mice) or 2 ml/kg (rats) was used throughout and all compounds were administered intraperitoneally (i.p.), except d-amphetamine that was given subcutaneously (s.c.).


Statistical Analysis

All the data are expressed as the mean±SEM. The statistical significance of effects was evaluated using separate one-way analysis of variance (ANOVA) with comparison between individual groups by Dunnett's test (when only one drug was given) or by the Tukey's test when two drugs were used; p<0.05, p<0.01 and p<0.001 were considered statistically significant. ED50 values were calculated using Graph Pad Prism 5 Software.


Apomorphine-Induced Stereotyped Behaviour

All tests were carried out in a sound-attenuated experimental room between 9:00 a.m. and 3:00 p.m. Within 24 h prior to testing, rats were habituated to glass observation so cages (25×25×40 cm, W×H×L) with wood chip bedding on the floor for 20 min. On the day of testing, stereotyped behaviour was observed 20 to 25 min. after apomorphine injection (s.c.) as described by Bristow et al. (L-745,870, a subtype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests. J Pharmacol Exp Ther, 1997; 283:1256-63) and Feldman et al. (Mixed D2/5-HT2 antagonism differentially affects apomorphine- and amphetamine-induced stereotyped behavior. Pharmacol Biochem Behav. 1997; 58:565-72). Rats were injected with apomorphine (0.6 mg/kg) and placed in the observation cages. Views of other rats in the experiment were prohibited. Twenty minutes later, the time spent licking/biting and sniffing downward was recorded by a trained observer for 5 minutes (300 s). Rats were pre-injected i.p. with a test drug 60 min. before the start of the 5-min. test session (the observation period).


The duration of stereotyped sniffing and licking/biting was analyzed with the aid of the Kruskal-Wallis analysis of variance (ANOVA). The Mann-Whitney U test was used for individual post hoc comparisons. P values lower than 0.05 were considered significant.


MK-801-Induced Stereotyped Behaviour

All tests were carried out in a sound-attenuated experimental room between 9:00 a.m. and 3:00 p.m. Within 24 h prior to testing, rats were habituated to glass observation cages (25×25×40 cm, W×H×L) with wood chip bedding on the floor for 20 min. On the day of testing, stereotyped behaviour was observed 15 min. after MK-801 so administration. Rats were injected with MK-801 (0.6 mg/kg, i.p.) and placed in the observation cages. Views of other rats in the experiment were prohibited. Fifteen minutes later, the time spent circling/head waving was recorded by a trained observer for 5 min. (300 s). Rats were pre-injected with a test drug 60 min. before the start of the observation period.


The duration of stereotyped circling was analyzed with the aid of the Kruskal-Wallis analysis of variance (ANOVA). The Mann-Whitney U test was used for individual post hoc comparisons. P values lower than 0.05 were considered significant.


2,5-Dimethoxy-4-Iodoamphetamine (DOI)-Induced Head Twitches

All tests were carried out in a sound-attenuated experimental room between 9:00 a.m. and 3:00 p.m. as described above for spontaneous head twitches. DOI-induced head twitches were scored as described by Millan et al. (518327 (1-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: II. Functional profile and a multiparametric comparison with haloperidol, clozapine, and 11 other antipsychotic agents. J Pharmacol Exp Ther 2000; 292:54-66). Rats were pre-injected i.p. with a test drug 60 min. before the start of the test session. Fifty five minutes later, rats were injected with DOI (2.5 mg/kg, i.p.) and placed in glass observation cages (25×25×40 cm, W×H×L) with wood chip bedding on is the floor. Five minutes later, head twitches were counted for 5 minutes. (300 s) by a trained observer.


Total numbers of head twitches (n/5 min.) were analyzed by means of the Kruskal-Wallis analysis of variance (ANOVA). The Mann-Whitney U test was used for individual post hoc comparisons. P values lower than 0.05 were considered significant but values lower than 0.1 are also reported.


Conditioned Avoidance Response (CAR)

The effects of a test drug on conditioned response in rats were evaluated using active avoidance responding test. The apparatus consisted of six identical shuttle boxes (PACS-30, Columbus Instruments, USA). Each stainless steel box was 22.8 cm wide, 48.3 cm long and 27.6 cm high and was divided into two equal-sized compartments, separated by a sliding door end equipped with an overhead lights audio generator. An infrared-type beam assembly was used for detecting subject transfers. Each chamber floor was composed of stainless steel grid wired for presentation of a scrambled electric food shock (0.5 mA).


Rats trained to avoid the foot shock were placed in the experimental chambers for a 3 min. habituation period followed by 50 CAR trials presented on a 15-s variable interval (VI) schedule. Each trial consisted of a 10 s warning tone and stimulus light (conditioned stimulus) followed by 10 s electric shock (0.5 mA). If during the initial 10 s of the trial an animal crossed through the sliding door, the tone and light were terminated, no shock was applied, and the response was considered as “an avoidance response”. If the animal crossed through the sliding door after a foot shock was initiated, the response was considered as an escape response. If the animal did not cross the sliding door the response was considered as “none”. If a response was made during an intertrial interval, it was punished with 0.5 s shock (0.5 mA). The PACS-30 software (Columbus) controlled the sessions and counted the number of trials in which a rat avoided the shock, escaped or did not respond. A stable demonstration of >80% of correct avoidance responses after 14-18 training sessions was a criterion for inclusion in subsequent drug tests. On test days, a tested drug was administered i.p. 60 minutes before the start of the test session. Each drug was tested at 3-4 different doses in the same group of eight animals. A 7-day wash-out period was introduced between the subsequent tests. Two CAR sessions were conducted during the wash-out in order to maintain stable conditioned responding. The number of CAR trials during the test and wash-out sessions was reduced to 30.


Avoidances, escapes, and “none” responses were analyzed with the aid of a one-way analysis of variance (ANOVA). The Newman-Keuls test was used for individual post hoc comparisons.


Passive Avoidance Procedure

Potentially impairing effects of test substance on learning and memory function in rats were evaluated using a step-through passive avoidance (PA) test. The apparatus consisted of 6 identical shuttle boxes divided into lighted and dark compartments (220×240×270 mm) and equipped with grid floors (PACS-30, Columbus Instruments, USA). The two compartments were separated by a sliding door.


In the training session (acquisition), animals were placed in the lighted compartment and allowed to explore it freely for 10 s. The sliding door was then opened, and the step-through latency for a rat to enter the dark compartment was measured. As soon as the rat entered the dark compartment, the door was closed. Three seconds later, an inescapable foot-shock (0.5 mA for 3 s) was delivered through the grid floor with a constant current shock generator. All animals entered the dark compartment within 300 s (a cut-off) and received a foot-shock.


Rats were pre-injected a test drug 60 minutes before the start of the training session.


The test (expression) session was performed 24 h after the training session. The same procedure was used (see above) but no foot-shock was delivered. A step-through latency for animals to enter the dark compartment was measured with a cut-off of 300 s.


Weights and step-trough latencies were analyzed with the aid of a one-way analysis of variance (ANOVA). The Newman-Keuls test was used for individual post hoc comparisons.


Prepulse Inhibition (PPI) Procedure

The PPI apparatus consisted of eight startle chambers (SR-LAB, San Diego Instruments, San Diego, Calif., USA). Each chamber consisted of a Plexiglas cylinder (8.9 cm diameter×20 cm long) resting on a Plexiglas frame in a sound attenuated, ventilated enclosure. Background noise and acoustic stimuli were presented via a loudspeaker mounted 24 cm above the animal. Startle responses, reflecting the motion of animals in the cylinder so following the acoustic stimulus, were detected by a piezoelectric transducer mounted below the frame. The administration of stimuli and response recording were controlled by the SR-LAB software. Test sessions started with a 5-minutes acclimatization period. Throughout the whole session, the chamber light was on, and the background white noise was set at 70 dB. The test session included 3 initial startling stimuli (intensity: 120 dB, duration: 40 ms) to accustom the rat to the experimental procedure. The initial stimuli were followed by 60 trials (6×10 trials) presented in a random order:

    • 10 background trials (B) which involved a presentation of a sham stimulus (intensity: 70 dB, duration: 40 ms),
    • two types (2×10) of prepulse trials (PP) which included only a prepulse stimuli (84 dB or 90 dB, 20 ms),
    • pulse trials (P) which included only a pulse startling stimulus (120 dB, 40 ms),
    • two types (2×10) of prepulse-and-pulse trials (PP-P) which involved a prepulse (84 db or 90 dB, 20 ms) followed 100 ms later by a 120-dB pulse stimulus (P).


The average inter-trial interval was 22.5 s (range: 15-30 s). This interval was randomized by the SR-LAB software. Startle responses were measured for 100 ms after the onset of the last trial stimulus. For each type of stimulation, startle amplitudes were averaged across the 10 trials. The magnitude of PPI was calculated as a percent inhibition of the startle amplitude in the pulse trial (treated as 100%) according to the formula: [(startle amplitude in P trials−startle amplitude in PP-P trials) startle so amplitude in P trials]×100%. Startle responses to the 3 initial stimuli were excluded from the statistical analyses.


Effects of Tested Compounds on PPI and on Amphetamine-Induced PPI Deficits

Rats were pre-injected with the test drug (60 min.). Each compound was tested in two separate experiments performed over two consecutive days (Experiments 1-2) in separate groups of drug-naive rats. Fifteen minutes before the start of the PPI session, rats were injected with saline (Experiment 1) or amphetamine (Experiment 2).


In Experiment 1, each reference compound, or its vehicle, was given in combination with physiological saline (0.9% NaCl). The purpose of this experiment was to assess effects of the reference drug on basic startle responses and PPI. Results of Experiment 1 determined a range of drug doses tested in Experiment 2. In Experiment 2, the so reference drug, or its vehicle, was administered in combination with amphetamine (6 mg/kg, i.p.). The purpose of Experiment 2 was to assess drugs effects on amphetamine-induced PPI deficits.


Startle responses (in manufacturer's arbitrary units), and magnitudes of PPI (%) were analyzed with the aid of a one-way analysis of variance (ANOVA). The Newman-Keuls is test was used for individual post hoc comparisons.


Forced Swimming Test (The Porsolt's Test)

The animals were individually subjected to two experimental trials during which they were forced to swim in a cylinder (40 cm high, 18 cm in diameter) filled with warm water (25° C.) to a height of 15 cm. A video camera was mounted 50 cm above the cylinder. The first (habituation) and second (test) trial lasted 15 and 5 minutes, respectively. There was a 24-h interval between the trials. The total duration of immobility was measured during the second trial by a trained observer located in a separate room.


Weights and time of immobility were analyzed with the aid of a one-way analysis of variance (ANOVA). The Newman-Keuls test was used for individual post hoc comparisons.


Elevated Plus Maze Test in Rats

The testing procedure was based on a method described by Pellow and File (1986). Plus-maze apparatus (an automated device produced by Kinder Scientific) made of durable, high density, non porous black plastic, elevated to a height of 50 cm, consisted of two open arms (50×10 cm) and two closed arms (50×10 cm, and 30 cm high walls), arranged so that the two arms of each type were opposite each other. Floor of the plus-maze was made of infrared transparent material what means that there are no visible sensors. The plus-maze was placed in a darkened room, and the center of the apparatus was illuminated with a 25W electric bulb hanging 100 cm above. Plus-maze apparatus was connected to PC software by control chassis. Each rat was gently placed in the center of the plus-maze, facing one of the closed arms, immediately after a 5-min adaptation period in a plastic black box (60×60×35 cm). During a 5-minutes test period, automated Motor Monitor System recorded the number of entries into the closed and open arms, the time spent in and the distance (cm) covered by a rat in either type of the arms. After each trial the maze was wiped clean. All compounds were administered to 5-8 rats per treatment group. Compounds 22 and 36 were administered so 60 minutes before the experiment.


Conflict Drinking Test (Vogel Test) in Rats

Anxiety Monitoring System “Vogel test” produced by TSE Systems was used. It was consisted of a polycarbonate cage (dimensions 26.5×15×42 cm), equipped with a grid floor made from stainless steel bars and a drinking bottle containing tap water. Experimental chambers (two) were connected to PC software by control chassis and a device that generates electric shocks. On the first day of the experiment, the rats were adapted to the test chamber for 10 min. After the adaptation period, the animals were deprived of water for 24 h and were then placed in the test chamber for another 10-min adaptation period during which they had free access to the drinking bottle. Afterwards, they were allowed a 30-min free-drinking session in their home cage. After another 24-h water deprivation period, the rats were placed again in the test chamber. Recording data started immediately after the first lick and every 20 licks rats were punished with an electric shock (0.5 mA, lasting 1 s). The impulses were released via the spout of the drinking bottle. If a rat was drinking when an impulse was released, it received a shock. The number of licks and the number of shocks received throughout a 5-min experimental session was recorded automatically. Compounds 22 and 36 were administered to 10 rats per treatment group, 60 min before the experiment.









TABLE 30







Results of tests in rats









Compound



MED [mg/kg]



Test










22
36












Apomorphine-induced stereotyped behaviour
10



(pharmacological dopamine-related psychosis model)




MK-801-induced stereotyped behaviour (pharmacological
3



glutamate-related psychosis model)




DOI- induced head twitches (pharmacological
 1 *



serotonin-related psychosis model)




Active-avoidance response (model of positive symptoms
3



of schizophrenia)




Passive-avoidance (model of memory disturbance)
>30



Prepulse inhibition disruption caused by amphetamine
30



administration (model of sensorimotor gating deficits




involved in schizophrenia pathomechanism;




dopaminergic psychotomimetic)




Porsolt forced swimm test (test indicative of potential
0.3
1 *


antidepressant activity)




Vogel test in rats (test indicative of potential anxiolytic
3
1 *


activity)




Elevated plus-maze (test indicative of potential
0.3 *



anxiolytic activity)





* -lower doses not tested






Results of behavioral tests described in Example 8 confirm potential activity of the compounds of invention in therapy of psychotic symptoms.


Data for the representative compound 22 in Examples 8 and 9 show its wide antipsychotic activity in all applied rodent models. It is noteworthy that the compound was active in models utilizing psychotomimetic substances affecting either dopaminergic (d-amphetamine, apomorphine), serotoninergic (DOI) or glutamatergic transmission (MK-801) as well as in specific conditioning procedure (active avoidance response). Compound 22 was active in procedures indicative of efficacy in either so positive symptoms of schizophrenia, such as: d-amphetamine and MK-801 induced hyperlocomotion, stereotyped behavior induced by apomorphine and DOI, active avoidance response, as well as in procedure assessing ability to treat attention deficits and information filtering (dimensions of cognitive deficits), underlying the pathomechanism of schizophrenia—reversal of deficits in prepulse inhibition in rats. Moreover compound 22 was active in well established models for detecting substances with potential antidepressant activity, i.e. tail suspension test in mice and forced swim test (Porsolt) in rats as well as potential anxiolytic activity, i.e. four plates test in mice, elevated plus maze and conflict drinking test (Vogel) in rats. Such a wide pharmacological activity, beyond the purely antipsychotic effects is a particularly so desirable feature of modern antipsychotic drug, considering complexity of clinical conditions associated with schizophrenia, including depression and anxiety.


Data for compound 36 show its wide antidepressant and anxiolytic activity in all applied models in mice and rats (tail suspension test in mice and forced swim test (Porsolt) in rats, four plates test in mice and conflict drinking test (Vogel) in rats). This confirms its potential efficacy in treatment of depression and anxiety, as well as its potential use as add on therapy for currently used antipsychotics in treatment of negative symptoms of schizophrenia.


REFERENCES



  • 1. Greengrass, P. and Bremner, R. (1979), Eur. J. Pharmacol., 55: 323-326.

  • 2. Devedjian et at. (1994), Eur. J. Pharmacol., 252: 43-49

  • 3. Grandy et al. (1989), Proc. Natl. Acad. Sci. U.S.A., 86: 9762-9766.

  • 4. Mackenzie et al. (1994), Eur. J. Pharmacol., 266: 79-85.

  • 5. Smit et al. (1996), Brit. J. Pharmacol., 117: 1071-1080.

  • 6. Peralta et al. (1987), Embo. J., 6: 3923-3929.

  • 7. Mulheron et al. (1994), J. Biol. Chem., 269: 12954-12962.

  • 8. Bonhaus et al. (1995), Brit. J. Pharmacol., 115: 622-628.

  • 9. Stam et al. (1994), Eur. J. Pharmacol., 269: 339-348.

  • 10. Monsma et at. (1993), Mol. Pharmacol., 43: 320-327.

  • 11. Shen et al. (1993), J. Biol. Chem., 268: 18200-18204.

  • 12. Shirayama et al. (1993), Eur. J. Pharmacol., 237: 117-126.

  • 13. Tatsumi et al. (1999), Eur. J. Pharmacol., 368: 277-283.

  • 14. Sur, C et al. (2003) Proc. Natl. Acad. Sci. U.S.A., 100: 13674-13679;

  • 15. Adham et al. (1998), J. Pharmacol. Exp. Ther., 287: 508-514;

  • 16. Kohen et al. (1996), J. Neurochem., 66: 47-56;

  • 17. Payne et al. (2002), J. Neurochem., 82: 1106-1117;

  • 18. Porter et al. (1999), Brit. J. Pharmacol., 128: 13-20;

  • 19. Miller, T. R et al. (1999) J. Biomol. Screen., 4: 249-258;

  • 20. Vicentic et al. (2002), J. Pharmacol. Exp. Ther., 302: 58-65;

  • 21. Missale et al. (1998), Physiol. Rev., 78: 189-225;

  • 22. Newman-Tancredi et al. (2001), Brit. J. Pharmacol., 132: 518-524;

  • 23. Regan, J. W et al. (1988) Biochem., 85: 6301-6305;

  • 24. Van Rossum J. M. (1963) Arch. Int. Pharmacodyn., 1963, 143, 299-330.


Claims
  • 1. A compound of the general formula (I)
  • 2. The compound or salt according to claim 1, wherein A is represented by the general formula (A1):
  • 3. The compound or salt according to claim 1, wherein A is represented by the general formula (A2):
  • 5. (canceled)
  • 6. The compound or salt according to claim 1, wherein E represents N.
  • 7. The compound or salt according to claim 1, wherein E represents CH.
  • 8. The compounds according to claim 1, wherein E represents C.
  • 9. The compound or salt according to claim 1, wherein D represents unsubstituted phenyl or phenyl substituted with one or more substituents independently selected from the group consisting of branched C1-C4-alkyl; straight C1-C4-alkyl in ortho or meta position with respect to sulphonamide group; C4-C3-alkyloxy; halogeno-C1-C3-alkyl; halogeno-C4-C3-alkyloxy; halogen atom; —CN; —OH; and phenyl.
  • 10. The compound or salt according to claim 1, wherein D represents unsubstituted naphthyl or naphthyl substituted with one or more substituents independently selected from the group consisting of C4-C4-alkyl; C1-C3-alkyloxy; halogeno-C1-C3-alkyl; halogen atom; —CN; —OH; and phenyl.
  • 11-12. (canceled)
  • 13. The compound or salt according to claim 1, wherein D represents benzene ring fused with 5-membered aromatic heterocyclic ring having 1 to 3 heteroatoms independently selected from the group consisting of N, O, S, and wherein D is unsubstituted or substituted with one or more substituents independently selected from the group consisting of C1-C4-alkyl; C1-C3-alkyloxy; halogeno-C1-C3-alkyl; halogen atom, —CN; —OH; and phenyl.
  • 14-18. (canceled)
  • 19. The compound or salt according to claim 1, wherein n is 2.
  • 20. The compound or salt according to claim 1, wherein n is 3.
  • 21. The compound or salt according to claim 1, wherein n is 4.
  • 22. (canceled)
  • 23. The compound or salt according to claim 1, wherein A is linked to E through carbon atom of heterocyclic ring.
  • 24. The compound according to claim 1 selected from the group consisting of the following compounds: N-(4-(4-(1,2-benzothiazol-3-yl)piperazin-1-yl)butyl)naphthalene-1-sulphonamide,N-(4-(4-(1,2-benzothiazol-3-yl)piperazin-1-yl)butyl)naphthalene-2-sulphonamide,N-(4-(4-(1,2-benzothiazol-3-yl)piperazin-1-yl)butyl)-3-methylbenzenesulphonamide,N-(4-(4-(1,2-benzothiazol-3-yl)piperazin-1-yl)butyl)-2-oxo-3H-1,3-benzoxazole-6-sulphonamide,N-(3-(4-(1,2-benzothiazol-3-yl)piperazin-1-yl)propyl)naphthalene-1-sulphonamide,N-(3-(4-(1,2-benzothiazol-3-yl)piperazin-1-yl)propyl)naphthalene-2-sulphonamide,N-(3-(4-(1,2-benzothiazol-3-yl)piperazin-1-yl)propyl)-3-methyl-benzenesulphonamide,N-(3-(4-(1,2-benzothiazol-3-yl)piperazin-1-yl)propyl)-2-oxo-3H-1,3-benzoxazole-6-sulphonamide,N-(2-(4-(1,2-benzothiazol-3-yl)piperazin-1-yl)ethyl)naphthalene-1-sulphonamide,N-(2-(4-(1,2-benzothiazol-3-yl)piperazin-1-yl)ethyl)naphthalene-2-sulphonamide,N-(2-(4-(1,2-benzothiazol-3-yl)piperazin-1-1,1)ethyl)-3-methylbenzenesulphonamide,N-(2-(4-(1,2-benzothiazol-3-yl)piperazin-1-yl)ethyl)-2-oxo-3H-1,3-benzoxazole-6-sulphonamide,N-(4-(4-(1,2-benzoxazol-3-yl)piperazin-1-yl)butyl)naphthalene-1-sulphonamide,N-(4-(4-(1,2-benzoxazol-3-yl)piperazin-1-yl)butyl)naphthalene-2-sulphonamide,N-(4-(4-(1,2-benzoxazol-3-yl)piperazin-1-yl)butyl)-3-methyl-benzenesulphonamide,N-(4-(4-(1,2-benzoxazol-3-yl)piperazin-1-yl)butyl)-2-oxo-3H-1,3-benzoxazole-6-sulphonamide,N-[4-(4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl)butyl]naphthalene-1-sulphonamide,N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]naphthalene-2-sulphonamide,N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-3-methylbenzene-sulphonamide,N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]naphthalene-1-sulphonamide,N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]naphthalene-2-sulphonamide,N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-3-methylbenzene-sulphonamide,N-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]naphthalene-1-sulphonamide,N-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]naphthalene-2-sulphonamide,N-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-3-methylbenzene-sulphonamide,N-{4-[4-(1H-indol-4-yl)piperazin-1-yl]butyl}naphthalene-2-sulphonamide,N-{4-[4-(1H-indol-4-yl)piperazin-1-yl]butyl}benzenesulphonamide,3-fluoro-N-{4-[4-(1H-indol-4-yl)piperazin-1-yl]butyl}benzenesulphonamide,3,4-difluoro-N-{4-[4-(1H-indol-4-yl)piperazin-1-yl]butyl}benzenesulphonamide,N-{4-[4-(1H-indol-4-yl)piperazin-1-yl]butyl}-imidazo[1,2-a]pyridine-3-sulphonamide,N-{4-[4-(1H-indol-4-yl)piperazin-1-yl]butyl}-1H-pyrrolo[2,3-b]pyridine-3-sulphonamide,N-{4-[4-(1H-indol-4-yl)piperazin-1-yl]butyl}-1-benzothiophene-3-sulphonamide,N-{4-[4-(1H-indol-4-yl)piperazin-1-yl]butyl}-1-benzothiophene-2-sulphonamide,N-{4-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]butyl}naphthalene-1-sulphonamide,N-{4-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]butyl}naphthalene-2-sulphonamide,4-fluoro-N-{4-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]butyl}benzene-sulphonamide,3-fluoro-N-{4-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]butyl}benzene-sulphonamide,4-chloro-N-{4-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]butyl}benzene-sulphonamide3-chloro-N-{4-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]butyl}benzenesulphonamide,3-methyl-N-{4-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]butyl}benzene-sulphonamide,3-hydroxy-N-{4-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]butyl}benzene-sulphonamide,4-methoxy-N-{4-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]butyl}benzenesulphonamideN-{3-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]propyl}naphthalene-1-sulphonamide,N-{3-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]propyl}naphthalene-2-sulphonamide,4-fluoro-N-{3-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]propyl}benzene-sulphonamide,3-fluoro-N-{3-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]propyl}benzene-sulphonamide,4-chloro-N-{3-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]propyl}-benzenesulphonamide,3-chloro-N-{3-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]propyl}benzene-sulphonamide,3-hydroxy-N-{3-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]propyl}benzene-sulphonamide,N-{2-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]ethyl}naphthalene-1-sulphonamide,N-{2-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]ethyl}naphthalene-2-sulphonamide,N-{2-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]ethyl}-4-fluorobenzene-sulphonamide,3-fluoro-N-{2-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]ethyl}benzene-sulphonamide,4-chloro-N-{2-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]ethyl}benzene-sulphonamide,3-chloro-N-{2-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]ethyl}benzene-sulphonamide,3-methyl-N-{2-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]ethyl}benzene-sulphonamide,3-hydroxy-N-{2-[4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]ethyl}benzene-sulphonamide,4-chloro-N-{4-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]-butyl}-benzenesulphonamide,N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-6-chloronaphthalene-2-sulphonamide,N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-6-chloronaphthalene-2-sulphonamide,N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-3-chloro-4-fluorobenzene-sulphonamideN-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-3-chloro-4-fluorobenzene-sulphonamide,N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-5-fluoro-3-methylbenzothiophene-2-sulphonamide,N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-5-fluoro-3-methyl-benzothiophene-2-sulphonamide,N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-3-chlorobenzenesulphonamide,N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-3-chlorobenzenesulphonamide,N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-3-fluorobenzenesulphonamide,N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-3-fluorobenzenesulphonamide,N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-3-cyanobenzenesulphonamide,N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-3-cyanobenzenesulphonamide,N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]imidazo[1,2-a]pyridine-3-sulphonamide,N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]-6-chloronaphthalene-2-sulphonamide,N-[3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl]-6-chloronaphthalene-2-sulphonamide,N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]-5-fluoro-3-methylbenzothiophene-2-sulphonamide,N-[3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl]-5-fluoro-3-methylbenzothiophene-2-sulphonamide,N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]-3-chlorobenzenesulphonamide,N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl]-3-chlorobenzenesulphonamide,N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]-3-fluorobenzenesulphonamide,N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]-1H-pyrrolo[2,3-b]pyridine-3-sulphonamide,N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]-3-(trifluoromethyl)benzene-sulphonamide,N-[3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl]-3-(trifluoromethyl)benzene-sulphonamide,N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]-3,4-dichlorobenzenesulphonamide,N-[3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl]-3,4-dichlorobenzenesulphonamide,6-chloro-N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]naphthalene-2-sulphonamide,6-chloro-N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]naphthalene-2-sulphonamide,5-fluoro-N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-3-methyl-benzothiophene-2-sulphonamide,5-fluoro-N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-3-methyl-benzothiophene-2-sulphonamide,3-chloro-N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]benzene-sulphonamide,3-chloro-N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]benzene-sulphonamide,3-fluoro-N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]benzene-sulphonamide,3-fluoro-N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]benzene-sulphonamide,3-bromo-N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]benzene-sulphonamide,3-bromo-N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]benzene-sulphonamide,N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-4-phenyl-benzene-sulphonamide,N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-4-phenylbenzene-sulphonamide,N-[4-[4-(1H-indol-4-yl)piperazin-1-yl]butyl]-3-chlorobenzenesulphonamide,N-[4-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]butyl]-3-chloro-benzenesulphonamide,N-[3-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]propyl]-3-chloro-benzenesulphonamide,N-[4-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]butyl]-3-fluoro-benzenesulphonamide,N-[3-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]propyl]-3-fluoro-benzenesulphonamide,N-[4-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]butyl]-4-tert-butyl-benzenesulphonamide,5-chloro-3-methyl-N-[4-[4-(2-oxo-1,3-dihydrobenzimidazol-4-yl)piperazin-1-yl]butyl]-1-benzothiophene-2-sulphonamide,3-chloro-N-[4-[4-(2-oxo-1,3-dihydrobenzimidazol-4-yl)piperazin-1-yl]butyl]benzene-sulphonamide,3-chloro-N-[3-[4-(2-oxo-1,3-dihydrobenzimidazol-4-yl)piperazin-1-yl]propyl]benzene-sulphonamide,3-fluoro-N-[4-[4-(2-oxo-1,3-dihydrobenzimidazol-4-yl)piperazin-1-yl]butyl]benzene-sulphonamide,3-fluoro-N-[3-[4-(2-oxo-1,3-dihydrobenzimidazol-4-yl)piperazin-1-yl]propyl]benzene-sulphonamide,N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-5-chlorothiophene-2-sulphonamide,N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-5-chlorothiophene-2-sulphonamide,3-chloro-N-[4-[4-(3-oxo-4H-1,4-benzoxazin-8-yl)piperazin-1-yl]butyl]benzene-sulphonamide,3-fluoro-N-[4-[4-(3-oxo-4H-1,4-benzoxazin-8-yl)piperazin-1-yl]butyl]benzene-sulphonamide,N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-4-fluorobenzenesulphonamide,N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-3,4-difluorobenzenesulphonamide,N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-4-chlorobenzenesulphonamide,N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-3,4-dichlorobenzenesulphonamide,N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-4-bromobenzenesulphonamide,N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-3-bromobenzenesulphonamide,N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-3-hydroxybenzenesulphonamide,N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-3-methoxybenzenesulphonamide,N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-4-tert-butylbenzenesulphonamide,N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-4-(trifluoromethyl)benzene-sulphonamide,N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-3-(trifluoromethyl)benzene-sulphonamide,N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-4-(trifluoromethoxy)benzene-sulphonamide,N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-4-phenylbenzenesulphonamide,N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]thiophene-2-sulphonamide,N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]benzothiophene-2-sulphonamide,N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]benzothiophene-3-sulphonamide,N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-6-chloro-benzothiophene-2-sulphonamide,N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-2,3-dihydrobenzofuran-5-sulphonamide,N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-1,3-benzothiazole-4-sulphonamide,N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-1H-indazole-6-sulphonamide,N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-1,3-benzodioxole-5-sulphonamide,N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]imidazo[1,2-a]pyridine-3-sulphonamide,N-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-1H-pyrrolo[2,3-b]pyridine-3-sulphonamide,N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-4-fluorobenzenesulphonamide,N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-3,4-difluorobenzenesulphonamide,N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-4-chlorobenzenesulphonamide,N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-3,4-dichlorobenzene-sulphonamide,N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-4-bromobenzenesulphonamide,N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-3-bromobenzenesulphonamide,N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-3-hydroxybenzenesulphonamide,N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-3-methoxybenzenesulphonamide,N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-4-tert-butylbenzenesulphonamide,N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-4-(trifluoromethyl)benzene-sulphonamide,N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-3-(trifluoromethyl)benzene-sulphonamide,N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-4-(trifluoromethoxy)benzene-sulphonamide,N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-4-phenylbenzenesulphonamide,N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]thiophene-2-sulphonamide,N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]benzothiophene-2-sulphonamide,N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]benzothiophene-3-sulphonamide,N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-6-chlorobenzothiophene-2-sulphonamide,N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-2,3-dihydrobenzofuran-5-sulphonamide,N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-1,2-benzoxazole-5-sulphonamide,N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-1,3-benzothiazole-4-sulphonamide,N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-1H-indazole-6-sulphonamide,N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-1,3-benzodioxole-5-sulphonamide,N-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propyl]-1H-pyrrolo[2,3-b]pyridine-3-sulphonamide,N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]-4-fluorobenzenesulphonamide,N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]-3,4-difluorobenzenesulphonamide,N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]-4-chlorobenzenesulphonamide,N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]-4-bromobenzenesulphonamide,N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]-3-bromobenzenesulphonamide,N-[4-[4-(1,2-benzoxazol-1-yl)piperazin-1-yl]butyl]-3-chloro-4-fluorobenzene-sulphonamide,N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]-3-hydroxybenzenesulphonamide,N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]-3-methoxybenzenesulphonamide,N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]-4-tert-butylbenzenesulphonamide,N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]-4-(trifluoromethyl)benzene-sulphonamide,N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]-4-(trifluoromethoxy)benzene-sulphonamide,N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]-3-cyanobenzenesulphonamide,N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]-4-phenylbenzenesulphonamide,N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]thiophene-2-sulphonamide,N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]-5-chloro-thiophene-2-sulphonamide,N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]benzothiophene-2-sulphonamide,N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]benzothiophene-3-sulphonamide,N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]-6-chloro-benzothiophene-2-sulphonamide,N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]-2,3-dihydrobenzofuran-5-sulphonamide,N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]-1,3-benzothiazole-4-sulphonamide,N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]-1H-indazole-6-sulphonamide,N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]-1,3-benzodioxole-5-sulphonamide,N-[4-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]butyl]imidazo[1,2-a]pyridine-3-sulphonamide,4-fluoro-N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]benzene-sulphonamide,3,4-difluoro-N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]benzene-sulphonamide,4-chloro-N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]benzene-sulphonamide,3,4-dichloro-N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]benzene-sulphonamide,4-bromo-N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]benzene-sulphonamide,3-chloro-4-fluoro-N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-benzenesulphonamide,N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-3-methoxybenzene-sulphonamide,4-tert-butyl-N-[4-[4-(6-fluoro-2-benzoxazol-3-yl)piperidin-1-yl]butyl]benzene-sulphonamide,N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-4-(trifluoromethyl)-benzenesulphonamide,N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-3-(trifluoromethyl)benzene-sulphonamide,N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-4-(trifluoromethoxy)-benzenesulphonamide,4-cyano-N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]benzene-sulphonamide,3-cyano-N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]benzene-sulphonamide,N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]thiophene-3-sulphonamide,5-chloro-N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]thiophene-2-sulphonamide,N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-2,5-dimethyl-thiophene-3-sulphonamide,N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-1-methyl-indole-4-sulphonamide,N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-1-methyl-indole-6-sulphonamide,N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]benzothiophene-2-sulphonamide,N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]benzothiophene-3-sulphonamide,6-chloro-N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]benzothiophene-2-sulphonamide,5-chloro-N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-3-methyl-benzothiophene-2-sulphonamide,N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]benzofuran-2-sulphonamide,N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-2,3-dihydrobenzofuran-5-sulphonamide,N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-1,3-benzothiazole-4-sulphonamide,N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-1H-indazole-6-sulphonamide,N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-1,3-benzodioxole-5-sulphonamide,N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-2,3-dihydro-1,4-benzodioxine-6-sulphonamide,N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]imidazo[1,2-a]pyridine-3-sulphonamide,N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-1H-pyrrolo[2,3-b]-pyridine-3-sulphonamide,N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]-2-oxo-indoline-5-sulphonamide,N-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butyl]thiophene-2-sulphonamide,4-fluoro-N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]benzene-sulphonamide,3,4-difluoro-N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]benzene-sulphonamide,4-chloro-N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]benzene-sulphonamide,3,4-dichloro-N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]benzene-sulphonamide,4-bromo-N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]benzene-sulphonamide,3-chloro-4-fluoro-N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]benzene-sulphonamide,N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-3-methoxybenzene-sulphonamide,4-tert-butyl-N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]benzene-sulphonamide,N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-4-(trifluoromethyl)-benzenesulphonamide,N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-3-(trifluoromethyl)-benzenesulphonamide,N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-4-(trifluoromethoxy)-benzenesulphonamide,4-cyano-N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]benzene-sulphonamide,3-cyano-N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]benzene-sulphonamide,N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]thiophene-2-sulphonamide,N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]thiophene-3-sulphonamide,5-chloro-N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]thiophene-2-sulphonamide,N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-2,5-dimethyl-thiophene-3-sulphonamide,N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-1-methyl-indole-4-sulphonamide,N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-1-methyl-indole-5-sulphonamide,N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]benzothiophene-2-sulphonamide,N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]benzothiophene-3-sulphonamide,6-chloro-N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]benzothiophene-2-sulphonamide,5-chloro-N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-3-methyl-benzothiophene-2-sulphonamide,N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]benzofuran-2-sulphonamide,N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-2,3-dihydrobenzofuran-5-sulphonamide,N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-1,3-benzothiazole-4-sulphonamide,N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-1H-indazolol-6-sulphonamide,N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-2-oxo-3H-1,3-benzoxazole-6-sulphonamide,N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-1,3-benzodioxole-5-sulphonamide,N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-2,3-dihydro-1,4-benzodioxine-6-sulphonamide,N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]imidazo[1,2-a]pyridine-3-sulphonamide,N-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl]-1H-pyrrolo[2,3-b]-pyridine-2-sulphonamide,6-chloro-N-[4-[4-(1H-indol-4-yl)piperazin-1-yl]butyl]naphthalene-2-sulphonamide,4-fluoro-N-[4-[4-(1H-indol-4-yl)piperazin-1-yl]butyl]benzenesulphonamide,N-[4-[4-(1H-indol-4-yl)piperazin-1-yl]butyl]-4-(trifluoromethyl)benzenesulphonamide,N-[4-[4-(1H-indol-4-yl)piperazin-1-yl]butyl]-3-(trifluoromethyl)benzenesulphonamide,3-cyano-N-[4-[4-(1H-indol-4-yl)piperazin-1-yl]butyl]benzenesulphonamide,6-chloro-N-[4-[4-(1H-indol-4-yl)piperazin-1-yl]butyl]benzothiophene-2-sulphonamide,5-fluoro-N-[4-[4-(1H-indol-4-yl)piperazin-1-yl]butyl]-3-methyl-benzothiophene-2-sulphonamide,N-[4-[4-(1H-indol-4-yl)piperazin-1-yl]butyl]-1,3-benzodioxole-5-sulphonamide,N-[3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl]naphthalene-1-sulphonamide,N-[3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl]naphthalene-2-sulphonamide,N-[3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl]-4-fluorobenzenesulphonamide,N-[3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl]-3,4-difluorobenzenesulphonamide,N-[3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl]-4-chlorobenzenesulphonamide,N-[3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl]-4-bromobenzenesulphonamide,N-[3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl]-3-bromobenzenesulphonamide,N-[3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl]-3-chloro-4-fluoro-benzene-sulphonamide,N-[3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl]-4-tert-butyl-benzenesulphonamide,N-[3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl]-4-(trifluoromethyl)benzene-sulphonamide,N-[3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl]-3-cyanobenzenesulphonamide,N-[3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl]-4-phenylbenzenesulphonamide,N-[3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl]-2,3-dihydrobenzofuran-5-sulphonamide,N-[3-[4-(1,2-benzoxazol-3-yl)piperazin-1-yl]propyl]-1,3-benzothiazole-4-sulphonamide,N-[4-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]naphthalene-1-sulphonamide,N-[4-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]naphthalene-2-sulphonamide,6-chloro-N-[4-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]naphthalene-2-sulphonamide,N-[4-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]-3-fluorobenzene-sulphonamide,N-[4-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]-3,4-difluorobenzene-sulphonamide,3-chloro-N-[4-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]benzene-sulphonamide,3-bromo-N-[4-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]benzene-sulphonamide,3-chloro-N-[4-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]-4-fluoro-benzenesulphonamide,N-[4-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]-3-hydroxybenzene-sulphonamide,N-[4-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]-3-methoxybenzene-sulphonamide,N-[4-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]-3-methylbenzene-sulphonamide,N-[4-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]-4-phenylbenzene-sulphonamide,N-[4-[4-(2,3-dihydro-1,4-benzodioxin-8-yl)piperazin-1-yl]butyl]thiophene-2-sulphonamide,5-chloro-N-[4-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]thiophene-2-sulphonamide,N-[4-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]benzothiophene-2-sulphonamide,N-[4-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]benzothiophene-3-sulphonamide,6-chloro-N-[4-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]-benzothiophene-2-sulphonamide,N-[4-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]-1H-indazole-6-sulphonamide,N-[4-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]-2-oxo-3H-1,3-benzoxazole-6-sulphonamide,N-[4-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]butyl]-1,3-benzodioxole-5-sulphonamide,N-[3-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]naphthalene-1-sulphonamide,N-[3-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]naphthalene-2-sulphonamide,6-chloro-N-[3-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]naphthalene-2-sulphonamide,N-[3-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]-4-fluorobenzene-sulphonamide,N-[3-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]-3-fluorobenzene-sulphonamide,N-[3-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]-3,4-difluorobenzenesulphonamide,3-chloro-N-[3-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]-benzene-sulphonamide,4-bromo-N-[3-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]benzene-sulphonamide,3-bromo-N-[3-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]benzene-sulphonamide,N-[3-[4-(2,3-dihydro-1,4-benzodioxin-8-yl)piperazin-1-yl]propyl]-3-methylbenzene-sulphonamide,N-[3-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]-4-phenylbenzene-sulphonamide,N-[3-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]benzothiophene-3-sulphonamide,N-[3-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]-2,3-dihydrobenzofuran-5-sulphonamide,N-[4-[4-(2-oxo-1,3-dihydrobenzimidazol-4-yl)piperazin-1-yl]butyl]naphthalene-1-sulphonamide,N-[4-[4-(2-oxo-1,3-dihydrobenzimidazol-4-yl)piperazin-1-yl]butyl]naphthalene-2-sulphonamide,4-fluoro-N-[4-[4-(2-oxo-1,3-dihydrobenzimidazol-4-yl)piperazin-1-yl]butyl]benzene-sulphonamide,4-chloro-N-[4-[4-(2-oxo-1,3-dihydrobenzimidazol-4-yl)piperazin-1-yl]butyl]benzene-sulphonamide,3-methyl-N-[4-[4-(2-oxo-1,3-dihydrobenzimidazol-4-yl)piperazin-1-yl]butyl]-benzenesulphonamide,N-[3-[4-(2-oxo-1,3-dihydrobenzimidazol-4-yl)piperazin-1-yl]propyl]naphthalene-1-sulphonamide,N-[3-[4-(2-oxo-1,3-dihydrobenzimidazol-4-yl)piperazin-1-yl]propyl]naphthalene-2-sulphonamide,4-chloro-N-[3-[4-(2-oxo-1,3-dihydrobenzimidazol-4-yl)piperazin-1-yl]propyl]-benzenesulphonamide,3-methyl-N-[3-[4-(2-oxo-1,3-dihydrobenzimidazol-4-yl)piperazin-1-yl]propyl]-benzenesulphonamide,N-[4-[4-(3-oxo-4H-1,4-benzoxazin-8-yl)piperazin-1-yl]butyl]naphthalene-2-sulphonamide,4-fluoro-N-[4-[4-(3-oxo-4H-1,4-benzoxazin-8-yl)piperazin-1-yl]butyl]benzene-sulphonamide,N-[4-[4-(3-oxo-4H-1,4-benzoxazin-8-yl)piperazin-1-yl]butyl]-4-(trifluoromethyl)-benzenesulphonamide,N-[4-[4-(3-oxo-4H-1,4-benzoxazin-6-yl)piperazin-1-yl]butyl]-3-(trifluoromethyl)-benzenesulphonamide,5-chloro-N-[4-[4-(3-oxo-4H-1,4-benzoxazin-8-yl)piperazin-1-yl]butyl]thiophene-2-sulphonamide,N-[4-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]butyl]-naphthalene-1-sulphonamide,N-[4-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]butyl]-naphthalene-2-sulphonamide,N-[4-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]butyl]-4-fluoro-benzenesulphonamideN-[4-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]butyl]-3-hydroxy-benzenesulphonamide,N-[4-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]butyl]-3-methyl-benzenesulphonamide,N-[4-[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]butyl]naphthalene-2-sulphonamide,3-fluoro-N-[4-[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]butyl]benzene-sulphonamide,N-[4-[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]butyl]-3-hydroxybenzene-sulphonamide,N-[4-[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]butyl]-3-methylbenzenesulphonamide,3-fluoro-N-[3-[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]propyl]benzene-sulphonamide,N-[3-[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]propyl]-3-hydroxybenzene-sulphonamide,N-[2-[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]ethyl]naphthalene-2-sulphonamide,3-fluoro-N-[2-[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]ethyl]benzene-sulphonamide,N-[2-[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]ethyl]-3-methylbenzene-sulphonamide,N-[3-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]propyl]-naphthalene-1-sulphonamide,N-[3-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]propyl]-naphthalene-2-sulphonamide,N-[3-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]propyl]-4-fluoro-benzenesulphonamide,4-chloro-N-[3-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]propyl]-benzenesulphonamide,N-[3-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]propyl]-3-hydroxy-benzenesulphonamide,N-[3-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]propyl]-3-methyl-benzenesulphonamide,N-[2-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]ethyl]naphthalene-1-sulphonamide,N-[2-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]ethyl]-naphthalene-2-sulphonamide,N-[2-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]ethyl]-4-fluoro-benzenesulphonamide,N-[2-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]ethyl]-3-fluoro-benzenesulphonamide,4-chloro-N-[2-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]ethyl]-benzenesulphonamide,3-chloro-N-[2-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]ethyl]-benzenesulphonamide,N-[2-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]ethyl]-3-hydroxy-benzenesulphonamide, andN-[2-[4-(5-chloro-2-methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]ethyl]-3-methyl-benzenesulphonamide,or pharmaceutically acceptable salts thereof.
  • 25. (canceled)
  • 26. A pharmaceutical composition comprising the compound of formula (I) as defined in claim 1 as an active ingredient in combination with pharmaceutically acceptable carrier(s) and/or excipient(s).
  • 27-28. (canceled)
  • 29. A method of treatment and/or prevention of disorders of the central nervous system related to serotoninergic and dopaminergic transmission in mammals, comprising administration of the pharmaceutically effective amount of a compound of formula (I) according to claim 1 or a pharmaceutical composition as defined in claim 26.
  • 30. A pharmaceutical composition comprising the compound of formula (I) as defined in claim 2 as an active ingredient in combination with pharmaceutically acceptable carrier(s) and/or excipient(s).
  • 31. A pharmaceutical composition comprising the compound of formula (I) as defined in claim 3 as an active ingredient in combination with pharmaceutically acceptable carrier(s) and/or excipient(s).
  • 32. A pharmaceutical composition comprising the compound of formula (I) as defined in claim 24 as an active ingredient in combination with pharmaceutically acceptable carrier(s) and/or excipient(s).
Priority Claims (1)
Number Date Country Kind
P.392436 Sep 2010 PL national
PCT Information
Filing Document Filing Date Country Kind 371c Date
PCT/EP2011/066054 9/16/2011 WO 00 3/22/2013